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ABSTRACT	
KATHERINE COLEMAN SISTRUNK: Hit Me With Your Best Shot: A Critical 
Analysis of the Resistance to Vaccine Utilization	
(Under the direction of Dr. Joseph “Jody” Holland)	
 
Vaccines have provided humans protection from infectious diseases for centuries, 
yet the vaccination rate in the United States fails to come near one-hundred percent, 
allowing vaccine-preventable diseases to re-emerge in communities across the nation. 
Vaccines have proven to be a safe and effective method in preventing the spread of 
infectious disease, but vaccine resistance remains high due to false information 
perpetuated by anti-vaxxers, greatly impacting the vaccination rate in our country. This 
thesis, by means of a literature review, provides a critical analysis the resistance to 
vaccine utilization in the United States to determine what policy recommendations and 
interventions can be made to reduce the resistance to vaccines and increase the 
vaccination rate in our country.	
Vaccine hesitancy has been around ever since the creation of the first vaccine and 
as the years went on, the modern anti-vaxx movement gained ground, voicing concerns 
over the ingredients in vaccines, the number of vaccines children receive in their first 
year, and the belief of the myth that vaccines cause autism. Even after medical science 
and years of research have validated the safety of vaccines and have shown no link to 
autism, vaccine hesitancy is still an issue as anti-vaxxers push to receive exemptions for 
medical, religious or philosophical reasons. Several states offer these types of 
exemptions, furthering the low vaccination rates in the United States and putting citizens’ 
health and safety at risk.  
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The findings of the critical analysis was comparable to the literature review: 
compulsory vaccine laws have proven to be a successful solution to increase vaccination 
rates; however, these laws are left up to the states, allowing many individuals to go 
unvaccinated as only Mississippi, West Virginia, and California do not allow religious 
and philosophical exemptions. In order to address the low vaccination rates in the United 
States, policy interventions must be made through the states, the federal government, 
health care providers, and community and government-based organizations to increase 
the vaccination rate in our country through measures intended to increase vaccine 
compliance. Without these policy interventions, our nation and our world will never be 
free from the threat of vaccine-preventable infectious diseases. 
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Chapter 1	
Introduction		
Introduction to Infectious Disease and Vaccination	
Infectious diseases have plagued humanity for thousands of years, infecting and 
killing millions of people in their path. In the seventeenth and eighteenth centuries as sea 
travel began to blossom, so did the spread of these diseases. Globalization and 
colonialism brought people together from disparate parts of the world, but also led to the 
transfer of dozens of deadly pathogens—both bacterial and viral—and contributed to new 
stresses such as vitamin and protein deficiencies. The New World was particularly hard 
hit since isolated indigenous peoples had not encountered a host of Old World diseases 
prior to first contact in 1492, and the conditions of colonialism facilitated the spread of 
these infectious agents. Before colonial contact with the New World, there were between 
five and ten million people in North America, and because of the devastation that disease 
brought along with colonization, by the twentieth century, there were only 237,000 
Indians left in the United States (Crosby, 1976).   
Morbidity and mortality in our history can be associated with many different 
factors including problems with sanitation, living conditions, starvation and malnutrition, 
and poor medical practices, but one thing is for certain: infectious diseases have been 
responsible for many of our world’s deaths over the centuries; however, we have made 
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significant steps in the right direction. With our world continuing to globalize, the threats 
that infectious diseases bring continue to linger, but because of the numerous medical and 
scientific advancements made over the years, we have been able to slow and even 
eradicate disease.  
The first ideas surrounding medicinal thought began with the idea that balancing 
bodily humors led to good health. Because of this idea, heroic medicine, which was 
extremely barbaric and often did more harm than good, was introduced to treat disease. 
Heroic treatments often included methods such as bloodletting, blistering, and using 
harmful drug concoctions that intended to treat or even cure patients, when really, it more 
often made the patients sicker. This was extremely primitive medicine, and emerging 
scientists and physicians in the medical field realized that something different was needed 
to combat diseases such as smallpox (Dary, 2008).	
It is unclear when the practice of “inoculation,” or purposefully infecting a patient 
with smallpox through the scabs or pus from another person infected with the disease to 
gain immunity, was first practiced. However, evidence suggests that the Chinese 
practiced the method over one thousand years ago and then the method spread to the rest 
of the western hemisphere and the Americas by the mid-eighteenth century. Because 
people realized that those who survived smallpox could never contract the disease again, 
inoculating people with the disease in turn made the resulting smallpox infection less 
harmful to the patient than naturally getting the disease, while also providing the patient 
lifetime immunity. There were some criticisms to this method, however. Some people 
complained that it interfered with God’s plan and that it was a dangerous method. But, it 
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was proven to be a successful solution, and was used by many medical professionals and 
even commoners at the time to combat the smallpox infection (Reidman, 1960). 	
As the practice of inoculation was gaining recognition worldwide, a scientist 
named Edward Jenner, who was subjected to a cruel inoculation practice in England as a 
child, was determined to find a safer and more effective method. Jenner noted that 
milkmaids rarely got smallpox and discovered it was because of their exposure to cows 
with cowpox. So, because of this discovery, the first smallpox vaccine was developed in 
1796 with the slightly safer method of using the pus from a cow with cowpox for 
inoculation rather than the full-blown smallpox virus. This new theory by Jenner was 
tested on an eight-year-old boy and was successful. When the boy later came into contact 
with smallpox after being inoculated with cowpox, he did not become infected with the 
smallpox virus, showing that the vaccine that Jenner developed had worked and made 
people resistant to smallpox (Link, 2005).	
Jenner’s research and experiments with cowpox led the way for the development 
of the first vaccination, and today, smallpox has been eradicated worldwide, representing 
a major milestone in the control of infectious diseases and further proving that through 
drastic public health and vaccination measures, disease can be conquered. (Greenwood, 
2014). Vaccines have allowed us to gain protection against diseases that have infected 
millions of people worldwide, including measles, mumps and rubella (MMR), pertussis, 
yellow fever, and tuberculosis. Because of this medical advancement, we are now able to 
protect ourselves from a multitude of preventable diseases that our world may still be 
suffering from without the formation of vaccines (Feemster, 2018).		
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Introduction to Vaccine Resistance	
There are many reasons, some being religious or philosophical, why parents 
specifically do not want to vaccinate their children, and many states offer exemptions to 
allow parents to do so. A majority of states allow exemptions to vaccines for both 
religious and medical reasons, but many states also allow exemptions for philosophical 
reasons as well. What is most interesting is that the states that are well behind most in 
health outcomes in our country are the ones that have the strictest vaccination laws: 
Mississippi and West Virginia. California also recently changed their laws to mimic those 
of Mississippi and West Virginia after a measles outbreak in Disneyland sickened dozens 
of children in 2015 (National Vaccine Information Center, 2018).	
Despite laws that mandate vaccination, there are still people in our world, mainly 
children, who are suffering from vaccine-preventable diseases. If we continue to ignore 
this problem, the health of our nation could be compromised as outbreaks of infectious 
diseases become too large to control. In fact, an estimated twenty-three million infants 
did not receive routinely recommended vaccinations in 2012 (Bårnighausen, Bloom, 
Cafiero-Fonseca & O’Brien, 2014). Additionally, the World Health Organization (WHO) 
estimated that measles cases spiked thirty percent worldwide in 2017 due to poor 
vaccination rates, and out of the 6.7 million people who got measles in 2017, 110,000 
died from the virus (Fox, 2018). In the 1970s, many medical experts thought that the fight 
against infectious diseases was over, and the Surgeon General at the time even said that it 
was “time to close the book on infectious diseases, declare the war against pestilence 
won, and shift national resources to such chronic problems as cancer and heart disease” 
(World Health Organization, 2018). Because of the increasing number of people refusing 
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vaccination over the last few decades, the progress that our world has made in 
eliminating infectious diseases is quickly being reversed. 	
With our ever-globalizing planet, infection control has become increasingly 
important. Our world is always subject to new outbreaks of infectious disease, as we have 
seen in Africa in 2012 with the Ebola virus epidemic that affected several African 
countries including Sierra Leone, Liberia, and Guinea. This outbreak not only highlighted 
our global vulnerability to disease, but also caused mass hysteria around the globe with 
the fear that the virus would spread to places such as the United States. The virus was 
mostly contained in Africa, but cases still persist in the continent even today, showing the 
resilience and dangers of infectious disease (Looke, Gottlieb & Jones, 2015). 	
In addition, as mentioned previously, the 2015 measles outbreak in Disneyland 
sent a message to many Californians on the importance of vaccination. Of the 110 
Californian patients infected with measles from their trip to Disneyland, 49 were 
unvaccinated; and of the 49, 12 were too young to receive vaccinations and the remaining 
37 had refused vaccination for personal beliefs. Because of one person’s exposure to 
measles, hundreds of people became infected and many who were sick were too young to 
even get vaccinated, prompting the California legislature to reconsider their vaccination 
laws. Today, California, along with Mississippi and West Virginia, have the strongest 
compulsory vaccination laws in the nation (Zipprich, Winter, Hacker, Xia, Watt & 
Harriman, 2015).		
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Magnitude of the Problem	
The magnitude of this problem is large, not only in the United States, but around 
the world, prompting the need for a solution to this public health problem. Whether it be 
through vaccine and public health education, increased compulsory vaccine laws, or other 
policy interventions, citizens in the United States need to be educated surrounding the 
facts of vaccination in order to be informed citizens who can make smart decisions in 
regard to their health and the health of those around them. Today, more than eighty-five 
percent of children worldwide are vaccinated annually against diseases such as 
diphtheria, tetanus, pertussis, tuberculosis, polio, measles, and hepatitis B, preventing an 
estimated 2.5 million deaths each year (Children’s Hospital of Philadelphia, 2018). 
People across the nation need to understand that vaccination is key to protecting the 
health and safety of our country and informing and educating the public on the 
importance of vaccination, coupled with compulsory vaccination laws and other policy 
interventions, is the solution. 		
Purpose of Study	
The driving question surrounding this thesis is, why do people resist vaccination 
and what policies and interventions can be introduced to mitigate this resistance? In order 
to answer this question, the author must fully understand the evolution of vaccination and 
the scope and evolution of the resistance to vaccination, which will be discussed in later 
chapters. The intent of this thesis is to critically analyze the evolution of vaccination and 
the evolution of resistance to vaccine utilization in the United States to determine what 
policy recommendations and interventions can be made to reduce the resistance to 
vaccines and increase the vaccination rate on our country.	
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In this thesis, the author will first outline the methodology for the research, which 
consists of a literature review. Next, in chapter 3, the author will give a historical 
background of vaccines and the effect of infectious diseases on humanity before outlining 
the evolution of vaccination. In chapter four, the author will provide the findings of the 
research through outlining the evolution of vaccination. Finally, the author will present 
final recommendations through policy interventions to attempt to solve the problems 
surrounding resistance to vaccine utilization.		
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  8 
 
 
 
Chapter 2	
Methodology		
 Using a literature review, the author developed a deeper understanding of 
vaccination as well as critically analyzed the resistance to vaccine utilization in the 
United States to determine what policy recommendations and interventions can be made 
to reduce the resistance to vaccines and increase the vaccination rates in our country. The 
author performed this review by means of computer search using the University of 
Mississippi Libraries OneSearch. The resources selected for this research analysis 
focused on the following: the effect of infectious diseases on humanity, history of 
vaccines, the evolution of germ theory, types of vaccines, components of vaccines, 
vaccination disasters, vaccinations for the future, the current state of vaccination, the 
history of vaccine resistance, the current anti-vaxx movement and vaccine controversy, 
policy recommendations to combat anti-vaxxers, and educational programs for the 
promotion of vaccine efforts.	
 This research provides a particular emphasis on the evolution of vaccines and the 
evolution of vaccine resistance in order for the author to develop a deeper understanding 
of the subject. The literature review research design aids the author in their efforts 
because there are thousands of sources pertaining to vaccines that have been published 
both online and in print. This research includes analysis of the resistance to vaccines as 
well as the impact that the resistance has had on humanity. By utilizing a literature 
  9 
review, the author aims to provide a comprehensive examination of vaccines and vaccine 
resistance by compiling these different areas of research into a comprehensive analysis so 
that a policy recommendation can be made.	
 The data collected ranged from scholarly peer-reviewed articles to published 
books, court cases, various websites, and quantitative and qualitative vaccination data. 
The approach to reviewing the available peer-reviewed journal articles is as follows: (1) 
advanced search vaccination in the University of Mississippi Libraries One Search using 
indicator words, (2) filtered responses for peer-reviewed and full article available online 
in the order of most relevant, (3) reviewed titles, descriptions, and article abstracts for 
content related to the author’s research, and (4) selected articles with varying content that 
together aid to help the author in their analysis of vaccines and vaccine resistance and 
also help them to find other useful print and online sources in order to accurately 
understand vaccines and vaccination resistance to make a policy recommendation.	
 The indicator words and phrases used in One Search included vaccination, 
vaccine, inoculation, vaccine history, vaccine resistance, vaccine schedule, anti-vaxx 
movement, vaccine education, current state of vaccination. This process produced a total 
of 51,633 results. Then, the results were narrowed by redefining the search to include full 
text online and peer-reviewed sources, giving 5,797 results. Then, the results were 
narrowed even further by defining results limited to journal articles in English published 
in the past year whose subject matter related to vaccines, vaccination, immunization, 
infectious diseases, medicine, United States, humans, epidemiology, public health, 
prevention, disease, vaccine, inoculation, disease control, epidemics, biology, smallpox, 
vaccination and immunization, which resulted in 200 sources. These sources were then 
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evaluated for their relevance to the author’s research by conducting an analysis of titles, 
descriptions and abstracts. The articles that were determined to be beneficial to the 
author’s research were then saved to a computer folder for analysis. The sources that 
were saved to a computer folder were then categorized into themes such as history, 
current state, pro-vaccination, anti-vaccination, vaccine resistance, and vaccine data. 
These themes appeared organically as the author collected and evaluated the research. 	
When evaluating the sources that were produced from the University of 
Mississippi Libraries OneSearch, several books, websites, and other journal articles were 
mentioned in the research, allowing my research to expand further with the introduction 
of these other sources. Additionally, when reviewing these OneSearch sources, the author 
was inspired to search for further sources in the forms of books, websites and other 
journals to aid in the analysis, so several other sources were introduced into the research. 
Current events were also taken into consideration within the research as outbreaks of 
disease have been common in the United States in 2019. 	
 This detailed analysis aided the author in answering the proposed research 
question. By focusing on the indicator words listed and breaking down the research into 
smaller subsection, the author was able to outline and organize the research, findings, and 
recommendations to present a comprehensive analysis of vaccines, vaccine resistance, 
and how to mitigate vaccine resistance. By using a literature review as the methodology 
for this research, the author was able to gather research and data in order to recommend 
policies that aim to decrease vaccine resistance and increase vaccination rates.	
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Chapter 3 	
Background	
Evolution of Vaccination	
 For centuries, man has attempted to prevent disease through whatever means 
necessary, formulating theories and methods on how to best prevent or treat disease. The 
first recorded description of disease, according to Cyril William Dixon in his text on 
smallpox, was in 1160 B.C. with the Egyptians. It is believed, through his mummified 
remains, that Ramses V, Pharaoh of Egypt, had died from smallpox (Fulginiti, 1982). 
This ancient disease was scouring the globe, and people began trying various methods in 
devising a solution. The first conceptual knowledge of vaccination occurred in ancient 
Greece, when physicians first started to understand that getting infected with smallpox 
could prevent later infections of the same disease. In fact, in 429 B.C., Greek historian 
Thucydides recorded the observation that people who survived smallpox in Athens, 
Greece were safe from re-infection (Bushak, 2016).	
 It was not until one-thousand years ago when the Chinese began their method of 
“variolation” that a solution to this dreadful disease was first observed. Variolation, or 
deliberately infecting a person with disease to cause a milder case and protect the 
individual from contracting the natural, more severe form of the disease, was used as a 
solution to smallpox at that time (Link, 2005). Historians debate on when this method 
was first seen in China, but most agree that it was about one-thousand years ago. Vincent 
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Fulginiti (1982) writes that the Chinese first utilized variolation as early as 590 B.C. by 
implanting bamboo splinters containing infected pustular material into the nasal passages 
of uninfected individuals. However, the agreement seems to be that this method was first 
introduced around 900-1000 A.D., and that the most common method was taking dried 
crusts or scabs from a smallpox patient, grinding them up, then placing the powder in the 
nose where the patient then inhaled it, triggering a less severe form of the smallpox virus 
along with lifetime immunity (Feemster, 2018). Through this method, the Chinese 
discovered that they could store the smallpox crusts from infected patients in sealed 
vessels for months, and the matter would still work and retain its potency when used on 
other patients months later. This method created by the Chinese, along with other similar 
interventions, were used for hundreds of years in Asia, the Middle East, and Africa until 
the idea finally spread to Europe in the eighteenth century (Reidman, 1960). 	
 In the early eighteenth century, the practice of inoculation was largely confined to 
the eastern countries of China, India and Turkey until Lady Mary Wortley Montague, 
wife of the British Ambassador to Turkey, learned of “smallpox parties” during her time 
in Turkey. She was disfigured from suffering from the disease herself in 1715 and was 
determined to find a solution to protect her family (Bushak, 2016). In 1717, during the 
reign of George I, she wrote to a friend in England, saying	
I am going to tell you a thing that I am sure will make you wish yourself here. 
The smallpox, so fatal and general among us, here is entirely harmless by the 
invention of engrafting (variolation). There is a set of old women who make it 
their business to perform the operation every autumn in the month of September 
when the great heat is abated… They make parties for the purpose… the old 
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woman comes with a nutshell full of the matter of the best sort of smallpox, and 
asked what veins would you please have opened. She immediately rips open… 
and puts into the vein as much matter as can lie upon the head of her needle. 
(Link, 2005, p. 11-12).	
Lady Montague was so enthusiastic about the procedure that she brought the practice to 
Britain, where she had her five-year-old son inoculated. Within a few days, she wrote to 
her husband that the boy was singing and playing and could not wait until supper was 
ready. In the years after, Lady Montague spread the practice throughout England, 
decreasing the number of smallpox cases dramatically (Reidman, 1960; Link, 2005). She 
has been credited as being the first to bring attention to the practice of inoculation in 
England, and eventually to the Western world (Bushak, 2016).	
 Some were still skeptical about this practice, including King George I. So, the 
King directed the embassy physician in Constantinople who witnessed the variolation of 
the Montague household to try the practice on seven criminals who were sentenced to 
death. The criminals survived inoculation and earned pardons, rendering the practice safe 
to the King, causing it to further spread throughout England and beyond. In fact, because 
of Lady Montague, Frederick the Great and the Crown prince of Denmark were 
inoculated by Dr. Thomas Dimsdale of London, and Empress Catherine of Russia invited 
Dr. Dimsdale to spread the practice in Russia. The popularity of this method had spread 
throughout Europe and Asia, and even to the Middle East, where Arabs had a custom 
called “buying the smallpox,” where they would squeeze pus from an infected child and 
introduce it to the skin of another person, paying the smallpox “donor” with raisins, 
dates, or candy (Reidman, 1960). 	
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In England, “Inoculation Houses” were formed by the apothecary Robert Sutton, 
where it became a business to inoculate patients and take care of them throughout the 
duration of the resulting illness. Sutton’s method was different than most in that he took 
precautions in preparing the patient and providing care afterward. He would prescribe a 
period of rest and proper diet before inoculation and during the procedure, he used a 
small amount of matter from an infected blister instead of from a crust, inserting it into 
the skin in the upper arm and avoiding the use of bandages after the fact (Reidman, 
1960). Additionally, after learning from a technique practiced in South Carolina in 1738, 
the Suttons acquired infectious matter from another inoculated patient, not from a victim 
of natural smallpox, making the resulting infection less severe. After inoculation, the 
patient was then quarantined from the community at large in a room that allowed the 
patients to have adequate air flow, allowing them to heal while protecting the community 
(Fenn, 2001). 	
This safer method became widely popular; however, it was not always done in the 
same safe way that Sutton introduced. Among the elite in England, this practice 
developed into a costly and elaborate procedure in which patients were subjected to 
blood-letting, purging, starving and purifying in inoculation houses before variolation, 
then confined to the buildings until the illness subsided. Edward Jenner, the man who 
invented the first smallpox vaccination in the late eighteenth century, was even subjected 
to this method as a child (Link, 2005). 	
As different methods of smallpox inoculation were spreading throughout the 
eastern hemisphere, it was finally introduced in America in 1721 by Zabdiel Boylston, a 
Boston doctor. He successfully inoculated his young son and his two servants; however, 
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there was more setback. After his success in inoculation led others to try the procedure, 
one person died as a result, causing many to refer to the practice of inoculation as the 
work of the devil that defied the will of God. However, many still believed in the method 
including Benjamin Franklin, who worked with Dr. William Heberden of London in 
writing a booklet on smallpox inoculation. Franklin advocated for those who could not 
afford the often-expensive inoculation practice, teaching in his booklet how to do the 
procedure in hopes that parents would inoculate their children. In the pamphlet, Dr. 
Heberden and Benjamin Franklin provided simple instructions that could be easily 
followed, allowing people to understand how to do the practice on themselves and their 
families that could not afford the procedure otherwise (Reidman, 1960).	
In the following decades during the late eighteenth century, American medical 
students traveled to England and Scotland to learn the safe Suttonian Method of 
inoculation, bringing it back to America. Among these students was Dr. Benjamin Rush, 
who promoted smallpox inoculation in Philadelphia and ultimately introduced the method 
to George Washington’s Continental Army, saving many lives that would have been lost 
to disease during the Revolutionary War (Reidman, 1960). However, the popularity of 
inoculation began to diminish as the years went on due to the often-unsafe methods used, 
coupled with the fact that the practice kept the disease alive and thriving in society, for 
people not inoculated were always exposed to those who had it in the mild form. 
Additionally, there were occasional deaths from the inoculation method, and many 
argued that it interfered with God’s plan. In fact, a law was passed in 1762 in France that 
prohibited the method entirely (Reidman, 1960). 	
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In addition, the practice became extremely controversial in the Americas and 
began to be restricted. After the Williamsburg smallpox outbreak in 1768, the Virginia 
Legislature received numerous petitions to stop the practice of inoculation in Virginia. 
While inoculation was not banned entirely in response to this, the regulations imposed in 
1770 were so restrictive to the practice that they essentially had the same effect as a ban. 
In Charleston, South Carolina, the first inoculation law was in 1738. It was an ordinance 
that imposed a large fine on anyone giving or receiving inoculation within two miles of 
the city. New York passed a similar law in 1747, further restricting the practice (Fenn, 
2001).	
Inoculation became a widely restricted and unpopular practice in New England, 
while it remained a popular practice among many across the ocean in the Eastern 
hemisphere. However, some colonies still allowed the practice, and it flourished in 
Maryland, New Jersey and Connecticut. The practice was again becoming hard to find 
and expensive for many people due to these restrictions, and often those who could afford 
it, the affluent Americans, fought for the practice, while those who could not afford the 
procedure, fought against it. The practice became more accessible in the years leading up 
to the Revolutionary War, and more people were inoculated as more outbreaks of 
smallpox occurred (Fenn 2001). It was clear that a new and safer solution was needed to 
combat and ultimately eradicate smallpox, and English scientist named Edward Jenner 
answered the call.				
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Edward Jenner and the Smallpox Vaccine	
Edward Jenner was born in Berkeley, Gloucestershire, a farming town, in 1749. 
Young Edward began his medical journey through an apprenticeship to Mr. Daniel 
Ludlow where he learned the practical art of medicine and surgery, while also learning to 
observe and care for the sick. Jenner continued to learn from more and more medical 
professionals over the years and took in everything he could about medicine and the 
body. He was passionate about learning, and never stopped exposing himself to new 
things, always looking for something new to discover. This began his long career in the 
medical practice and ultimately led to his creation of the first vaccine (Reidman, 1960).	
Jenner grew up in a farming community, dairy farming in particular, where he 
constantly noticed and observed the contagious disease of cattle that the farmers referred 
to as “cowpox.” This infection affected the cow’s udders where red pimples erupted over 
the surface, later becoming watery blisters that formed a scab, leaving behind a pitted 
scar (Reidman, 1960). Cowpox, named after its similarities to smallpox, was not as 
severe as smallpox, but along with the pustules and fever, it also caused aching joints and 
limb pain in humans. However, the biggest difference between the two was that cowpox 
did not cause disfigurement or death (Feemster, 2018). This disease among cattle was 
medically-termed “Vaccinia,” and it was spread from cow to cow by the milker’s hands. 
Herds of cows would become infected and sometimes it would be passed to the 
milkmaids or dairymen, resulting in a sickness that caused a slight fever and pimples on 
the hands that blistered, scabbed, and scarred just as the cowpox affected the cattle 
(Reidman, 1960). 	
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Jenner noticed that most faces in his city bore scars of smallpox, while the faces 
of milkmaids and dairymen were unblemished. He theorized that the frequent occurrence 
of cowpox and its association with the daily work on a dairy farm somehow protected the 
milkmaids and dairymen from smallpox (Link, 2005). He even recorded a similar theory 
during his apprenticeship with Mr. Ludlow when a young girl came in during a smallpox 
outbreak in the community, boasting how she was not afraid of catching the disease 
because she had previously been infected with cowpox as a child (Reidman, 1960). 	
Jenner decided to test his theory with an experiment. On May 14th, 1796, he 
obtained a sample of pus from a cowpox ulcer on the hand of Sarah Nelmes, a milkmaid, 
and administered the sample to a young boy by the name James Phipps. A few weeks 
later on July 1st, Jenner inoculated Phipps with smallpox and waited for the result. The 
conclusion was remarkable: James Phipps was immune to smallpox. Jenner termed this 
new procedure “vaccination” after the Latin word for cow, and by 1801, one-hundred 
thousand people throughout Europe had been vaccinated with the first cowpox-based 
smallpox vaccine (Link, 2005; Feemster, 2018). Vaccination was the updated word for 
this new method of inoculation created by Jenner as it differentiated between injection 
with cowpox matter rather than inoculation with smallpox matter. Today, these two terms 
“vaccination” and “inoculation” are often used interchangeably, but in Jenner’s time, 
vaccination distinguished his method from the older method of inoculation (Reidman, 
1960).	
Even after Jenner’s remarkable breakthrough, some doctors and scientists were 
still skeptical about the method. Jenner presented his discovery to the Royal Society in 
1796, but his paper was refused. He was told to investigate further and publish his result 
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in a book, so for the next two years, Jenner collected more evidence and was finally ready 
to present his work again. He traveled to London to share his discovery with many 
skeptics about his methods but again was met with criticisms about the safety of his 
method and was unable to find a patient to demonstrate his work. So, Jenner once again 
returned home to try to gather more evidence, but he left a small amount of smallpox 
matter and a vaccination with a surgeon named Henry Cline as well as leaving his 
manuscript with a London printer in hopes that they would possibly believe in his 
methods. His hope came true when Dr. Cline tested Jenner’s matter on a child, and Cline 
wrote to Jenner, saying	
The cowpox experiment has succeeded admirably… Dr. Lister, who was formerly 
a physician to the Smallpox Hospital, attended the child with me, and he is 
convinced that it is not possible to give him the smallpox. I think the substituting 
of cowpox poison for the smallpox promises to be one of the greatest 
improvements that has ever been made in medicine; for it is not only safe in itself, 
but also does not endanger others by contagion… (Reidman, 1960, p. 35).	
Jenner’s seventy-five-page manuscript, An inquiry into the Causes and Effects of the 
Variolae Vaccine, a Disease Discovered in some of the western counties of England, 
particularly in Gloucestershire, and known by the name of Cowpox, was printed and 
distributed worldwide. Finally, the world knew that those who had cowpox were immune 
to smallpox, cowpox could be transmitted by vaccination, and it gave the same protection 
as the disease itself (Reidman, 1960). Jenner’s theory was finally gaining acceptance in 
the world of medicine, and his discovery has led the battle of infectious disease ever 
since.	
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Evolution of Germ Theory	
 Even though Edward Jenner did not necessarily know the science behind his 
discovery, he still found a way to protect people against smallpox. It was not until the 
mid-nineteenth century that microorganisms, or germs, that caused infectious diseases 
like smallpox were understood. Microorganisms were first observed under a microscope 
by Robert Hooke and Antoni van Leeuwenhoek in the mid-seventeenth century (Gest, 
2004). However, it was not until two centuries later with English physician, John Snow, 
that the connection between germs and disease was discovered. Modern epidemiology 
was born in 1854 when Snow determined that the source of the Cholera epidemic in 
London was due to water that was contaminated in the city’s pump. After he ordered the 
pump closed, the epidemic ended, showing his observation was correct. Was this a 
coincidence or a major scientific discovery? Many physicians at the time refused to 
believe that invisible microorganisms could spread and cause disease. However, research 
later done by Louis Pasteur and Robert Koch solidified Snow’s argument (Kusinitz, n.d.).	
 Louis Pasteur was born on December 27th, 1822, in Dole, France and at a young 
age became interested in research. Pasteur began his first major studies with fermentation 
when he was appointed to a lab in Lille in 1854. Pasteur believed that fermentation was 
carried out by living microorganisms but had to prove his theory to other scientists who 
believed that it was caused by spontaneous generation. Through his experiments, he 
discovered that fermentation was caused by microorganisms and that they could be 
helpful in this way, and he eventually learned through his observations on fermentation 
that spoilable foods could be preserved, or “pasteurized.” He realized that the reason that 
food spoiled was because of unwanted microorganisms in foods and that the 
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microorganisms could be destroyed by heating and proper sealing, allowing the substance 
to be stored for long periods of time without spoiling. This practice was coined 
“pasteurization” and is technique used to this day (Science History Institute, 2017). 	
Through his research with microbes, Pasteur proved that microbes could not come 
out of nothing, disproving the idea of spontaneous generation that had long been believed 
by many scientists, and he was sure that microbes must also cause disease, promoting his 
studies of germs and their relation to disease (Reidman, 1960). He observed that, “There 
are similarities between the diseases of animals or man and the diseases of beer and 
wine” (Kusinitz, n.d.). The idea of spontaneous generation also received a blow in 1858 
when Rudolf Virchow, a German scientist, introduced the concept of biogenesis, the idea 
that living cells can only arise from other preexisting cells. Germ Theory was finally 
taking shape, and scientists were beginning to understand that microorganisms can invade 
the body and cause certain diseases. However, it was not until 1876 that German 
physician Robert Koch proved that bacteria can cause disease, confirming the validity of 
Germ Theory once and for all (Kusinitz, n.d.). 	
Robert Koch was born in 1843 in northern Germany. A miner’s son, he was one 
of thirteen children and studied to become a doctor at the University of Gottingen. He 
studied under Berlin anatomist, Jacob Henle, who worked out the theory that infectious 
diseases were carried out by invisible forms of life. Koch was eager to learn and with the 
help of his wife, got his first microscope and got to work. He observed the deadly disease 
anthrax that was plaguing Germany, not only killing sheep, but also killing the farmers, 
wool sorters, and hide dealers that dealt with the sheep. No one could explain why 
healthy sheep suddenly died within a day, and Koch decided he would investigate. Using 
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his microscope, he examined a drop of blood from a dead sheep, and among the usual 
components of blood, he also saw small, short rod-shaped structures within the liquid. He 
decided to test the blood of a healthy animal to see if they contained these same rods, and 
to his amazement, they did not (Reidman, 1960).	
He set up a laboratory in his office and set out to study these rods that he had 
found. He began infecting mice with the anthrax-infected blood from the sheep and 
discovered that he was able to transfer the deadly disease to mice, as they lay dead in 
their cages the day after inoculation. He examined the mice blood under his microscope 
and once again observed the tiny rod-shaped structures that he saw in the anthrax-
infected sheep’s blood. He transferred the infected blood from the dead mouse to another 
mouse and did this over and over all ending with the same conclusion: many dead mice 
with the same rod-shaped structures found in their blood (Reidman, 1960).	
He then set out to prove what he observed by attempting to grow the structures 
outside of the mouse’s body. He theorized that he would have to create an incubator as he 
knew that an animal’s warm body was able to grow the structures, so he created a 
makeshift one with an oil lamp. He added a tiny scraping of an infected mouse spleen to 
the incubator and waited for the rod structures to multiply. Amazingly, his incubator 
worked, and the tiny rods began to multiply. He did this same procedure over and over 
until he ran out of infected mouse spleen. Then, he began to wonder if this lab-grown 
matter could kill a mouse or sheep if it were injected into them. This was his next 
question to answer. Koch transferred the lab-grown matter into a healthy mouse and the 
next morning awoke to another dead mouse. He examined the spleen and again saw the 
tiny rod-shaped structures, proof that tiny microbes caused disease (Reidman, 1960). 	
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This experiment allowed Koch to prove that one kind of bacillus was the cause of 
one particular disease, and in this case, he showed that the bacterium Bacillus anthracis 
was the cause of anthrax in animals. This experiment allowed Koch to come up with 
specific guidelines for determining the cause of infectious diseases, now known as 
Koch’s Postulates. His postulates are:	
1. The organism must be present in every case of the disease. 
2. The organism must be isolated from a host with the corresponding disease 
and grown in pure culture. 
3. Samples of the organism removed from the pure culture must cause the 
corresponding disease when inoculated into a healthy, susceptible 
laboratory animal. 
4. The organism must be isolated from the inoculated animal and identified 
as being identical to the original organisms isolated from the initial, 
diseased host. 
These postulates are followed by every researcher that attempts to obtain proof that a 
particular organism causes a particular disease. By showing how specific organisms can 
be identified as the cause of specific diseases, Koch disproved the theory of spontaneous 
generation while finally proving the validity of Germ Theory, which was a major 
milestone in the world of science and medicine. Along with other scientists like Hooke, 
van Leeuwenhoek, and Pasteur, Koch laid the foundations of microbiology and allowed 
the creation of even more medical advancements, including vaccinations, that have 
impacted our world’s health (Kusinitz, n.d.).	
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 Koch’s postulates began the Golden Era of medicine, allowing microbiologists to 
isolate the microbes that caused cholera, typhoid fever, diphtheria, pneumonia, tetanus, 
meningitis and gonorrhea between 1879 and 1889 and later allowing scientists to create 
vaccines for several of these diseases. Additionally, Koch’s work influenced Joseph 
Lister, a surgeon who wanted to find a way to prevent infection in the operating room. By 
using phenol to prevent infection, Lister was one of the first to use his knowledge of 
Germ Theory to control infectious diseases. After his methods of infection control 
became known, public health measures were created in communities to increase hygiene 
and reduce contamination through keeping communities clean and utilizing vaccinations 
(Kusinitz, n.d.). Germ Theory was revolutionary and allowed the creation of more and 
more vaccines and public health measures up through the twentieth century until a new 
hurdle was reached: the battle against polio.		
A New Fear: Polio	
 The start of the twentieth century brought many successes in the battle against 
infectious diseases but also brought new fears thanks to a disease that frightened young 
and old alike: poliomyelitis. Poliomyelitis, often just shortened to polio, comes from the 
Greek words for grey and marrow, referring to the spinal cord, and the suffix -itis, 
meaning inflammation. The disease caused paralysis and was mostly seen in children, 
which led it to be called infantile paralysis, but it did not only affect the young, it affected 
everyone. The virus was spread through contact between people by nasal and oral 
secretions, and also through contact with contaminated feces. In about 98% of cases, 
polio is only a mild illness with no symptoms. However, in the other 2%, paralytic polio 
can develop, attacking nerve cells and causing paralysis that often leads to death if 
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artificial breathing support is not used (The College of Physicians of Philadelphia, 2019). 
Even though this disease did not affect people on epidemic proportions as smallpox once 
did, the crippling paralysis it caused ensued fear among many, and the iron lung became 
a symbol of the fear that this disease brought in the twentieth century.	
Polio was by no means a new disease in the twentieth century. It was first seen 
over three-thousand years ago in ancient Egypt through a drawing on a stone slab of a 
young boy leaning on a crutch with his muscles shrunken and limbs useless. However, 
unlike other infectious diseases that spread rapidly and caused large epidemics, polio is 
harder to spread, which allowed it to slip through the cracks from century to century until 
re-emerging as a force to be reckoned with in the twentieth century. The first to recognize 
polio as a distinct disease was Dr. Michael Underwood, a British physician, in 1784. It 
was not until over one-hundred years later that it was discovered that polio was caused by 
an infectious agent. The first case to occur in the United States was in 1894 in Vermont, 
when a child began to show symptoms of polio including nausea, high fever, headache, 
stiff neck, and later paralysis. After this case, more and more children became sick as 
outbreaks began spreading throughout the United States (Reidman, 1960). 	
For the first time in its history, polio reached epidemic proportions in the early 
1900s at a time when other diseases such as diphtheria, typhoid, and tuberculosis were 
declining due to vaccination. Strangely enough, the disease spread with great virulence 
into parts of the world where sanitation and infection control were good while epidemics 
in the more primitive parts of the globe were unheard of. Many scientists think that this 
was because as hygiene practices were becoming more advanced, fewer people were 
becoming exposed to polio as infants through practices such as breastfeeding, which did 
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not allow them to form antibodies that protected against the disease in their blood. So, 
because better sanitary conditions meant that exposure to polio was delayed until later in 
life, children became more vulnerable to the disease (Reidman, 1960; The College of 
Physicians of Philadelphia, 2019).	
As ironic as this phenomenon was, polio was threatening young and old alike, and 
a solution was needed in order to stop this terrifying disease. In 1921, Franklin Delano 
Roosevelt was infected with polio and became paralyzed from the waist down. He turned 
his unfortunate situation into a positive outcome, using his experience with the disease to 
inspire courage among millions of people. Up until he was elected President, Roosevelt 
fought for those with polio and created a foundation to fundraise for a cure. The March of 
Dimes, a fundraiser for the cure of polio, was an event celebrated on Roosevelt’s birthday 
and raised over a million dollars in its first year in 1934. Four years later, the National 
Foundation for Infantile Paralysis was founded in order to further research the polio virus 
in order to find a cure (Reidman, 1960).	
Unlike diseases such as diphtheria and anthrax that infect the blood and that 
scientists were able to create a vaccine for using the knowledge of Germ Theory, polio is 
caused by a virus that attacks nerve cells, which is another beast of its own. Viruses are 
more difficult to combat than bacterial infections, and because polio lives inside nerve 
cells, it was hard to study. In 1949, researchers at Harvard found a way to grow the polio 
virus in a test tube, which allowed for more effective research without the use of polio-
infected monkeys to ensue. Also, their discovery allowed scientists to realize that the 
disease was spread through the mouth where it would eventually affect the nerves, 
earning them a Nobel Prize (Riedman, 1960).	
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The start of the polio vaccine trials began in 1935 with Dr. Maurice Brodie and 
Dr. John Kolmer, and both trials came to disastrous ends. Dr. Brodie researched at New 
York University and developed a killed polio vaccine and tested it on chimpanzees, 
himself, and children. He enrolled about eleven-thousand individuals in his trial. 
Similarly, Dr. Kolmer of Temple University developed an attenuated polio vaccine and 
tested it in about 10,000 children. Both trials ended poorly as several children died of 
polio and many others were left paralyzed or ill from the vaccinations (The College of 
Physicians of Philadelphia, 2019).	
After the failure from the 1935 trials, scientists were determined to find a cure but 
were met with controversy from the public as more vaccines were being developed due to 
the harsh and deadly consequences that they had brought in the past. In 1950, Dr. Hilary 
Koprowski of Poland conducted the first human trial of his oral polio vaccine on twenty 
children, and his experiment demonstrated that none of them became ill with polio, and 
they all developed polio antibodies. What was most astonishing is that Dr. Koprowski 
had tested his vaccine two years earlier, but on himself. At this time Koprowski’s 
methods generated considerable controversy among others who were working on 
vaccines, as they believed that testing on human subjects was dangerous as the 1935 trial 
demonstrated (The College of Physicians of Philadelphia, 2019). However, his method 
worked, which was a huge step in the battle against polio.	
Dr. Koprowski’s cure for polio is far less well-known than later scientists such as 
Salk and Sabin’s methods because it was never approved for use in the United States. 
However, it was so successful because his oral version was much cheaper than injectable 
vaccinations, and because they involved a live virus, they were able to confer herd 
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immunity in communities (Fox, 2013). Because his version of the vaccine was difficult to 
make in large quantities, a new solution was needed.	
Dr. Jonas Edward Salk in the mid-twentieth century answered the call. In 1952 at 
the peak of the epidemic, polio had killed around three-thousand Americans, and 58,000 
new cases were reported. The disease was causing more and more fear and illness among 
Americans and Salk worked toward a solution (science.jrank.org, 2019). He believed to 
make an effective vaccine, there had to be plenty of virus, it had to be grown on non-
nervous tissue to avoid possible damage to human nerves, there must be a proper broth 
for growing the virus, three types of the virus had to be included in the same vaccine, and 
the virus must be killed or weakened but still left intact to stimulate the production of 
protective antibodies (Reidman, 1960). 	
In 1952, Salk was ready to test his first vaccine. He enlisted a person who had 
already had the polio virus to test it, and he would evaluate its effectiveness by measuring 
how their antibody level changed before and after receiving the vaccination. The vaccine 
worked, and Salk then looked to test it on patients who had not had the disease. He went 
into the Pittsburgh community and injected adults and children including his own three 
children. After vaccinating one-thousand subjects with his vaccine, it turned out to be 
completely safe and effective as the patients had developed antibodies against all three 
types of polio viruses while having no bad reactions to the injection. Salk was now ready 
for a mass trial of the vaccine, but he was also met with objections from some who 
believed that testing only one-thousand people was not enough to show the safety of the 
vaccine. However, Dr. Salk began his trial in April of 1954 after approval in hopes of 
slowing the outbreak that would happen as the warmer months began (Reidman, 1960).	
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 Salk’s trial began on April 26th, 1954 with 1,830,000 children taking part with 
their parent’s permission. The vaccine was given to 440,000 children while 210,000 were 
given dummy injections. The other 1,180,000 received neither and were the control 
group. The children in this test were ages five to nine, and it took the effort of millions of 
people to make sure that this test was a success. Over one-hundred and fifty million 
pieces of data were sent to the Polio Evaluation Center at the University of Michigan to 
be evaluated, and on the morning of April 12th, 1955, the results were ready: it was 
determined that the Salk vaccine was sixty to ninety percent effective. Over six times as 
many more of the unvaccinated children were paralyzed by polio than among the 
vaccinated, and there was not a single death among the vaccinated group. Dr. Salk was 
praised for his work and even given a Congressional Medal of Honor by President 
Eisenhower (Reidman, 1960). However, his success took a turn for the worse when there 
was a tragic setback on his vaccine campaign.	
 Weeks after the announcement of the success of Salk’s vaccine trials, there were 
reports that polio had developed in a number of children who had been vaccinated with 
Salk’s vaccine. Further distribution was stopped and the vaccines that had been shipped 
were recalled. It was discovered that a batch of vaccine had not been completely 
inactivated and there was live virus still present in the vaccine. By the end of the incident, 
eleven people had died and over two hundred had developed polio (Reidman, 1960). This 
setback caused production problems with the Salk vaccine and it later was discontinued 
as a safe polio vaccine (science.jrank.org, 2019). Again, a new solution was needed to 
solve the polio problem.	
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 In 1956, Dr. Albert Sabin tested his live oral polio vaccine on his wife and 
children with success, and the Soviet Union decided to put the Sabin Vaccine to the test 
with a mass trial. In June of 1959, the International Scientific Congress on Live Virus 
met in Washington, D.C. where Dr. Sabin announced that his live polio vaccine had been 
safely given to 4.5 million people (Reidman, 1960). By 1961, the United States licensed 
Sabin’s oral vaccine for use and millions of Americans were vaccinated against polio 
(science.jrank.org, 2019). One advantage of the Sabin Vaccine over the Salk vaccine was 
that because it was a weakened live virus, it provided lifetime immunity and also 
provided protection to unvaccinated people in contact with those who were vaccinated 
(Reidman, 1960). Additionally, because it is taken orally, the Sabin vaccine was more 
convenient and less expensive than the Salk vaccine (science.jrank.org, 2019). 	
Regardless, a solution was finally found, and because of widespread vaccination 
efforts in the years following, polio was eradicated from the Western Hemisphere in 
1994. Polio continues to circulate in small numbers in particular areas of the globe even 
today, which is why polio vaccination is still required for infants and children in the 
United States. However, vaccination programs are still working around the globe to 
eliminate these last strands of the virus for good (The College of Physicians of 
Philadelphia, 2019). The evolution of vaccinations has a long history, but it is evident 
that through the work of many scientists, researchers, microbiologists, doctors, and even 
ancient Egyptians and European royals, infectious diseases can be conquered through 
vaccination. 		
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Evolution of Vaccines After Polio	
After a solution to polio was found through Salk’s vaccine and large-scale vaccine 
production was possible, disease control efforts continued through the creation of more 
and more vaccines that were being distributed around the globe. In the 1960s, the measles 
vaccine was developed and later turned into a vaccine created in 1971 that protected 
against both measles, mumps and rubella, more commonly known as the MMR vaccine. 
The recommended vaccines during this time included smallpox, DTaP (diphtheria, 
tetanus and pertussis), polio (IPV), and the MMR vaccine, and by the 1970s, one less 
vaccine was required: smallpox. Because of successful global eradication efforts, the 
smallpox vaccine was no longer recommended for use after 1972 (Offit, 2014).	
A decade later, the vaccine for hepatitis B and Haemophilus influenzae type b 
(Hib) were created and added to the list of recommended vaccines. At first, it was only 
recommended that people who were directly at risk for hepatitis B such as infants whose 
mothers are hepatitis B antigen positive, healthcare workers, drug users, homosexual 
men, and people with multiple sexual partners get the vaccine; however, the 
immunization of only these high-risk groups did not effectively stop transmission, and 
the recommendation for vaccination was changed to include all infants (Offit, 2014).	
In 1995 as more vaccines become available, the immunization schedule began 
being updated annually, allowing healthcare providers to have detailed information about 
who should receive each vaccine, age of receipt, number of doses, time between doses, 
and use of combination vaccines. Important changes to the vaccine schedule since 1995 
include the introduction of the varicella (chicken pox) vaccine in 1996, the updated 
rotavirus vaccine in 1998, 1999, 2006, and 2008, the introduction of the hepatitis A 
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vaccine in 2000, and the pneumococcal vaccine in 2001. In addition, more 
recommendations for existing vaccine that extended to children included the influenza 
vaccine in 2002 and the hepatitis A vaccine in 2006. New versions of the existing 
pertussis (DTaP) and influenza vaccines were also created in 1997 and 2002, 
respectively, with the influenza vaccine being an intranasal version. Lastly, the oral polio 
vaccine was discontinued for use in 2000 after an injectable vaccine was preferred by 
most healthcare providers (Offit, 2014).	
Today, there are ten recommended immunizations for infants, including polio 
(IPV), Hib, hepatitis B, Varicella, hepatitis A, pneumococcal, influenza, rotavirus, DTaP, 
and MMR. This list differs for adolescents, as adolescents, like adults, are recommended 
to get tetanus boosters every ten years after the first vaccination around age eleven. Other 
than this, most adolescents do not require additional vaccines unless they missed one 
from childhood. Although not required, the vaccine for meningococcus and human 
papillomavirus (HPV) has become more recommended over the past decade to protect 
young adolescents as they enter their teenage years (Offit, 2014).	
Historically, most vaccines were deemed to be only for children. However, 
vaccines for adults are becoming increasingly common and necessary as well. Adults, 
especially those who are around infants, should get the Tdap vaccine as it protects against 
tetanus and pertussis, and in infants, pertussis can be fatal. The difference between the 
Tdap vaccine and the DTaP vaccine is that the Tdap one is approved for adults, as it is 
just a “booster” with a reduced dose, while the DTaP, although it protects against the 
same thing, is approved for children and is a full dose. In addition to these, the influenza 
vaccine is also recommended for all adults, adolescents, children, and infants over six 
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months, and the MMR and chickenpox vaccines are also recommended for adults who 
have not had the disease and the hepatitis A, hepatitis B, pneumococcus, and 
meningococcal vaccines, are also recommended for certain subgroups of the adult 
population. Lastly, the HPV and shingles vaccines are specifically recommended for 
certain age groups in the adult population. Unlike childhood vaccines that are often 
required for entrance to schools, adult vaccines are not mandated, leading to a lack of 
preventative healthcare measures through vaccine usage in the adult population (Offit, 
2014).		
Vaccine Types	
A vaccine’s composition influences the type of immune response it causes in the 
human body; therefore, they are classified into one of six categories: live attenuated, 
inactivated (or killed), protein subunit and toxoid, polysaccharide, conjugate, and 
recombinant. Live attenuated vaccines utilize viruses only and are made from a virus that 
are weakened to the point that it cannot cause disease, but it can create an immune 
response to protect one from the disease if exposed to it. With this type of vaccine, a 
weakened virus enters a cell and reproduces just enough to induce an immune response 
but not enough to infect many other cells and cause illness. Three different methods are 
used to make weakened viruses for this type of vaccine: the virus can be grown in 
nonhuman cells, it can be grown at a temperature lower than body temperature, or it can 
be grown using both human and nonhuman viruses. Examples of live virus vaccines 
include the rotavirus, MMR, and chickenpox vaccines (Feemster, 2018).	
Inactivated, or killed vaccines are made from a whole virus or bacteria that has 
been killed or neutralized through the application of a chemical substance, usually 
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formaldehyde. Killed viruses are not able to reproduce and cannot cause infection or 
disease but can still create an immune response in the body, protecting it. Examples of 
this type of vaccine include the hepatitis A, polio, and most influenza vaccines. The third 
type of vaccine is called a protein subunit vaccine, which works by isolating the antigens 
or proteins on the bacteria that are known to be important for introducing a protective 
immune response. Some protein subunit vaccines, called toxoid vaccinations, target 
antigens known to act as toxins, inactivating the toxins that those bacteria produce, 
creating toxoids, or inactivated toxins. Examples of this include the diphtheria and 
tetanus vaccines. The pertussis vaccine is also a protein subunit vaccine that is made up 
of two to five different proteins that are either toxoids or part of the bacteria itself. These 
inactivated proteins cannot cause infection or disease but lead to an immune response that 
protects the host from the actual disease (Feemster, 2018).	
 Similar to protein subunit vaccines for bacteria, recombinant vaccines are made 
from individual proteins from viruses that are known to induce a positive immune 
response. These vaccines are made by inserting the gene that is responsible for making 
the selected protein into the DNA of a yeast cell, then as the yeast reproduces, the DNA 
reproduces as well, allowing the resulting reproduced protein to be grown and used in a 
vaccine. Both hepatitis B and human papillomavirus (HPV) vaccines are made through 
this technique (Feemster, 2018).	
The last type of vaccine is the polysaccharide vaccine, which target a certain 
group of bacteria that have capsules around them that are made of sugars or 
polysaccharides. Because the capsule, or outer layer of the bacteria, is what the body 
interacts with first, it is also what the immune response targets. So, vaccines for this type 
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of encapsulated bacteria are made from the capsules rather than the proteins from the 
bacteria. A problem with this type, however, is that polysaccharide capsules do not 
induce immune memory well and they do not work well in children younger than two, 
making it difficult to protect young children against pneumococcus, meningococcus, and 
Haemophilus influenzae b (Hib). So, conjugate vaccines, an additional type, were created 
and allowed for the polysaccharide capsule to attach to a protein that is able to turn on 
memory cells, allowing a better immune response to the bacteria when exposed for a 
second time (Feemster, 2018).	
In addition to these types of vaccinations that protect against individual bacteria 
or viruses, there are also combination vaccines, which protect against several. This 
method of combining vaccinations started in the early 1950s when there were only four 
vaccines available: diphtheria, tetanus, pertussis and smallpox. Instead of giving children 
four individual vaccinations, three of these vaccines, diphtheria, tetanus, and pertussis, 
were combined into one, forming the single DTaP vaccine. By the mid-1980s, there were 
seven vaccines: DTaP, measles, mumps, rubella and polio. So, the measles, mumps and 
rubella vaccines were formed to make one MMR vaccine, so children only received three 
vaccines but were protected against seven diseases. Since the 80s, several vaccines have 
been added to the schedule for children to receive and making combination vaccines has 
made this much easier. Today, there are several combination vaccinations on the market 
besides just the MMR and DTaP vaccines, again making vaccination children much 
easier (Offit, 2014).	
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Vaccine Components	
 Besides antigens, vaccines have several other ingredients that keep them safe and 
help to increase their effectiveness. These components include, preservatives, stabilizers, 
inactivating agents, and adjuvants. The preservatives include phenol and thimerosal, 
which are used to prevent vaccine contamination from any bacteria in the environment. 
Typically, these preservatives are most important in preventing contamination when the 
vaccine vial has been open for use, so typically these types of preservatives are only 
required in vials of vaccination and not in single-dose vaccines (Feemster, 2018). 	
One of the most common preservatives is thimerosal, which is a mercury-
containing compound with high antibacterial factors. It has been used successfully since 
the 1930s in millions of doses of vaccinations, but because of the concern over small 
amounts of mercury in the vaccine, it is recommended that vaccines containing 
thimerosal as a preservative be given to infants over six months of age. Now, there are 
even thimerosal-free vaccines due to concerns, but it is important to note that there has 
been no case of mercury toxicity from any vaccines (Link, 2005).	
The next component in vaccines are stabilizers, which include sugars, amino 
acids, or proteins, that act to keep the vaccine functional for long periods of time. 
Without these stabilizers, the antigens in vaccines would be degraded during the 
temperature changes that take place during the production, transportation, and storage of 
vaccines (Feemster, 2018). The third component of vaccines are inactivating agents, such 
as formaldehyde, that inactivate viruses or bacterial toxins for inactivated virus or 
bacterial toxoid vaccines. Formaldehyde is used during the production of some vaccines 
to inactivate, or kill, viruses or bacteria. So, although formaldehyde is removed from the 
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killed virus or bacteria, there can be a small amount of residue left behind in production. 
This amount left behind is much lower than the amount of formaldehyde that naturally 
occurs within the body (Feemster, 2018).	
The last component of vaccines are adjuvants, which are substances that help to 
enhance the immune response to vaccines. This ingredient is especially important in the 
elderly and immunocompetent populations who may have weaker immune responses to 
vaccinations. Adjuvants also help to enhance the immune response to vaccines that only 
use a few antigens, but they are not needed in weakened or killed (inactivated) whole-
virus vaccines that induce more complete immune responses. The most common type of 
adjuvant used in licensed vaccines in the United States are aluminum salts, because they 
help to boost immune responses by either stimulating the uptake of antigens by immune 
cells or by slowing the release of an antigen at the site of injection to promote a more 
sustained antibody production (Feemster, 2018). All of these components in vaccinations 
are necessary in ensuring the safety and effectiveness of vaccine production and have 
been heavily researched and tested over the years, ensuring their safety within the 
vaccines themselves.		
Vaccine Schedules	
 Each year, the vaccine schedules for infants, children, adolescents, and adults are 
discussed and updated if needed. After they are discussed, the year’s new versions are 
first recommended by the Advisory Committee on Immunization Practices and then 
approved by the Centers for Disease Control and Prevention, the American Academy of 
Pediatrics, the American Academy of Family Physicians, and American College of 
Obstetricians and Gynecologists before being published on the CDC’s website (National 
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Center for Immunization and Respiratory Diseases, 2019). The vaccine schedules 
indicate the recommended ages for routine administration of currently licensed vaccines 
for infants, children, adolescents and adults. Any dose not administered at the 
recommended age should be administered at a later visit, when indicated in the timeline 
in the schedule (American Academy of Pediatrics, 2019). 	
The following tables outlining the vaccine schedules on the CDC’s website 
(2019) are included in the Appendix: Table 1a - Recommended Child and Adolescent 
Immunization Schedule for ages 18 years or younger, United States, 2019, Table 2a - 
Catch-up immunization schedule for persons aged 4 months-18 years who start late or 
who are more than 1 month behind, United States, 2019, Table 3a - Recommended Child 
and Adolescent Immunization Schedule by Medical Indication, United States, 2019, 
Table 1b - Recommended Adult Immunization Schedule by Age Group, United States, 
2019, Table 2b - Recommended Adult Immunization Schedule by Medical Condition 
and Other Indications, United States, 2019.		
Vaccination Disasters	
 Vaccines are considered to be the most revolutionary and important medical 
discovery by many. However, it took several trials and errors to get where we are today 
in ensuring the safety of vaccinations. We can look at several cases of vaccine disasters 
throughout history and learn from them not for the purpose of discouraging vaccinations, 
but to show that there have been many mountains climbed and lessons learned that have 
all lead to the production of safe and effective vaccines that keep us healthy today (Link, 
2005).		
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Marblehead, Massachusetts, 1800	
 In July of 1800, Edward Jenner sent a sample of smallpox vaccine to Benjamin 
Waterhouse in Marblehead, Massachusetts in order to initiate a vaccine program. 
Unbeknownst to either, the vaccine that Jenner gave Waterhouse contained an attenuated 
(weakened) smallpox virus that reverted to full virulence, ultimately killing sixty-eight 
people that Waterhouse had vaccinated in an effort to protect them from smallpox (Link, 
2005).		
Bremen, Germany, 1893	
 During a smallpox vaccination campaign in the Port of Bremen in 1893, 1,289 
shipyard workers were vaccinated. But apparently the same serum was passed from one 
patient’s pustules to the next patient, causing 191 of the vaccinated men to develop 
hepatitis and jaundice, or yellowing of the liver, within eight months of the procedure. It 
was concluded that the men had experienced a form of hepatitis transferred by human 
lymph fluid, leading to our understanding now that some chronic disease can be 
transferred by blood, allowing us to further understand diseases that were caused by 
blood-borne pathogens. This marked an important discovery in medicine, but did come at 
a cost (Link, 2005).		
St. Louis, Missouri, 1901	
In 1901, diphtheria antiserum was derived from the serum of horses that had been 
immunized with the diphtheria toxin. In this particular case, the horse in which they were 
making the antiserum from had developed tetanus, and before he developed symptoms of 
the disease, his blood was drawn to prepare the diphtheria antiserum for the vaccines. 
  40 
Because there was no way to know that the horse’s blood already contained the tetanus 
toxin, twenty children who were vaccinated from the infected horse’s diphtheria 
antiserum became ill, and fourteen later died from the paralytic effects of tetanus (Link, 
2005).		
Dallas, Texas, 1919	
 This disaster was caused by another rogue diphtheria vaccine gone wrong. A new 
type of diphtheria vaccine, called TAM, was developed that contained a mixture of 
diphtheria toxin and antitoxin that was meant to stimulate antibodies but not poison the 
child because of the protective effect of just the right amount of antitoxin. However, this 
was a fine balance because if it was thrown off in the slightest bit, the child would be 
exposed to the deadly diphtheria toxin. Between October 23rd and November 13th, 1919, 
the city of Dallas Health Department injected over three-hundred children with the TAM 
diphtheria vaccine. Of these, one-hundred twenty became ill and ten later died. This 
TAM approach to the diphtheria vaccine was abandoned in the 1920s due to many deaths 
reported from the vaccine (Link, 2005).		
Lubeck, Germany, 1929	
 In 1919, tuberculosis was rampant in Europe and lead to many deaths. During this 
year, Albert Calmette, a student of Louis Pasteur’s, along with Camille Guerin, spent 
years developing a tuberculosis vaccine. They found that cow tuberculosis bacterium lost 
its virulence when grown through many generations in a medium containing bile, but that 
it could still evoke an antibody immune response in humans. So, they created a vaccine, 
the earliest of which were taken by mouth, but later given by injection. In 1929, Calmette 
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received a request for a tuberculosis culture that he and Guerin had created from the 
director of public health in Lubeck. The culture was sent, and labs in Lubeck prepared the 
vaccine and gave it to 242 children (Link, 2005). 	
Within weeks, seventy-two of these children were dead from tuberculosis. At 
first, Calmette and Guerin were blamed for the disaster, but it was later found that the 
Lubek lab directors had accidentally contaminated the cultures with a virulent strain of 
the human tuberculosis bacteria. The two men in charge of the lab were convicted of 
criminal behavior and jailed, and the Bacille Calmette-Guerin (BCG) vaccine for 
tuberculosis became used extensively worldwide (Link, 2005). 	
Bundaberg in Queensland, Australia, 1928	
 Bundaberg, a city of approximately 43,000 people, was constantly plagued by 
diphtheria at this time, so any attempt to fix the problem was welcome. On January 12th, 
1928, twenty-one children received the diphtheria vaccine and within hours became 
violently ill. Twelve later died. This disaster was not because of the vaccine itself, but 
because it had become contaminated with staph bacteria, most likely causing toxic shock 
syndrome among those who received the vaccine (Link, 2005).		
Yellow Fever II: Hepatitis, 1942	
 An epidemic of hepatitis began in March of 1942 among United States army 
personnel, ultimately leading to the hospitalization of fifty-one thousand troops during 
the next seven months and one-hundred and fifty deaths. The hepatitis emerged several 
weeks after the administration of a vaccine for yellow fever. At the time, the vaccine 
contained human blood serum, which carried the hepatitis virus. The human serum from 
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the original vaccine came from medical student volunteers, one of which was ill at the 
time of donation while several others had a history of hepatitis. This disaster is the largest 
hepatitis epidemic ever recorded (Link, 2005).		
Kyoto, Japan, 1948	
 In October of 1948, more than fifteen-thousand babies and children in Kyoto, 
Japan were injected with a diphtheria toxoid vaccine, and 606 later became ill, and 
around sixty-eight died. These deaths were caused by the diphtheria toxin not being fully 
neutralized in the vaccine (Link, 2005).		
SV40, 1950	
The mid-twentieth century was filled with constant fear of polio and prompted 
scientists to find quick solutions. When the Salk polio vaccine was finally licensed for 
use, it was given to as many as ten million people, mostly children, between 1955 and 
1963. What many did not know at the time, however, was that by receiving this vaccine, 
they were also receiving a dose of a live monkey virus called SV40. The polio vaccine 
was prepared from cultures from rhesus monkey kidneys, and unknown to scientists, the 
vaccines were contaminated with the SV40 virus that otherwise go undetected in 
monkeys (Link, 2005).	
The SV40 virus can cause cancer and is often found in various human cancers. 
So, because of the early polio vaccine, the SV40 virus was introduced into the human 
population and since then, the infection is able to be transmitted from person to person. 
So, although the original polio vaccines contained SV40, the ones made after 1963 went 
through a screening process to detect the virus, making all polio vaccines from then on 
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free of SV40. However, because the virus was already introduced into the human 
population, it has continued to spread and can still be seen in people with cancer even 
today (Link, 2005).		
The Cutter Incident, 1955	
 As mentioned previously, in the spring of 1955, the Salk polio vaccine, which had 
an inactivated polio virus, had been tested on hundreds of thousands of volunteers and 
declared safe and effective. Its licensure was welcomed reverently and was called one of 
the greatest achievements in medical science. People were overjoyed to have a 
preventative measure against the paralyzing polio virus. However, before the vaccine 
became a major success, it did have some downfalls. On April 25th, two weeks after the 
release of the vaccine, an infant with paralytic polio was admitted to a hospital in 
Chicago after being vaccinated for polio nine days before. Five similar cases were also 
reported nine days after vaccination that caused paralysis. An investigation by 
epidemiologists quickly uncovered a connection between the cases and vaccines prepared 
by Cutter Laboratories, and two days after the first case, Cutter recalled all of their polio 
vaccines (Link, 2005).	
 While this event was unfolding, a related event happened. About two weeks after 
the first wave of cases, a second, larger wave was occurring, and family and community 
members of the original group that was ill started to get sick. It was discovered that the 
Cutter vaccine contained live, virulent polio that not only infected the recipients of the 
vaccine, but also the family and community members surrounding the recipient. The 
formaldehyde step in these vaccines was done incorrectly, so the live virus was not killed. 
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The Cutter epidemic was soon contained, but it resulted in around 460 polio-infected 
children before it was all over (Link, 2005).		
Yellow Fever I: Avian Leukosis, 1960	
 Yellow fever, a viral tropical disease transmitted by mosquitoes and then man to 
man and closely resembles symptoms of the flu, had been wreaking havoc on tropical 
societies since the seventeenth century. It ultimately leads to jaundice and later death, 
which is why it was nicknamed yellow fever. It caused problems in several American 
port cities in the twentieth century, and scientists pushed to find a solution. In 1930, a 
highly effective and safe vaccine was created. It was not until 1966, however, that 
researchers realized that the vaccine had been contaminated by a bird virus, avian 
leukosis, which causes various cancers in birds and can cause cancers in humans as well. 
Millions of people received the vaccine in the 30s without obvious harm and were 
protected from yellow fever. But it is hypothesized that the avian leukosis in these early 
yellow fever vaccines could have been a contributing factor for an increased incidence of 
cancers among people twenty years after receiving the vaccination. It is not one-hundred 
percent connected, but this coincidence is important to consider when looking at the 
effects of early vaccines (Link, 2005).		
“Atypical” Measles, 1960s	
 The live measles vaccine was licensed in 1963 in addition to a killed, inactivated, 
version of the vaccine. People usually preferred the killed virus vaccine at this time 
because it just seemed like the safer option, but that was not always the case. Tested on 
children, the killed vaccine showed that there was a brisk antibody response with minimal 
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side effects, so it was widely used. However, within a year or two, measles cases began to 
pop up in immunized children and isolated epidemics began to occur. This killed vaccine 
was not preventing measles, and it was discovered that the reason behind it was that the 
antibodies rapidly disappeared in the vaccinated children, so by one year later, the 
children were no longer protected, even after booster doses (Link, 2005).	
 In 1967, Vincent A Fulginiti, a pediatrician at the University of Colorado in 
Denver, reported on a series of children who contracted measles five years after 
vaccination, saying that these children had a “new disease termed atypical measles” (p. 
32). The symptoms of this atypical strain were high fever lasting four to seven days, 
headache, muscle pain, severe pneumonia, pleurisy and a rash that spread from the feet to 
the neck. They became ill enough to need hospitalization but recovered. In addition, most 
children who had developed this “atypical” measles had received the live virus vaccine 
after being immunized with the killed vaccine, causing the harsh reaction to the live 
vaccine. It was later theorized that the killed vaccine had somehow sensitized the children 
to the measles virus so that they were able to get the atypical strain when exposed to the 
live measles vaccine. After this development, Fulginiti wrote, “It is our conclusion that 
no healthy child should electively receive killed-measles vaccine” (p.33) and the vaccine 
was withdrawn from production. Since then, the atypical measles virus has not been seen 
again (Link, 2005).		
Swine Flu Fiasco, 1976	
 In the winter of 1976, an epidemic of respiratory infections affected around five-
hundred soldiers at Fort Dix in New Jersey. One of the soldiers became critically ill and 
died within twenty-four hours, and it was determined that a strain of the flu virus was 
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responsible that closely resembled the 1918 strain that infected 20 million people 
worldwide. The possibility of another pandemic influenza like 1918 alarmed health 
officials, but there were only cases of this new strain present at Fort Dix. Nevertheless, 
the Centers for Disease Control and Prevention (CDC) recommended a national swine flu 
immunization policy, presenting President Ford with a $136 million plan to immunize 
every person in the United States (Link, 2005).	
 There was tremendous pressure on vaccine companies to produce this much 
product, and it did not help that the insurance companies refused to provide liability 
coverage for vaccine manufacturers. The vaccine production companies refused to 
distribute the vaccine without liability protection, but, the political pressure was too 
strong, and Congress passed the Swine Flu Act of 1976, which provided for the federal 
government to assume the liability for any vaccine mishaps. The first batch of the new 
vaccine produced no antibodies to swine flu as the CDC had given the manufacturer the 
wrong strain of the flu virus, causing two-million useless doses to be wasted. Subsequent 
batches of the virus only provided adequate antibody levels when large doses that 
produces many side effects were used (Link, 2005).	
 Eventually, the program started on October 1st, and two weeks later, three elderly 
people in Pittsburgh, Pennsylvania died within hours of receiving the swine flu vaccine. 
The Program was then suspended in Pennsylvania and in several other states, but the 
program was still recommended by the CDC and President Ford, so it persisted 
everywhere else. A month later in November, reports came in of people suffering from 
neurological damage, later identified as Guillain-Barre syndrome (GBS), after receiving 
the swine flu vaccine. This disease can cause paralysis and death if not properly treated. 
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This GBS epidemic put an end to the swine flu immunization program and it officially 
ended on December 6th, 1976. The whole program started with a reasonable concern that 
a flu pandemic might occur from the flu occurring in Fort Dix, but it was soon taken too 
seriously and blown up to monstrous proportions, in the end causing fifty-three deaths 
among the 43 million who were vaccinated. Most GBS patients made a full recovery, but 
it could have been much worse (Link, 2005).		
Jordan, 1998	
 On September 28th, 1998, the annual Jordanian process of immunizing children 
began with the start of the school year. A day later, two boys came to school complaining 
of being dizzy and fainted. Health officials arrived, and twenty other students had also 
fainted from the mysterious illness. By the end of the day, eighty students were 
hospitalized and by the next day, that number rose to 122. All had been vaccinated with a 
well-established tetanus and diphtheria (DTaP) vaccine and all were home and healthy 24 
hours after falling ill (Link, 2005).	
 All of the children affected had received the vaccine the day before, and no child 
who did not get the vaccine was affected. One batch of the vaccine was associated with 
more cases than other batches, and of the first fifty-five children, 58 percent had fever, 15 
percent had chest tightness and needed oxygen, and 13 percent had abnormal EKGs. 
Most of the symptoms were mild and were symptoms that were often associated with this 
type of DTaP vaccine, so one or two children with these symptoms would not have raised 
much concern. It seemed that the vaccine itself did not cause the illness among all these 
children, but rather, the panic from the school staff that caused the children to act in a 
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way that looked as if they became ill. It was determined that this was biologically 
impossible that all of these children became sick at the same time, and that the reaction of 
the school staff to the first two boys who were actually sick prompted more children to 
“fake it” essentially. So, it was concluded that there was no unusual adverse reaction to 
this vaccine after all (Link, 2005).		
China, 2002	
 China has an active immunization program, but something went wrong in 2002 in 
the city of Mishan. 8,300 children aged seven through sixteen received the killed-virus 
Japanese encephalitis vaccine. Japanese encephalitis is a mosquito-borne viral illness that 
is very common in Asia. A majority of infections cause no symptoms or just a flu-like 
illness, but in some cases, encephalitis, or swelling of the brain, can occur, causing severe 
brain damage and often death. After the immunization of the 8,300 children, nine-
hundred were hospitalized, and some became seriously ill. It is not clear what had exactly 
happened, and researchers are still looking into this vaccine disaster (Link, 2005).		
Vaccines for the Future	
In his 2010 article, Gary Finnegan asked the important question, “The 
development and widespread adoption of vaccines has been hailed as the public health 
triumph of the 20th century, but what does the future hold?” We have seen the successes 
of vaccines in combating infectious diseases like polio and smallpox. However, what 
does the future hold for the prevention of other diseases such as cancers, tuberculosis, and 
Alzheimer’s? 	
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Gregory Poland and Alan Barrett, at the Mayo Clinic and the University of Texas 
Medical Branch respectively, published an article in 2009 outlining the successful 
vaccines of the 20th century and approaches for making future vaccines for important 
disease of the 21st century. In this article, they outline that in the twentieth century, 31 
vaccines that prevented acute infectious diseases were licensed in the United States and 
that in the twenty-first century, the challenge of developing vaccines for chronic 
infectious and noninfectious diseases is becoming increasingly important as morbidity 
and mortality due to these conditions are becoming an ever-increasing public health 
problem, with ensuing hefty economic costs to Americans. Poland and Barrett agree that 
in the twenty-first century, the approach to how we make vaccines needs to change in 
order to combat these different illnesses, and that the approach includes enhancing the 
immune response of vaccines through three different approaches: adjuvants, prime-
boosting strategies, mucosal immunity, and also through the addition of therapeutic 
vaccines for chronic diseases (Poland & Barrett, 2009).	
The first approach to improving immunogenicity, which is the ability of a vaccine 
to provoke an immune response in the body, as laid out by Poland and Barrett (2009) is 
through adjuvants and the increased use of them to have this immune response. Second is 
the use of prime-boost regimens, which when used in heterologous vaccines can improve 
immunogenicity greatly in both chronic infectious and noninfectious diseases. Next is 
mucosal immunity, which is important when we consider the effectiveness of nasal and 
oral vaccinations that can continue to be used and developed in the 21st century. Lastly, 
therapeutic vaccines have started to become more popular in the hope that chronic 
noninfectious diseases such as Alzheimer's can be prevented. These therapeutic vaccines 
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have been developed to target plaque buildup between neurons in the brain, which 
degenerates the brain and can lead to Alzheimer’s. These have not been super successful, 
but they are something to consider when we think about the potential for vaccines in the 
future (Poland & Barrett, 2009).	
 The growing cost of caring for our aging population, where noninfectious diseases 
like Alzheimer’s and dementia are becoming increasingly common, is creating a new 
need in the evolution of vaccines. But, the complexity of these diseases makes it hard for 
vaccines to be created. In addition, vaccines for cancer are always being researched. The 
HPV vaccine created hope that other cancer vaccines can be created, but they are often 
much more complicated, which is why we do not have vaccines for cancer - yet. 
Additionally, scientists are constantly battling the human immunodeficiency virus (HIV) 
and yearning for a vaccine solution, but because HIV is a viral infection, it presents a new 
set of challenges (Finnegan, 2010)	
 The National Institute for Allergy and Infectious Diseases (2008) also has ideas 
for vaccines for the future, mentioning that vaccines delivered through a needle have 
shortcomings, including that they must be kept sterile and must be administered by 
medically trained personnel, making vaccination measures somewhat challenging in the 
case of a widespread outbreak. Because of this, scientists are investigating new ways to 
deliver vaccines, including through the use of edible vaccines, patch and nasal mist 
vaccines, and universal and therapeutic vaccines (The National Institute for Allergy and 
Infectious Diseases, 2008). Overall, the success of vaccine development in the twentieth 
century has laid the groundwork for the battle against infectious diseases and the attempt 
to control chronic infectious and noninfectious diseases in the 21st century (Poland  
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& Barrett, 2009).	
It is clear that in the twentieth century, vaccination was known as the greatest 
revolution in health. Mixed with the success of increased hygiene habits among people 
and the development of antibiotics, vaccination led to the elimination of many childhood 
infectious diseases in America (Rappuoli, 2011). In the twenty-first century, the hope is 
that vaccination will fully eradicate remaining childhood infectious diseases, but this goal 
does come with challenges. As the anti-vaxx movement has swept across the globe, the 
question of why people resist vaccination needs to be discussed in order mitigate the 
resistance towards vaccines that many have. Additionally, the question of what policies 
can be introduced to mitigate this resistance and that aim to increase public trust in 
vaccination needs to be discussed so that vaccines can be perceived among all as the best 
way to keep out country and our world healthy.													
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Chapter 4	
Findings	
 
Evolution of Vaccine Resistance	
 Fear of vaccines and myths against them are not a new phenomenon. In fact, 
opposition to vaccines can be seen as far back as the eighteenth century in England, when 
Reverend Edmund Massey called vaccines “diabolical operations” in his 1772 sermon, 
“The Dangerous and Sinful Practice of Inoculation.” The main argument at that time was 
that vaccines went against God’s plan, and similar opposition was seen in Massachusetts 
around the same time with Reverend John Williams, who said that vaccines were the 
devil’s work. However, opposition began to shift from religious arguments to political 
and legal arguments a century later (A. Hussain, Ali, Ahmen, & S. Hussain, 2018).	
In the mid nineteenth century, there was growing attention toward the new idea of 
public health after the introduction of the first vaccine by Edward Jenner. Local and 
national governments became interested in the health of the people living in their 
communities and countries for many reasons, but mainly due to the fears that disease 
would lead to a breakdown of the social, religious and economic order (Blume, 2017). 
So, many governments began initiating vaccine programs and vaccinated a majority of 
their citizens.	
 In the 1830s after an initial generation had been vaccinated and the incidence of 
smallpox declined in the United States and in Europe, the first anti-vaccination, or anti-
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vaxx movement, emerged (Stern & Markel, 2005). The unpopularity of vaccination was 
due in part to the procedure itself in that it involved scraping the arm to break the skin 
before applying the vaccination to the open wound. It was often badly done and left 
people with large scars (Blume, 2017). Others opposed the method because they 
considered vaccination as an intrusion of privacy and bodily integrity or because they had 
sanitary, religious, scientific, or political objections (historyofvaccines.org, 2018). Two 
primary themes can be seen throughout anti-vaxx movements of the past and even the 
present: first, the perception that vaccines cause more harm than the diseases that they 
were made to prevent, and second, the close association between promotion of vaccines 
and the introduction of compulsory vaccination policies (Schwartz, 2012).	
The first compulsory vaccination law for smallpox was passed in 1827 in the 
United States in Boston, Massachusetts, requiring the smallpox vaccination in order for 
children to attend school. After the introduction of this policy in Boston, the practice 
spread throughout the country and the world by the end of the nineteenth century 
(Schwartz, 2012). In 1853 in England, a similar compulsory vaccination law, entitled “the 
Vaccination Act of 1853” was passed and required vaccination for infants up to three 
months old, and the Act of 1867 extended this age requirement to 14 years, adding 
penalties for vaccine refusal (historyofvaccines.org, 2018). Parents or guardians who 
failed to vaccinate their children in their first three months of life were subject to fine or 
imprisonment. Although the number of cases of smallpox were steadily decreasing, a 
number of people spoke out publicly against compulsory vaccination, either because they 
thought the inoculation method was unsafe or because they opposed the involvement of 
the government in the field of health, especially when it came to the decisions about 
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one’s body. The opposition continued, but similar compulsory laws were put into place in 
other European countries anyway. For example, in the Netherlands, despite objections 
from Protestant communities, a law was created in 1872 that required proof of 
vaccination before a child could be admitted to school. Because of this policy, the rate of 
vaccination rose to ninety percent (Blume, 2017).	
In Germany, there had been ideas that the health of a population wasn't the 
responsibility of the state. However, opinions gradually shifted to favor compulsory 
vaccination to model what other countries had successfully been doing, and the Imperial 
Vaccination Law of 1874 made vaccination compulsory in Germany. Other countries 
such as the United States, India, and Brazil followed suit and also created their own 
compulsory vaccination laws, but they were still met with some opposition (Blume, 
2017).	
The original anti-vaxx organization, the Anti-Compulsory Vaccination League 
was established in the United Kingdom in 1866 to protest the compulsory smallpox 
vaccination laws. In the United States, the Anti-Vaccination Society of America was 
formed in 1879 and the American Medical League was founded a few years later. There 
are some similarities and differences between the opposition to vaccination in different 
periods of history. In the 19th century, vaccine resistance was mainly due to the concern 
about the safety and efficacy of vaccines, which was a largely unregulated industry at the 
time, coupled with the opposition of the extension of government into the lives of 
citizens. At this time, the opposition was mainly aimed at the smallpox vaccine, because 
it was the only one available (Vanderslott & Roser, 2015). Even though there was 
opposition to these laws, nations responded by articulating that they possessed the right to 
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protect the common good and the health of all citizens, further advocating for compulsory 
vaccine laws. The reasons for opposition shift in the 20th and 21st centuries will be 
mentioned in a later section. 		
Court Cases	
By the beginning of the twentieth century, nearly half of the states in the United 
States had requirements for children to be vaccinated in order to attend school (Malone & 
Hinman, 2003). In 1902, following a smallpox outbreak in Cambridge, Massachusetts, 
the Board of Health of the City of Cambridge mandated all city residents be vaccinated 
against smallpox. Henning Jacobson, a Cambridge resident, refused vaccination, saying 
that the law violated his right to care for his own body. In turn, the City of Cambridge 
filed criminal charges and was persecuted in the local court system. After losing his court 
battle in the local court, Jacobson appealed to the United States Supreme Court 
(historyofvaccines.org, 2018).		
Jacobson v. Massachusetts, 1905	
In 1905, the U.S. Supreme Court, in Jacobson v. Massachusetts, ruled in favor of 
the State of Massachusetts’ compulsory vaccination law, citing that the need to protect 
the public’s health through mandating the smallpox vaccine outweighed an individual’s 
right to choose. This was the first U.S. Supreme Court case concerning the power of 
states in public health law (historyofvaccines.org, 2018). The Court held that a health 
regulation requiring the smallpox vaccination was a reasonable exercise of the State’s 
power and did not violate the rights of individuals under the Fourteenth Amendment to 
the U.S. Constitution because “such reasonable regulations established directly by 
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legislative enactment as will protect the public health and the public safety.” The Court 
also rejected the idea of vaccine exemption because it “would practically strip the 
legislative department of its function to care for the public health and the public safety 
when endangered by epidemics of disease” (Malone & Hinman, 2003). This tenet of 
protecting the health of the public over the right of the individual has been consistently 
reiterated in the argument for vaccines, bolstering the idea of “herd immunity,” which is 
when a high percentage of a population, usually around 85-90%, are vaccinated in order 
to protect the entire population and those who are unable to be vaccinated within a group 
(Stern & Markel, 2005).	
 Following the 1905 Supreme Court Ruling in Jacobson v. Massachusetts, there 
was even more opposition. A 1906 news report from Yolk, Pennsylvania, entitled 
“Vaccination Stirs Revolt,” reported “Threats to burn schoolhouses, whip teachers, and 
punish school directors have been the outcome of the enforcing of the compulsory 
vaccination law” (Schwartz, 2012). People were upset that they had to get vaccinated for 
various reasons, but the health of the general population was at stake, which is why these 
compulsory laws remained in effect. 		
Zucht v. King, 1922	
 In 1922 with Zucht v. King, the Supreme Court addressed the constitutionality of 
vaccination requirements once again. The Court denied a due process Fourteenth 
Amendment challenge to the constitutionality of city ordinances that exclude children 
from attending school for not providing evidence of vaccination, holding that “these 
ordinances confer not arbitrary power, but only that broad discretion required for the 
protection of the public health” (Malone & Hinman, 2003). In this case, the Supreme 
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Court unanimously upheld the local government’s mandate requiring vaccination for 
public school attendance, giving precedent for state and local municipalities to develop 
their own standards for immunization requirements, allowable exemptions, and 
enforcement mechanisms (Feemster, 2018).		
Commonwealth v. Green, 1929	
In October of 1929, a court case in the Massachusetts Supreme Judicial Court 
entitled Commonwealth v. Green outlined a case in which a parent refused to vaccinate 
his children and therefore did not send them to school. In this case, the defendant was 
convicted of failing to send his two children to school, saying that “he refused to have his 
children vaccinated and that he knew that the authorities would not allow them to attend 
school unless vaccinated.” The conviction was upheld by the court, and data collected 
showing “Deaths During Week Ended November 30, 1929” was attached to the record in 
an attempt to show the importance of compulsory vaccine laws in hopes of decreasing 
opposition (Court Decisions Relating to Public Health, 1929).		
Prince v. Massachusetts, 1944	
Further authority to require the vaccination of children came under the parens 
patriae doctrine, which asserted the authority of states over child welfare. In 1944 in the 
case of Prince v. Massachusetts, the Supreme Court summarized the doctrine, saying	
Neither rights of religion nor rights of parenthood are beyond limitation. Acting to 
guard the general interest in youth’s well-being, the state as parens patriae may 
restrict the parent’s control by requiring school attendance, regulating or 
prohibiting the child’s labor, and in many other ways. Its authority is not nullified 
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merely because the parent grounds his claim to control the child’s course of 
conduct on religion or conscience. Thus, he cannot claim freedom from 
compulsory vaccination for the child more than for himself on religious grounds. 
The right to practice religion freely does not include liberty to expose the 
community or the child to communicable disease or the latter to ill health or 
death. (Malone & Hinman, 2003, p. 273).	
In this case, the Court’s ruling had large implications for a parent’s right to refuse 
vaccination for their children based on religious beliefs. The case focused on a Jehovah’s 
witness parent who claimed the right to have her child distribute religious pamphlets on 
the street, and the Court ruled this as a violation to child labor laws, saying that religious 
freedom did not trump child labor laws. By doing this, the Court also spoke on vaccine 
refusal and religious beliefs, as stated above (Feemster, 2018).	
 This case also points back to the Fourteenth Amendment’s equal protection 
clause, and that every person, including children, should have equal protection from 
harm. So, because vaccines are meant to protect one from the harm of vaccine-
preventable diseases, the clause implies that a decision not to vaccinate a child violates 
that child’s right to be protected. Even with these precedents, immunization requirements 
did not become a central feature of United States vaccine policy until the 1960s and 
1970s, when states began to enact legislation in response to measles outbreaks. Prior to 
that time, many health departments only required immunization in response to outbreaks, 
not to prevent them before they started. Now, state legislatures require vaccination as a 
condition of school attendance to prevent outbreaks of vaccine-preventable diseases 
(Feemster, 2018). 
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Return to Vaccine Policy: Peace and Protest	
In the 1920s and 1930s, the Anti-Vaxx movement rose to new heights as 
progressive thinking took over, leading many to mistrust the growing medical profession 
and dislike the change in the government’s role as it began to interfere more in the lives 
of citizens. This, coupled with the Great Depression, made many believe that the 
government and the medical profession had no right in telling its citizens what they can 
and cannot do. However, anti-vaccine thinking began to decline in the 1940s for three 
reasons: a boom in medical knowledge, specifically in vaccine science, discovery and 
manufacturing; increased public awareness of widespread infectious disease outbreaks 
and the need to protect children from the threat of disease; and a baby boom coupled with 
increasing levels of education and wealth among people. All of these things led to more 
public acceptance for vaccines in the 40s and resulted in lower levels of disease 
outbreaks, illnesses, and deaths (Poland & Jacobson, 2011). In the years leading up to the 
1960s, a series of new vaccines that prevented polio, measles, mumps, and rubella, were 
developed, and they were greeted with great enthusiasm by parents who lived in fear that 
their children could be sickened (Conis, 2019). By 1963, twenty states, the District of 
Columbia, and Puerto Rico had compulsory vaccination laws for several different types 
of vaccinations, requiring children to be vaccinated in order to be able to attend school 
(Malone & Hinman, 2003). 	
As the 1960s began, public health officials believed that because new vaccines, 
especially the polio vaccine, were greeted with such positivity in the past, that these new 
vaccines would attract the same enthusiasm (Conis, 2019). However, they were wrong. 
As the prevalence of disease began decreasing, so did the belief among the public that 
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vaccines were important and necessary, leading many to disregard getting their children 
vaccinated (Poland & Jacobson, 2011). Families that were used to living with the threat 
of measles dismissed the new vaccine against the disease thinking it wasn’t necessary, 
and middle-class parents usually only got their children vaccinated with these new 
vaccines if the family doctor recommended, which did not always happen (Conis, 2019). 	
This sentiment among the public, along with the development of more vaccines 
and the addition of them to the vaccine schedule, as well as the media perpetuating the 
dangers associated with vaccines, led to the anti-vaxx idea to once again spread and 
flourish in the 1970s (Poland & Jacobson, 2011). This shift in the nation’s vaccine 
agenda coincided with an increase in social movements that encouraged Americans to 
question authority and sources of expertise in the medical practice. Women pushed back 
against the patriarchy, environmentalists pushed back against the nation’s growing 
industry, and patients pushed back against doctors as the vaccine schedule and 
compulsory laws expanded, causing a growing number of pushback against vaccines. The 
prevalence of infectious diseases began to increase once again among all classes, lower, 
middle and upper. As health officials tried to revamp the vaccine rates in order to 
decrease these infection rates through promotional propaganda, they realized that their 
plan was not working, and ultimately decided to return to implementing policies that 
required vaccination (Conis, 2019).	
This signaled a new era of vaccination in the United States for four reasons: the 
federal government was assuming an increasingly prominent role in determining 
vaccination policy; vaccines increasingly targeted diseases that medical experts once 
considered “mild”; vaccination campaigns aimed not to just reduce disease, but to 
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eradicate it; and an increasing reliance on the vaccination of children through mandatory 
school vaccination laws in order to ensure a society free of preventable infectious disease 
(Conis, 2019). In the 1970s, states that had compulsory vaccination laws for the measles 
vaccine in place for children to attend school had measles incidence rates that were forty 
to fifty percent lower than states without compulsory vaccination laws. In 1976 and 1977, 
there were measles outbreaks in Alaska and Los Angeles, leading health officials to more 
strictly enforce these compulsory vaccine laws in these areas (Malone & Hinman, 2003).	
Once enforcement began in Alaska, 7,418 students out of 89,109 total students, or 
around eight percent, failed to provide proof of vaccination and were not allowed to 
attend school. One month later, only fifty-one students still had not been vaccinated and 
were still unable to attend school, and no further cases of measles occurred. On the other 
hand, in Los Angeles, approximately 50,000 students out of 1.4 million total students, or 
four percent, were unvaccinated. After most were vaccinated and returned to school, the 
number of measles cases dropped dramatically, demonstrating that compulsory 
vaccination laws could be enforced and were effective (Malone & Hinman, 2003).	
Because vaccination levels in children were declining everywhere throughout the 
United States at this time, not just in Alaska and Los Angeles, a nationwide vaccination 
program, called the Childhood Immunization Initiative, was created in 1977 to attempt to 
raise vaccination levels to ninety percent by 1979. This initiative supported the enactment 
and enforcement of school vaccination requirements, and during a two-year period, more 
than 28 million records of schoolchildren were reviewed, and the vaccination process 
began. An analysis of six states that strictly enforced compulsory vaccine laws during the 
1977-1978 school year compared to the rest of the United States showed incidence rates 
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of disease that were half of those of the rest of the country. A school year later after the 
Childhood Immunization Initiative was put into place, the incidence rates were less than 
one-tenth of those of the rest of the country. By the 1980-1981 school year, all fifty states 
had compulsory vaccine laws, and since 1981, vaccination levels in schools have been 
95% or higher for the DTaP, polio, and MMR vaccines (Malone & Hinman, 2003).	
In the 1970s and 1980s, the diphtheria, tetanus, and pertussis vaccine was 
questioned in connection with permanent brain injury, but studies showed no connection 
(Vandersloot & Roser, 2015). However, the public was still scared of these claims, and a 
1982 television documentary, entitled DPT: Vaccination Roulette, became a turning point 
in the modern history of vaccine safety controversies. The program featured emotional 
stories of children believed by their parents to have been harmed by the diphtheria, 
tetanus, and pertussis combination vaccination (Schwartz, 2012). 	
This program led to a national debate on the use of the vaccine, even though the 
program was just a collection of unproven claims. However, it led to many countries 
stopping their DPT vaccination programs as public protests became strong, leaving 
behind a period in which pertussis had been well-controlled through vaccination. 
Countries that dropped routine pertussis vaccination due to this program had a large 
increase in the incidence of pertussis compared to countries that retained their high 
immunization rates. Ultimately, these countries that eliminated their vaccine programs 
ended up reinstating them (Poland & Jacobson, 2011) One of the groups that came from 
the popularity of Vaccine Roulette was called Dissatisfied Parents Together, which was a 
group of parents that advocated for safer vaccines, greater government oversight over 
vaccination, and federal compensation for the families of children harmed by vaccines. 
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This group helped to pass the National Childhood Vaccine Injury Act of 1986 (Conis, 
2019). 
 
The Anti-Vaxx Movement Reaches New Heights	
 As the 1990s approached, the anti-vaccination movement continued to accelerate 
due to a few reasons. First, the chickenpox, hepatitis A, and rotavirus vaccines were 
licensed in this decade, and many parents believed that the diseases that these vaccines 
prevented were minor and became increasingly skeptical about the necessity of the 
continued use of vaccines. Secondly, during this time, people began to become more 
concerned about chemicals in processed foods and in the environment, and they also were 
more concerned about the ingredients in vaccines. In this decade, the demand for organic 
and natural products increased dramatically. Third, the passage of the 1994 Dietary 
Supplement Health and Education Act required the United States Food and Drug 
Administration to regulate nutritional supplements as foods rather than apply more 
regulations on them used to verify the safety of pharmaceutical drugs. So, demand for 
nutritional and herbal remedies exploded among consumers who thought they were safer 
than traditional drugs and could be used to replace them. Fourth, the practice of 
alternative medicine including holistic healing, chiropractic medicine, herbal treatments, 
and others became more popular. Lastly, purchasing home computers became more 
affordable, making the internet available to more people. So, families began having easy 
access to the internet from their own homes and public blogs and websites became 
common ground where people shared information on certain topics, allowing anti-
vaxxers to connect and further promote their views over the web (Davidson, 2018).	
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Andrew Wakefield’s 1998 Study	
 These factors helped to gather more support for the anti-vaxx movement in the 
1990s, but it did not stop there. In 1998, a spark came that lit the fuse to the anti-vaxx 
movement that continues around the world until this day, and that spark came from a 
member of the traditional medical community (Davidson, 2018). British physician and 
researcher Andrew Wakefield ignited the controversy over the link between vaccines and 
autism when he announced that he had uncovered evidence that the measles, mumps, and 
rubella (MMR) vaccine inflamed and damaged the digestive systems of children, 
allowing toxins and chemicals to enter the bloodstream and damage the brain, leading to 
autism (Goldberg, 2010). 	
As a researcher at the Royal Free Hospital in London, Wakefield called a press 
conference to announce the findings of the research conducted by him and twelve 
colleagues that showed that the MMR Vaccine was associated with the development of 
autism and intestinal problems in children. He specifically identified the measles 
component of the combined MMR vaccine as the problematic element. The British media 
treated his announcement as credible and newsworthy because the research was 
published in the credible, peer-reviewed journal, The Lancet, and the news spread like 
wildfire (Davidson, 2018).	
The story spread across Europe, Australia, Japan and eventually landed in the 
United States (Davidson, 2018). The damage was done, and the MMR vaccine rates 
began to plummet in Britain, Ireland, the United States, and in several other countries 
(Poland & Jacobson, 2011). The vaccination rate fell to 70% in the United Kingdom after 
the announcement of Wakefield’s study, with rates as low as 50% in some areas that used 
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to be around 90% previously. Measles began to reemerge in communities with low 
vaccination rates, and doctors tried to reassure the population that the MMR vaccination 
was safe, but did not succeed (Goldberg, 2010).	
In the original paper, Wakefield and his twelve co-authors claimed to have 
investigated a “consecutive series” of twelve children referred to the Royal Free Hospital 
and School of Medicine with chronic enterocolitis and regressive developmental 
disorders. The study reported that the parents of the children associated their loss of 
acquired skills, including language, with the MMR vaccination. The authors concluded 
that “possible environmental triggers,” or the MMR vaccine, were associated with the 
onset of both the gastrointestinal problems and the developmental mental regression, or 
autism (Eggerston, 2010).	
In reality, the published research did not support Wakefield’s conclusion that the 
MMR vaccine was linked to autism and other gastrointestinal issues (Davidson, 2018). 
Six years after the research was published, concerns began to circulate about the conduct 
and methods of the study. In March of 2004, ten of the paper’s thirteen authors, excluding 
Wakefield, retracted the “interpretation” section, which claimed an association between 
MMR, enterocolitis, and regressive developmental disorders, or autism (Laurance, 2013). 
When The Lancet asked for more information on the research from the Royal Free 
Hospital, where Wakefield conducted the study, Professor Humphrey Hodgson, the then 
vice-dean of the Royal Free and University College School of Medicine, wrote back to 
the journal, saying “We are entirely satisfied that the investigations performed on 
children reported in the Lancet paper had been subjected to appropriate and rigorous 
ethical scrutiny” (Boseley, 2010).	
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Two years later, in 2006, measles outbreaks occurred across Britain, and the first 
death in the United Kingdom from measles in fourteen years was reported (Laurance, 
2013). The anti-vaxx movement was becoming more and more dangerous as more people 
began refusing vaccinations due to the fears associated with them. Many scientists and 
medical doctors were still questioning Wakefield’s research, and the General Medical 
Council (GMC) opened a case against the study and its authors in July of 2007, alleging 
serious professional misconduct by Dr. Wakefield and two co-authors of the study 
(Laurance, 2013). Although Wakefield’s research was being accepted by many around 
the globe, other scientists and researchers were unable to duplicate his findings and 
questioned his results and methodology (Goldberg, 2010).	
It was later discovered by the GMC disciplinary panel that the study was “utterly 
false,” and that children had been subjected to invasive procedures that were not 
warranted, and that they had undergone lumbar punctures and other tests without ethical 
approval (Boseley, 2010). In addition to the highly unethical practices used to gather 
data, Wakefield’s sample for his study was extremely small and included only twelve 
children, making it nearly impossible to determine if a pattern was valid or simply 
coincidence. When other scientists began to look more closely at the research, they found 
that most of the children in the study had intestinal issues prior to receiving the MMR 
vaccine. It was also found that the theory in the study was scientifically implausible for 
two reasons: first, measles is not correlated with autism, and second, only a small number 
of children with autism also have gastrointestinal issues, which eliminated the possibility 
that MMR was a major trigger of autism (Goldberg, 2010).	
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The General Medical Council also uncovered that the children what were 
included in Wakefield’s study were carefully selected and some of the research was 
funded by lawyers acting for parents who were involved in lawsuits against vaccine 
manufacturers. The GMC ultimately found that Wakefield had acted unethically and had 
shown “callous disregard” for the children in his study, upon whom invasive tests were 
performed (Eggerston, 2010). On February 2nd, 2010, nearly twelve years after the study 
was first published, The Lancet retracted Wakefield’s study following the GMC’s 
decision that Wakefield had been dishonest. The Lancet’s editor, Richard Horton, stated 
that “It was utterly clear, without any ambiguity at all, that the statements in the paper 
were utterly false… I feel I was deceived” (Boseley, 2010).	
Although the study was finally retracted and Andrew Wakefield was stripped of 
his medical license, by the time the scientific community studied and rejected the MMR-
autism connection, Wakefield’s theory had already been publicized worldwide 
(Davidson, 2018). Over the twelve years it took to disclaim Wakefield’s arguments and 
mark them as completely invalid, his ideas were fueled by speeches and public 
appearances in which Wakefield recommended single vaccines rather than the combined 
MMR, and many parents seeking a cause for their children’s illness, such as autism, 
jumped upon the opportunity to blame it on a routine vaccination. Dr. Suzanne Lewis, a 
pediatrician and clinical professor of medical genetics at the University of British 
Columbia in Vancouver, said “I was quite thankful to see the retraction, it’s long 
overdue… why The Lancet published it is completely beyond me, the risk-benefit 
equation was really tipped the wrong way by this research that was so egregious” 
(Eggerston, 2010). She also mentioned that tens of millions of dollars were spent on 
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additional studies to validate or disqualify the original Wakefield study (Eggerston, 
2010).	
This was not the first time Wakefield published a faulty study. In 1993, he blamed 
measles for Crohn's disease, but his findings were impossible to replicate, leading to his 
results being killed before even having the chance to be published. His strategy in using a 
press conference to announce his results in 1998 to announce a said link between 
vaccinations and autism worked devastatingly well (Goldberg, 2010).	
Despite the study being deemed fraudulent, many autism advocacy groups and 
parents continued to defend Wakefield on websites such as one called Generation 
Rescue, which was a group founded by actors Jenny McCarthy and Jim Carrey who used 
their platforms as celebrities to further the idea of a link between vaccines and autism. In 
addition, the “conspiracy theory” that the manufacturers of vaccines were hiding the truth 
about the MMR vaccine and autism was fueled by parents wanting an answer to the 
causes of autism, according to Margaret Spoelstra, executive director of Autism Ontario. 
Spoelstra mentioned, “We know that autism has a genetic cause and that there are 
environmental factors that we don’t understand yet… there’s enormous pressure in the 
field to come up with those answers” (Eggerston, 2010).		
Other Vaccine Fears: Thimerosal and RotaShield	
 At the same time that the anti-vaxx movement was being fueled by Andrew 
Wakefield’s false study, there were also two other events that added to the vaccine 
debate, the first being the concerns over thimerosal. When the public became aware that 
some vaccines contained a preservative called thimerosal, which helps to keep vaccines 
contaminate-free but also is about 50% mercury be weight, many had concerns. Mercury 
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in some forms, although not in the form found in thimerosal, is known as a neurotoxin, 
which is why this issue quickly became connected with Wakefield’s claims of the link 
between vaccines and neurological problems such as autism. Soon, people were claiming 
that the MMR vaccine caused autism because it contained thimerosal (Davidson, 2018).	
Thimerosal had been used without controversy since the 1930s, and it came to the 
attention of the public after the Food and Drug Administration, with the support of the 
National Institutes of Health, the Centers for Disease Control and Prevention, the 
American Academy of Pediatrics, and the American Academy of Family Physicians, sent 
a letter to vaccine manufacturers requesting that they remove the ingredient from 
vaccines. Congressional hearings were held on the issue and were covered widely by the 
press, and by 2001, manufacturers no longer added thimerosal to vaccines in the United 
States for children under six years of age, except for the influenza vaccine (Davidson, 
2018)	
After an analysis found that children could get up to 187.5 micrograms of 
mercury from vaccines in their first six months, concerns were struck among many. 
However, even after the CDC recommended with the other organizations to take 
thimerosal out of vaccines, others on the CDC’s vaccine advisory committee believed 
that thimerosal was safe at the levels found in vaccines and that suggesting that it was not 
would lead to a decline in immunization. At the same time, the European Medicines 
Agency (EMEA), after a thorough investigation, announced that there was “no evidence 
of harm to children caused by the level of thimerosal in vaccines currently being used and 
that it was imperative for vaccination to continue in accordance with national 
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immunization schedule to prevent disease outbreaks.” However, they also mentioned that 
to ease public concern, thimerosal should be phased out of vaccines (Goldberg, 2010).	
By 2002, in the United States, only some flu shots still contained more than a 
trace amount of thimerosal, even though it had never been proved that there was a link 
between this ingredient and autism. Nevertheless, during the years following the removal 
of thimerosal from vaccines, the anti-vaxx movement still persisted, taking a massive 
online presence and in other forms of media, allowing more and more to question 
vaccines. Because of this, vaccine rates in some areas in the United States fell below 90-
95%, which is what was needed in order to retain herd immunity, which prevents diseases 
from spreading in a community if they are introduced and protects those who are unable 
to get vaccinated for medical reasons (Goldberg, 2010).	
Anti-vaxxers were not satisfied even after the ingredient thimerosal was removed 
from vaccines, and they continued to demand proof that vaccines do not cause autism. In 
2005, journalist David Kirby published Evidence of Harm-Mercury in Vaccines and the 
Autism Epidemic: A Medical Controversy that kept the vaccine-autism debate in the 
public eye. It claimed that because scientists were not able to prove definitively at the 
time that MMR did not cause autism or other harm that it was still possible that it did 
(Davidson, 2018).	
The second incident that sparked concern over vaccine safety after Wakefield’s 
study and the concerns over thimerosal had to do with the RotaShield vaccine. The 
RotaShield vaccine protects against rotavirus, which is a disease that causes severe and 
sometimes fatal diarrhea and dehydration in infants. In 1999, the vaccine was voluntarily 
withdrawn from the market after data suggested that in infants, RotaShield slightly 
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increased the chance of intussusception, which is a rare condition in which one part of the 
bowel folds in on itself, causing life-threatening problems if not treated. Although this 
was extremely rare, anti-vaxx parents claimed that because RotaShield was withdrawn 
from the market, “big pharma” was pushing harmful vaccines on children and hiding data 
that showed that vaccines caused damage in the name of profits (Davidson, 2018). 
 
The Truth Between the Correlation of Increased Rates of Autism and Vaccination	
 The fear that perpetuated the anti-vaxx movement in the late 90s and early 2000s 
was the fear that vaccines cause autism, when really, they do not. One of the main 
reasons that many parents believed in this was not just because of Andrew Wakefield’s 
study, but because an increased number of children in the 90s were being diagnosed with 
autism. Barbara Loe Fisher stated that before the 1990s, “You didn't see autistic children. 
Autism was so rare. Most people had never heard of it.” So, because of the increased 
number of diagnoses at the time, many anti-vaxx parents believed it was because of 
vaccines (Goldberg, 2010).	
However, the truth is that the source of the apparent autism “epidemic” at this 
time was not due to vaccines at all, but due to the changes in how children were classified 
and diagnosed with autism spectrum disorders in the 1990s. It was not until 1994 that the 
criteria for autistic disorders were defined in the DSM-IV along with the criteria for other 
disorders such as Asperger’s syndrome and other developmental disorders. Some 
researchers on autism believe that the 50 to 75 percent increase in autism diagnoses at 
this time were milder cases of the autism spectrum that were finally defined in the DSM-
IV. Research has shown that as the criteria changed, so did the diagnoses that children 
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received, allowing the number of autism diagnoses to increase during this period in 
correlation with the rise of the modern anti-vaxx movement. The reporting of autism 
cases also increased at this time due to the educational aid provided by the 1990 
Americans with Disabilities Act. Autism became a category for special education in 
1991, and the resulting explosion in the number of cases of autistic children in the 
database is seen because of these things (Goldberg, 2010).	
 
Media and its Influence on Anti-Vaxxers 	
Despite the fact that Wakefield’s study was discredited by reputable scientists, 
that thimerosal was no longer used in vaccines, and that by the end of 2004, following the 
Institute of Medicine’s report, the link between vaccine and autism was disproved, the 
idea still continued to gain momentum in the 2000s, especially through media and 
through endorsements by celebrities, including Jenny McCarthy and Jim Carrey 
(Goldberg, 2010). McCarthy’s son was diagnosed with autism in 2005, and after 
educating herself with what she termed “the University of Google,” she claimed that her 
“mommy instinct” told her that vaccines had caused her son’s autism. She went on a 
series of live television appearances in 2007, including appearances on The Oprah 
Winfrey Show, Larry King Live, and Good Morning America. On these programs that 
were seen by millions, she blamed vaccines for her son’s autism and went on to praise 
Andrew Wakefield and his work. McCarthy also joined forces with other organizations 
that blamed vaccines for autism, and her efforts helped to further perpetuate the anti-vaxx 
movement, especially in the United States (Davidson, 2018).	
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Unfortunately, because of McCarthy’s ability to gain substantial and continued 
media attention for her anti-vaxx views, thousands of Americans have bought into the 
anti-vaxx movement and the belief that vaccines caused their children’s autism. In 
addition to the ideas perpetuated by celebrities like McCarthy, following the retraction of 
the Lancet study by Andrew Wakefield, the media gave far less coverage to the truth of 
the study than they had about the lie that it had originally told. However, over the recent 
years, there has been a shift in the news media in that many have finally made it clear that 
research shows no connection between immunizations and autism, and new articles are 
coming out daily that further expose the lies that many anti-vaxxers believe. The problem 
now isn't with the news media perpetuating false information, but with social media and 
the information that is spread by anti-vaxxers on those sites daily (Goldberg, 2010). 		
The Modern Anti-Vaxx Movement	
 Today, the anti-vaxx movement is prospering as access to medical information 
online has dramatically changed the dynamics of healthcare knowledge. Medical 
knowledge that was previously only found in textbooks and journals can now be found 
online and is accessible to the layman, which had allowed shared decision-making 
between patients and healthcare physicians to flourish. However, while this has been 
beneficial, it also has led to the dissemination of false and misleading information 
regarding vaccines that can be found on the internet, which can lead to negative 
consequences such as parents not giving consent to having their children vaccinated. 
False information regarding vaccines is plentiful and easy to find on the internet (A. 
Hussain et al., 2018).	
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A 2018 article entitled The Anti-vaccination Movement: A Regression in Modern 
Medicine by Azhar Hussain, Syed Ali, Madiha Ahmen, and Sheharyar Hussain cited 
several analyses and studies regarding social media and the perception of vaccines online. 
The first was an analysis of YouTube videos about immunization that found that 32% 
opposed vaccination and that these videos that opposed had higher ratings and more 
views than pro-vaccine videos. A similar analysis of MySpace blogs regarding HPV 
immunization found that 43% were negative and that most of these blogs cited inaccurate 
data. Another analysis of Canadian internet users tracked the sharing of influenza vaccine 
information on sites such as Facebook, Twitter, and YouTube and of the top search 
results during the study period, 60% promoted anti-vaccination sentiments. The fourth 
study examined the content of the first one-hundred anti-vaccination sites found after 
searching “vaccination” and “immunization” on Google, and it concluded that 43% of 
websites had anti-vaxx views, including all of the first ten listed (A. Hussain et al., 2018).	
Online anti-vaxxers skew science, shift hypotheses, censor opposition, attack 
critics, claim to be “pro-safe vaccines” and not “anti-vaccine” and claim that vaccines are 
toxic and unnatural among several other reasons in their objective to forward their 
agenda. These tactics are not only deceitful and dishonest, but also have caused a 
decrease of vaccination rates in the United States as parents believe their messages 
online. Azhar Hussain, Syed Ali, Madiha Ahmen, and Sheharyar Hussain in their 2018 
article also reported on a study that evaluated how effectively users assessed the accuracy 
of medical information about vaccines online and concluded that 59% of student 
participants thought the sites were entirely accurate. However, out of the 40 sites they 
were given, only 18 were entirely accurate, and the other 22 were inaccurate. The 
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inaccurate sites presented in the study were not evidence-based and argued that vaccines 
were inherently dangerous without any merit-based argument, and 53% of participants 
led the exercise with misconceptions about vaccines. The 2018 article also reported that 
research has shown that viewing an anti-vaxx website for five to ten minutes increased 
perceptions of vaccinations’ risks and decreased perceptions of the risks of vaccine 
omission, and that the anti-vaxx sentiments obtained from viewing the websites still 
persisted five months later, causing the children of these parents to get fewer vaccines 
than recommended by medical professionals (A. Hussain et al., 2018). Online media, 
especially social media, has played a major role in perpetuating the anti-vaxx movement 
in the twenty-first century, and because of it, our country is still threatened by vaccine-
preventable diseases every day.		
The Current State of Vaccination	
According to the National Center for Health Statistics (2017), the percent of 
children aged 19-35 months receiving vaccinations for vaccine-preventable diseases in 
2017 are as follows: Diphtheria, Tetanus, Pertussis (DTaP), 83.4%; Polio: 91.9%; 
Measles, Mumps, Rubella (MMR), 91.1%; Haemophilus influenzae type b (Hib), 81.8%; 
Hepatitis B, 90.5%; Chickenpox (Varicella), 90.6%; Pneumococcal conjugate vaccine 
(PCV), 81.8%; and combined 7-vaccine series, 70.7% . Tables 4a, 4b, 4c and 4d show 
the vaccination coverage for selected disease among children aged 19-35 months, by 
race, Hispanic origin, poverty level, and location of residence in metropolitan statistical 
area in United States for the selected years between 1998 and 2016, compiled by the 
CDC in 2017. These tables show how although vaccination rates have increased for the 
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most part since 1998, these numbers have fluctuated over the years and for the most part 
have decreased in 2016, influencing how our nation is protected from infectious disease. 	
A drop in immunization poses a threat to the herd immunity, or the protection of 
communities from infectious diseases by vaccinating a vast majority of its members, that 
the medical profession had worked hard to achieve over the years. It takes around 90-
95% of a community to be vaccinated for herd immunity to work in protecting those 
unvaccinated individuals who cannot be vaccinated due to medical reasons. The only 
thing that can protect populations against a rapidly spreading disease is the herd 
immunity created when the majority of a population are immune thanks to vaccinations 
(A. Hussain et al., 2018).	
Over the past five years, outbreaks of infectious disease in the United States has 
influenced policies in states and has caused the general public to rethink the importance 
of vaccines. Dr. Amanda Cohn, senior advisor for vaccines for the CDC’s National 
Center for Immunization and Respiratory Diseases mentioned that the “strong 
recommendation for children… to get vaccinated is incredibly influential on a parents’ 
choice to get vaccinated...reiterating the importance of vaccination and helping parents 
understand the benefits of vaccination and the severity of diseases they are preventing is 
really important” (Jenco, 2018). The World Health Organization had listed vaccine 
hesitancy, or the reluctance or refusal to vaccinate despite the availability of vaccines, as 
a top ten threat to global health in 2019 (World Health Organization, 2019).  Our current 
state of vaccination is one that needs to be drastically changed in order to keep our nation 
free from the threat of infectious disease.	
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2015 Measles Outbreak in Disneyland	
On January 3rd, 2015, the California Department of Public Health received a call 
about a suspected measles case in an unvaccinated 11-year-old boy who recently visited 
Disneyland. Two days later, six additional suspected measles cases were reported, two 
from Utah and four from California, and all patients had recently traveled to Disneyland. 
The California Department of Public Health alerted the CDC and the other local health 
jurisdictions in California, but the damage was already done, and the measles outbreak 
was spreading. The measles case originated from one infected child at Disneyland on 
December 27th, 2014 and spread nationally and internationally to infect 131 total people 
located in Arizona, Utah, Nebraska, Washington, Colorado, Oregon, Mexico, and Canada 
(Harriman, 2015).	
Of the 131 total cases, 42 were exposed to measles at Disneyland, 31 were 
exposed in their household or by other close contact to an infected person, 11 were 
exposed in a healthcare setting, 3 were healthcare personnel, 3 were exposed in a 
shopping mall, and 44 had an unknown exposure setting. 82 of the 131 total cases had 
their immunization statuses verified, and of the 82 cases, 70%, or 57 people, were 
unvaccinated. When probed as to why they were unvaccinated, 49% said because of 
personal beliefs, 28% were too young to receive the vaccine, 4% missed the dose, and the 
other 19% had unknown reasons. Only 25 people, or 31% of the 82 cases were 
vaccinated. The other 49 of the 131 total cases did not have immunization records 
(Harriman, 2015).	
On June 30th, 2015, a few months after the outbreak, California Governor Jerry 
Brown signed SB 277 into law, eliminating personal and religious vaccine exemptions 
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for children to attend daycare, preschool, and K-12 schools in California (California 
Department of Public Health, 2015). Because of this, California has some of the strictest 
compulsory vaccine laws in the country.		
Current State Compulsory Vaccine Laws	
 States have different laws regarding vaccines, and some are much stricter than 
others. The three states with the strictest compulsory vaccination laws in the United 
States include West Virginia, Mississippi and most recently California. Who would have 
thought that two of the states with some of the worst health rankings would have the 
strictest vaccine laws? West Virginia has maintained strong vaccination policies for 
decades and is the only state that has never had non-medical exemptions, keeping the 
state free of any measles outbreaks for decades. The state of Mississippi followed West 
Virginia’s lead in 1979, when its Supreme Court found the state’s religious exemptions to 
be unconstitutional, citing a previous ruling of Prince v. Commonwealth of 
Massachusetts that determined “the right to practice religion freely does not include 
liberty to expose the community or the child to communicable disease or the latter to ill 
health or death.” Because of Mississippi’s laws, the State has not had a measles outbreak 
since 1992 (Moon, 2019). Figure 1, provided by the National Vaccine Information 
Center (2018), shows the exemptions allowed in each state:	
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Figure 1: State Vaccine Exemptions	
		
All 50 states allow medical exemptions to vaccination, which means that 
immunocompromised people or people that are allergic to certain vaccinations are not 
required to get them. Forty-seven states, not including Mississippi, West Virginia, and 
California, allow for either religious or personal belief exemptions, and some states allow 
both. However, each state has their own laws dictating how difficult it is to obtain an 
exemption. States that have easier exemption policies, such as those in Colorado, have 
ongoing problems with outbreaks of disease (Marcus, 2017).	
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Current Events: Vaccination in the News in 2019	
 From January 1st to April 11th, 2019, there have been 555 cases of measles 
confirmed in twenty states across the United States, representing the second-greatest 
number of cases reported in the U.S. since measles was eliminated in 2000. This number 
is continuing to grow every day, and the states that have reported cases to the CDC 
include Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, 
Kentucky, Maryland, Massachusetts, Michigan, Missouri, Nevada, New Hampshire, New 
Jersey, New York, Oregon, Texas and Washington. Of these fifteen states, six outbreaks 
are currently ongoing in 2019 in four states: New York, Washington, California, and New 
Jersey. All of these outbreaks have been linked to travelers who brought measles back 
from other countries such as Israel, Ukraine, and the Philippines (CDC, 2019).		
Williamsburg, Brooklyn, New York	
 On April 9th, 2019, the New York City Department of Health and Mental 
Hygiene commissioner, Oxiris Barbot, ordered that	
Any person who lives, works, or resides within the 11205, 11206, 11211, and/or 
11249 zip codes and who has not received the MMR vaccine within forty-eight 
(48) hours of this Order being signed by me shall be vaccinated against measles 
unless such person can demonstrate immunity to the disease or document to the 
satisfaction of the Department that he or she should be medically exempt from 
this requirement. (Barbot, 2019).	
This order was in response to the ongoing measles outbreak in the area that has seen over 
250 cases and is still growing. Barbot cited that his reasoning for the Order is to stay 
consistent with the New York Health Code that states that no person “shall do or assist in 
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any act which is or may be detrimental to the public health or to the life or health of any 
individual…”. Failure to comply with this Order results in a violation of the New York 
City Health Code and is a misdemeanor, which can result in fines and potentially 
imprisonment. (Barbot, 2019).		
Rockland County, New York	
 The current outbreak in New York is located in Rockland County, and as of April 
3rd, 2019, there were 161 confirmed cases of measles. Of these 161 cases, 83.2% of the 
people were unvaccinated (County of Rockland, 2019). In response to the growing 
measles outbreak, Rockland County officials have declared a state of emergency had 
have placed a 30-day ban on any unvaccinated individuals under the age of 18 from being 
in public places. By declaring this state of emergency, officials hope that parents will 
realize how serious the problem of vaccine hesitancy brings to communities and hopes 
that parents will rethink their decision not to vaccinate their children. Rockland County 
Executive Ed Day declared “I must take this step to protect the infants, infirm, and ill of 
this County who are unable to be vaccinated against the measles or who are 
immunocompromised... I must make every effort to protect them” (Schwartz, 2019).		
Brooklyn and Queens, New York City	
 As of April 3rd, 2019, there was 259 confirmed cases of measles in Brooklyn and 
Queens, most involving members of the Orthodox Jewish community. The disease was 
initially brought to the neighborhoods of Brooklyn and Queens from an unvaccinated 
child who acquired measles on a visit to Israel (City of New York, 2019). This is around 
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the same area as Williamsburg where there has also been a large outbreak as mentioned 
above.		
Washington State	
 As of March 22nd, 2019, there were 74 confirmed cases of measles in Clark and 
King counties in Washington State (Washington State Department of Health, 2019).		
New Jersey	
 As of April 3rd, 2019, there were 11 confirmed cases of measles. There were 9 
outbreak-associated cases including 7 in Ocean County residents and 2 in Monmouth 
County residents and of these cases, individuals could have been potentially exposed to 
the infection in New Jersey between March 9th and March 14th (State of New Jersey, 
2019).		
California	
 As of March 27th, 2019, 16 confirmed measles cases, including 11 outbreak-
associated cases, were reported (California Department of Public Health, 2019).		
 Of all of these current outbreaks of measles in the United States, a majority of 
cases are due to unvaccinated individuals. As unvaccinated travelers continue to acquire 
diseases and bring them back to the United States, our public’s health is put at risk, 
especially those who cannot receive vaccinations due to medical reasons (CDC, 2019). In 
addition to these cases of measles threatening the health and safety of Americans, the low 
rates of vaccination of other infectious diseases have left populations vulnerable and have 
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cost our health care sector hundreds of thousands of dollars, as seen with a recent case of 
tetanus in an unvaccinated child in Washington state. 	
There is hope, however, that our vaccination rates will begin to increase after the 
link between autism and the MMR vaccine was completely debunked by a large study 
that was published on March 5th, 2019. Although this has been proven before in years 
prior, this study is extremely significant because it contained over 600,000 participants, 
the largest sample of any study of its kind, further adding fuel to the fire in the argument 
against the link between vaccines and autism. The study, published by the Annals of 
Internal Medicine with authors Anders Hviid, Jorgen Vinslov Hansen, Morten Frisch, and 
Mads Melbye, is entitled Measles, Mumps and Rubella Vaccination and Autism: A 
Nationwide Cohort Study. It was done in Denmark and began in 1999 and ended in 2010, 
with follow-ups through 2013 (Hviid, Hansen, Frisch & Melbye, 2019).	
The study used Danish population registries to link information on MMR 
vaccination, autism diagnoses, other childhood vaccines, sibling history of autism, and 
autism risk factors to children in the cohort, which included 657,461 children total. Of the 
657,461 children in the study, 6,517 were diagnosed with autism, which is an incidence 
rate of 129.7/100,000 people. The study presented evidence that strongly supports that 
MMR vaccination does not increase the risk for autism, does not trigger autism in 
susceptible children, and is not associated with clustering of autism cases after 
vaccination, further proving that there is no link between the MMR vaccine and autism 
(Hviid et al., 2019). This study once again disproving the link between vaccines and 
autism comes nearly twenty years after Andrew Wakefield’s bogus study, and yet, the 
anti-vaxx movement is still alive and well in today's society. 	
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Current Resistance	
 The World Health Organization has listed vaccine hesitancy as one of the top 
threats to global health in 2019. In its publication, The State of Vaccine Confidence, the 
SAGE working group defines vaccine hesitancy as	
A behavior influenced by a number of factors including issues of confidence, 
complacency, and convenience. Vaccine-hesitant individuals are a heterogeneous 
group who hold varying degrees of indecision about specific vaccinations or 
vaccines in general. Vaccine-hesitant individuals may accept all vaccines but 
remained concerned about vaccines; some may refuse or delay some vaccines but 
accept others; some individuals may refuse all vaccines. (Feemster, 2018).	
Vaccination is one of the most cost-effective ways of avoiding disease and it currently 
prevents two to three million deaths a year and could potentially avoid 1.5 million more 
deaths if global coverage of vaccinations was improved. Reasons why people choose to 
not vaccinate are complex and range from complacency, inconvenience in accessing 
vaccines, and lack of confidence in vaccines (World Health Organization, 2019). 	
Fear of disease has wreaked havoc on our planet throughout the years, and even 
today it remains a concern among many as more and more people are becoming infected 
with vaccine-preventable diseases. Vaccination has made such an enormous impact on 
global health and has eradicated horrendous diseases; however, there is an increasing 
number of people opposing vaccination even in today’s society for a number of reasons, 
as cited by the World Health Organization. These reasons include the belief that vaccines 
cause autism, that the ingredients in vaccines cause harmful side effects, that diseases 
have been virtually eliminated from the world, so there is no need to vaccinate and that 
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giving a child multiple vaccinations at the same time increases the risk of harmful side 
effects and overloads the immune system (World Health Organization, 2018). Changing 
the opinions of anti-vaxxers is not as easy as it may seem, and because of this, other 
measures must be taken in order to increase vaccination rates in our country, and that is 
where policy steps in.																								
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Chapter 5	
Recommendations	
 	
 Childhood vaccination has proven to be one of the most effective public health 
strategies to control and prevent disease, yet some parents do not vaccinate their children 
because of medical, religious, philosophical, or socioeconomic reasons. As our 
immunization rates continue to stray away from the percentage required to maintain herd 
immunity, more and more vaccine-preventable diseases are emerging in the United States 
due to the refusal to vaccinate, incomplete vaccination series, waning immunity, and 
imported cases of disease. Many misconceptions about vaccines exist, and because of 
this, the public is often misinformed about the importance of vaccines on public health 
(Ventola, 2016). 		
Using Instruments of Public Policy to Increase Vaccination Rates	
In order to increase our country’s immunization rates, there are several policy 
recommendations and government interventions that can be made. The instruments of 
public policy that can be used include the use of regulation, government management, 
education, information, and persuasion, and market mechanisms. Governments can also 
regulate, use market incentives, educate, and conduct research to improve immunization 
rates. Along with these instruments of public policy, it is also important to evaluate the 
criteria for public policy proposals in order to determine its effectiveness, efficiency, 
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equity, liberty, political feasibility, administrative feasibility, and technical feasibility. A 
combination of these, or all of them, can be used to increase the immunization rates in the 
United States, and directions that can be taken to do so will be discussed and 
recommended in detail in this section by the author.	
 
Compulsory Vaccine Laws at the State Level	
 The first policy tool that can be used to increase vaccination rates in the United 
States include the use of regulation, or laws enacted by state or even federal legislatures 
that require vaccination. As mentioned previously, vaccination is compulsory for school-
aged children in the United States, but there are exemptions for religious, medical and 
philosophical reasons. Public health officials have become increasingly worried about the 
option for parents to claim exemptions from vaccination requirements, and because of 
several recent outbreaks of vaccine-preventable diseases, more attention has been brought 
to these exemptions, causing many states to rethink their vaccine laws (Ventola, 2016).	
Currently, medical exemptions, which are exemptions for immunocompromised 
individuals or people who cannot receive vaccines for medical reasons, are accepted in all 
states. Herd immunity is important in protecting these people who are medically unable 
to get vaccinated, and this exemption is the one that stands apart from the rest in that it is 
a legitimate medical and health safety reason to not be able to receive a vaccine. Forty-
seven states allow religious exemptions to vaccines and another twenty offer exemptions 
for philosophical reasons. It has been estimated that one to three percent of children are 
excused from immunization because of these exemptions, but in some communities, the 
exemption rate is as high as twenty percent, increasing the risk of disease outbreaks 
(Ventola, 2016).	
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As mentioned previously, there are three states that do not allow religious or 
philosophical exemptions: Mississippi, West Virginia and California. These states have 
had some of the highest immunization rates in the country because of their strict 
compulsory vaccination policies, showing that regulating vaccine laws through the states 
is an effective measure in increasing immunization rates. Promoting best practices at the 
state level is one strategy to improving vaccine coverage rates, and there is a growing 
body of evidence showing the impact that state vaccination requirements for school aged 
children has on vaccination coverage and the association of non-medical exemption rates 
with increased disease incidence (Centers for Disease Control and Prevention, 2015).	
Recent findings that support the fact that stricter vaccination laws lead to better 
immunization rates and less outbreak of disease include that the use of philosophical 
exemptions tend to cluster geographically, making some communities greater for risk of 
outbreaks, including immigrant communities specifically. In addition, the geographic 
clustering of exemptions is associated with increased local risk of vaccine-preventable 
diseases such as pertussis and measles, which are both highly contagious. The CDC’s 
Public Health Law Program compiled state statutes and regulations regarding school 
vaccinations and has concluded that states have successfully implemented these 
compulsory laws by requiring proof of vaccination for school entry, applying their 
immunization requirements to both public and private school, and establishing 
vaccination requirements for children in day care (Centers for Disease Control and 
Prevention, 2015).	
Vaccine mandates and laws in states have had a positive impact on overall 
vaccination rates and are a solution to increasing vaccine rates in the United States. 
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However, gaps still exist in several states, and they need to be fixed in order for our 
general public to be free from the threat of infectious disease. As seen from Mississippi, 
West Virginia and California, compulsory vaccine laws are effective in preventing 
infectious disease and lead to higher immunization rates, however, there are some 
limitations that exist in implementing these laws in every state. Political feasibility and 
social acceptability are a challenge because there are many that still are hesitant about 
vaccines and therefore, it may be hard to pass in every state. However, a solution to this 
would be to further education that disproves the fears that many have about vaccines and 
to promote the benefits that a vaccinated population brings to a community through 
education. 	
Administratively and technologically wise, these laws are extremely feasible to be 
implemented in states as several states have already done. In addition, the argument of a 
person’s individual rights also come into play, but as seen with several supreme court 
cases, maintaining the public’s health outweighs one’s decision to get vaccinated or not, 
so these laws are necessarily in protecting our country’s citizens. Unfortunately, it may 
take a disease outbreak disaster like the one seen in California in 2015 to get more states 
to follow suit and implement stricter vaccine laws, but once all states have compulsory 
vaccine laws that only allow for medical exemptions, it can be assumed that the rate of 
disease outbreaks will decrease as the immunization rate increases.		
Compulsory Vaccine Laws at the Federal Level	
 Currently, all compulsory vaccine laws are left up to the states to decide on and 
enact. However, as more disease outbreaks have happened and the rate of immunization 
has decreased over the years, people have started to question the role of the federal 
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government in protecting its citizens through the creation of federally-mandated 
compulsory vaccine laws. In fact, on February 21st, 2019, the Food and Drug 
Administration’s Commissioner, Dr. Scott Gottlieb, said the federal government might 
someday need to begin regulating vaccine policies if “lax” state vaccine laws continue to 
allow the resurgence of vaccine-preventable diseases to occur. Gottlieb also said that the 
widespread exemptions allowed by states are “creating the opportunity for outbreaks on a 
scale that is going to have national implications” and could “force the hand of the federal 
health agencies” in order to attempt to control the continued disease outbreaks 
(Ducharme, 2019).	
 Although there have been no actual steps toward implementing federal 
compulsory vaccine laws, Gottlieb’s comments bring up many good points in the battle 
against infectious diseases and the obligation that the government has to protect the 
health of its citizens. Medical groups such as the American Medical Association (AMA), 
the American Academy of Family Physicians, and the American Academy of Pediatrics 
have opposed vaccine exemptions for years, except for medical exemptions. In a 2015 
release from the AMA, board member Dr. Patrice Harris stated that, “protecting 
community health in today’s mobile society requires that policymakers not permit 
individuals from opting out of immunization solely as a matter of personal preference or 
convenience” as many religious and philosophical exemptions have become more 
common (Ducharme, 2019). 	
When comparing to state compulsory vaccine laws, federal laws also reach 
political and social acceptability barriers, but also, it faces some administrative feasibility 
issues as policies like this have never been enforced on the federal level. A policy like 
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this would be effective and efficient at increasing vaccine rates in the United States, but it 
would have a much harder time in garnering support because many support the idea of 
federalism, or the separation of the state and federal government, and believe that vaccine 
laws should be left up to the states. However, if states do not reconsider their current 
vaccine laws that allow for numerous exemptions, the federal government may have to 
intervene in order to protect the citizens of the United States from the threat of infectious 
disease.		
Health Care Provider-Based Interventions	
 Another policy tool that can be used to increase vaccination rates is increasing 
education, information, and persuasion and also using government management and 
market mechanisms to get more people vaccinated. The CDC’s Task Force on 
Community Prevention Services identifies three categories for interventions to overcome 
vaccine noncompliance: increasing community demand for vaccination, enhancing access 
to vaccination services, and provider-based interventions. There are several health care 
provider-based interventions that can be made to overcome vaccine noncompliance that 
include patient counseling, improving access to vaccines, maximizing patient office 
visits, offering combination vaccines, and using electronic medical records and practice 
alerts to better identify a patient's vaccine schedule (Ventola, 2016).		
Patient Counseling	
 Studies have consistently shown that absent or weak recommendations from 
health care providers have led to decreased vaccine rates. So, it is important to develop 
interventions that target health care providers and their practices so that they may be the 
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primary educators for parents who may question the safety or necessity of vaccines. The 
first intervention is patient counseling, or patient education. Studies have found that the 
most important factor influencing parental decisions about vaccinations is 
communication with the health care provider, so parental and patient education provided 
by primary care physicians, or the physician giving the vaccine, is especially important in 
increasing vaccine rates. Most parents are not familiar with vaccines or have been 
improperly informed about them due to lies spread on social media, so educating them in 
the healthcare setting that vaccines are indeed safe and effective is the most important 
part in increasing vaccine compliance (Ventola, 2016).	
 With the intervention of providing parent and patient counseling, providing 
training and materials to providers who may encounter vaccine-hesitant patients is also 
important. Research has focused on training healthcare providers to use proven 
communication strategies when vaccine hesitancy is encountered while also discussing 
the research concerning safety concerns about immunizations with parents. The health 
care provider’s office should also provide parents with information about upcoming 
immunizations before a child’s scheduled visit so that they can gain an understanding of 
any recommended vaccinations. Parents should also be provided with a vaccination 
record that summarizes all of their child's past immunizations and the recommended 
dates for future immunizations. Patient-reminders are also important because keeping 
with the vaccine schedule ensures that a child is as protected as they can be from 
infectious diseases (Ventola, 2016). A summary of these interventions is included in 
Table 5 in the appendix.	
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 In addition to this intervention, the National Foundation for Infectious Diseases 
(2016) also addresses how vaccine rates can be increased through ongoing 
communication with parents and adolescents about vaccines. It is essential that parents 
and adolescents have the correct information from health care providers regarding 
vaccines and not information from social media that often is laced with misinformation. 
This intervention is politically, socially, administratively, and technologically feasible in 
that most people agree that providing more information to patients is a good thing. 
However, an obstacle may be reached when determining how to administer this 
information in a standardized way as not all health care practices are the same and use the 
same methods. Either way, this intervention is an effective one that can be done with 
little costs while having a large impact. 		
Maximizing Opportunities During Patient Visits	
 The second intervention that can be made by health providers to improve 
vaccination compliance is maximizing opportunities during patient visits. In the U.S., 
around two-thirds of under-vaccination in children younger than two years of age has 
been due to missed opportunities that have led to missed visits and failure to provide 
needed immunizations at every opportunity that contributes to complete vaccination 
requirements. After age two, most children are only brought to the doctor when they are 
sick. However, they need to be brought in much more frequently to get the vaccines that 
are needed according to the vaccine schedule. Because of this, all clinical encounters, 
including visits for injuries or mild illness, should be considered as an opportunity to 
administer needed vaccines. In addition, in order to get more children vaccinated when 
they come to see a healthcare professional, a standing order for the vaccination of 
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patients should be issued to allow nurses to do so independently of physicians. Nurses 
should routinely verify a patent’s vaccination status and offer to administer any other 
needed vaccines (Ventola, 2016). A summary of this intervention is included in Table 5 
in the appendix.	
 The National Foundation for Infectious Diseases (2016) also recommends that 
during patient visits, all health care providers should be involved in vaccine delivery. 
While school-based vaccine delivery is not routine, vaccine recommendations and 
reminders from school nurses can be very valuable. So, expanding support to all 
healthcare providers and ensuring that their messages to patients about the importance of 
vaccines are all positive can make a difference. This intervention is politically, socially, 
administratively, and technologically feasible because many believe that every corner 
should be accounted for at a doctor’s visit, so minimizing wasted time and resources and 
instead giving more vaccines and ensuring that the schedule is being followed is a good 
thing. Like educating patients on the important of vaccination, this intervention is an 
effective one that can be done with little costs while having a large impact. 		
Administering Combination Vaccines	
The third intervention that can be made by health providers to improve 
vaccination compliance is through administering more combination vaccinations. The 
simultaneous administration of childhood vaccinations through combination vaccines 
such as the MMR and DTaP vaccines have been deemed both safe and effective and 
avoid the need for as many return visits. It has also been observed that when the 
advantages of combination vaccines are explained to patients and parents, adherence is 
improved (Ventola, 2016). So, anything that can be done to increase the use and creation 
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of combination vaccines in healthcare can help increase immunization rates as well. A 
summary of this intervention is included in Table 5 in the appendix. 	
This intervention may have a harder time being politically and socially feasible 
because many parents worry that combination vaccines can overload the immune system 
and are not safe. However, through education, these individuals can learn from their 
healthcare providers that they are indeed safe and are effective at preventing illness. 
Additionally, there are setbacks in administrative and technological feasibility because 
there are only a few vaccines that are offered in combination, so if more were to be 
created, they would have to go through the process of rigorous testing and approval to get 
there, which takes time. However, with the combined vaccines we already have, this 
intervention is doable and is effective and efficient in preventing disease.		
Improving Access to Vaccinations	
The fourth intervention that can be made by health providers to improve 
vaccination compliance is by improving access to vaccinations. Individuals in 
disadvantaged socioeconomic groups encounter many obstacles that can interfere with 
getting vaccinations according to the vaccine scheduled, affecting compliance. 
Circumstances such as job responsibilities, not being able to keep up with appointments, 
unreliable transportation, relocating frequently, or having other difficult circumstances 
can affect the opportunity of staying on the vaccine schedule. Making vaccinations easier 
to obtain for people who fall in this group is the most effective intervention in increasing 
vaccination rates. This can be done by allowing patients to be seen on the same day that 
they call to make an appointment via walk-in appointments and having a supportive staff 
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and convenient office with limited wait times also helps with this (Ventola, 2016). A 
summary of this intervention is included in Table 5 in the appendix.	
There are so many other ways in which vaccinations can be delivered to low 
socioeconomic communities, but they differ from community to community based off of 
what services they can offer for their citizens. In-school vaccination centers may be the 
best way to combat this issue, but again, it comes down to the policies that are in place in 
each state in whether this is a feasible solution. However, making it easier for people to 
receive vaccines through greater accessibility is necessary to increase the vaccination rate 
in our country. This is politically and socially feasible because most agree that improving 
access to health services such as vaccination is a good thing. However, administratively, 
it does come at a cost to improve access, but if the benefits outweigh the costs, then it is a 
smart move to provide better access to vaccines and it would be an effective and efficient 
way to increase compliance.		
Using Electronic Medical Records and Practice Alerts	
The fifth intervention that can be made by health providers to improve 
vaccination compliance is through the use of electronic medical records (EMRs) and 
practice alerts. Computerized tracking of patient records across health care has improved 
communication in the healthcare setting and is the ideal avenue for reducing vaccine 
errors and missed opportunities for vaccination. Most health care systems now utilize 
EMRs, and data has shown that practices with these systems in place have increased 
immunization rates, which is why all health care practices should switch to electronic 
patient management in order to allow vaccination rates to increase further in our nation. 
These EMRs also improve efficiency and accuracy by standardizing record-keeping 
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regarding vaccinations and missed visits, so that healthcare professionals can use the 
system to identify patients who are not up to date with their immunizations and can send 
them a notice (Ventola, 2016). A summary of this intervention is included in Table 5 in 
the appendix.	
The National Foundation for Infectious Diseases (2016) also recommends this 
same intervention is that one of the most effective tools in increasing vaccination rates is 
a standing order, which allows the administration of vaccines who all patients who meet 
certain criteria in the EMR system. The system also provides reminders to patients when 
vaccinations are due so that they can make an appointment. This intervention is 
politically, socially, and administratively feasible in that these systems already exist and 
anything that makes the process of standardizing medical records is effective and 
efficient and increases benefits while decreasing costs. However, not all practices have 
this type of technology, so some do not have the technical feasibility to implement this 
type of intervention yet.		
Community and Government-Based Interventions	
In addition to health care provider-based interventions, there are also community 
and government-based interventions that aim to enhance vaccination rates. They include 
increasing outreach and educational programs, using recall and reminder strategies, 
providing financial incentives, and offering vaccination at nontraditional sites (Ventola, 
2016).	 			
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Public Education	
It has been shown that parent-driven or patient-based education coupled with 
community or government-based measures can improve immunization rates. Rather than 
relying solely on patient/parent education, using newer educational methods that 
incorporate community input and web-based tools for information dissemination can be 
effective. Examples include educational brochures and other brief public messaging 
interventions directed at parents and adolescents. It is also important to evaluate the effect 
of different messaging strategies on intention and vaccine receipt when the messages are 
delivered in a setting where vaccinations can be administered. Without awareness, many 
do not know the truth and importance of vaccination (Ventola, 2016). A summary of this 
intervention is included in Table 6 in the appendix.	
Similar to patient and parent counseling, this intervention is politically, socially, 
administratively, and technologically feasible in that most agree that providing more 
information to the general public is a good thing. However, an obstacle may be reached 
when determining how to administer this information in a standardized way and in an 
efficient and effective way to the general public. Either way, this intervention is an 
effective one that can be done with potentially little costs if done digitally while having a 
large impact. 		
Public Reminder and Recall Strategies	
 As discussed previously, parent and clinician reminders regarding upcoming 
vaccinations and recalls for vaccinations that are past due is another evidence-based 
approach for improving vaccination rates. These can be done by mail or by phone and are 
instituted at the individual practice level, so it can differ from practice to practice, city to 
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city and state to state. However, if it can be standardized among most practices, it can 
make a huge difference in reminding people to get their vaccinations according to the 
vaccine schedule. With the advances in technology and in the EMR system, this process 
can potentially be centralized so that a coordinating agency, possibly a health department, 
can implement it. Advancements in electronic communications have been essential in the 
rapid sharing of health and safety information and these communications have allowed 
for real-time health updates and the broad sharing of information that has enhanced 
public health partnerships. With the increased use of mobile phones for health-related 
activities, the impact of a reminder or recall message is something that needs to be 
examined as it can greatly increase the vaccination rates in our country (Ventola, 2016). 
A summary of this intervention is included in Table 6 in the appendix.	
 Politically, socially, and administratively, this intervention can be done of the 
system in place is able to send these reminders and recalls, because most agree that 
reminders and recalls are beneficial in keeping patients in the loop and up to date in 
regard to their health. However, technical feasibility is hard when some practices do not 
have the technology to send these sorts of reminders electronically, but they can also be 
sent via mail and by a phone call. So, it may not be standardized across all boards, but it 
will still be effective and efficient in reminding people to get their vaccines according to 
the vaccine schedule.		
Free Vaccines and Other Financial Incentives	
 Another intervention that communities and governments can use to increase 
vaccination rates is by issuing financial incentives to parents or patients, such as an entry 
into a lottery for a gift or providing free vaccines for free to the uninsured. This is 
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especially beneficial for people who may not have health insurance or cannot afford to 
see a doctor (Ventola, 2016). A summary of this intervention is included in Table 6 in the 
appendix. 	
This intervention comes with more problems with political, social, and 
administrative feasibility because it does cost money to offer free vaccines and other 
financial incentives for them, so not everyone may approve of this sort of policy because 
it costs money. However, if the benefits of this intervention outweigh the costs, then they 
may be more likely to accept it. Also, many may agree with the policy because they 
otherwise would not be able to afford visiting a doctor or may not have insurance, so they 
would accept this intervention. Overall, if the benefits outweighed the costs, it could be 
an effective and efficient intervention.		
Alternative Public and Private Venues for Vaccination	
 The last community and government-based intervention to improve vaccine 
compliance is the use of alternative venues for vaccination. Many studies have provided 
evidence supporting school and daycare-based vaccination programs and improvement in 
vaccination rates has also been seen by opening walk-in vaccination clinics run by nurse 
practitioners on evenings and weekends for people who cannot make it to the doctor’s 
office during the day. Offering vaccinations at pharmacies that have convenient hours has 
also proved beneficial. Other possible alternative immunization venues include 
emergency departments, Women, Infants and Children (WIC) program offices, impatient 
settings, and home visits (Ventola, 2016). A summary of this intervention is included in 
Table 6 in the appendix.	
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 This intervention could be politically and socially feasible because it provides 
immunizations to those who cannot visit the normal hours of a healthcare facility due to 
work or other responsibilities during the week. So, this intervention would increase 
access, which most agree with. However, administratively and technologically, getting 
these alternative venues for vaccination is not always easy, but when it is able to be done, 
it is an effective and efficient intervention to increase the vaccination rates in the nation.		
Discussion	
 Vaccines to prevent infectious diseases were created for a reason, and their ability 
to protect and save lives from disease can only be successful when parents and patients 
comply with health officials and health care providers and get the recommended vaccines 
according to the vaccine schedule. Because of the perpetuation of the anti-vaxx 
movement and the continued hesitancy and resistance toward vaccines in our country, 
interventions by state governments, the federal government, health care providers, and 
community and government-based organizations are needed so that vaccine coverage can 
be increased in our nation. If policy interventions are not made soon, infectious diseases 
that once were virtually invisible because of the success of vaccination will continue to 
spread at a dangerous rate across our nation, putting the health and safety of our citizens 
at risk.		
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Chapter 6	
Conclusions	
 	
Vaccines have proven successful in preventing infectious disease for years and 
have even allowed for the eradication of smallpox in the twentieth century. However, the 
growing number of people refusing to vaccinate has caused vaccine-preventable 
infectious diseases to continue to flourish in our modern world, putting the public’s 
health at risk. Vaccine hesitancy is not a new concept, as people have questioned the 
medical profession since the before the birth of our nation. Time and time again, medical 
science has proven the safety and effectiveness of vaccines, yet, many still resist this 
solution to infectious disease. Now, it is up to policy interventions through the states, the 
federal government, health care providers, and community and government-based 
organizations to increase the vaccination rate in our country through measures intended to 
increase vaccine compliance.		
Limitations	
There were a few limitations to the author’s research strategy. Because the author 
conducted a literature review and collected secondary information only, the author did 
not collect primary research. In order to have collected primary information, the author 
would have had to go out into the community and conduct interviews and distribute 
surveys in order to collect data for primary information. This primary information could 
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have helped the author in determining attitudes toward vaccination in different 
communities and why there is resistance in these communities. Additionally, this 
information could have helped the author determine how individuals learned about 
vaccination and how much they know about the vaccination, which could aid the author 
in determining the best way to educate the public on the importance of vaccines for the 
recommendations section.	
In addition to the limitations surrounding the author’s decision to do a literature 
review and collect secondary information only, there are also limitations surrounding the 
recommendations section in that there are many more recommendations for policy 
interventions that can be made and could be successful for increasing vaccination rates. 
However, only a few that were deemed most important and relevant were mentioned by 
the author. Lastly, a hurdle in the research was the fact that there was a plethora of 
information regarding the topic, so narrowing down to the sources deemed important and 
relevant to my research was a difficult task.		
Future Research	
 As the author conducted research, there were questions that were brought forward 
that were not anticipated originally by the author. This included the fact that many 
communities in the United States that are affected by disease outbreaks usually consist of 
unvaccinated ethnic or religious populations in addition to outbreaks in natural born 
American populations. For future research, the author could look at these communities 
and analyze the demographic makeup of them, determine the breakdown of religious 
beliefs in these different communities to see if religious beliefs correlates with their 
resistance, and then further investigate why there are other types of resistance in these 
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ethnic or religious populations and how that resistance compares and contrasts to that of 
natural born American anti-vaxxers. 
 In addition, it would be interesting to research the manifestation of fears 
associated with immigration due to decreased vaccination rates and increased disease 
outbreaks in the United States because disease that is spread in the United States often 
originates overseas. Lastly, as vaccination has not been an issue that has been politicized 
heavily, going further to research the potential implications of politicizing the anti-vaxx 
movement would also be something to consider. As our political system is becoming 
more and more polarized, if the issue of vaccination becomes politicized, it could have 
serious implications that could affect the passage of compulsory vaccination laws in the 
future. 
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APPENDIX 
 
 
 
 
Vaccines in the Child and Adolescent Immunization Schedule*
Vaccines Abbreviations Trade names
Diphtheria, tetanus, and acellular pertussis vaccine DTaP Daptacel
Infanrix
Diphtheria, tetanus vaccine DT No Trade Name
Haemophilus influenzae type b vaccine Hib (PRP-T)
Hib (PRP-OMP)
ActHIB
Hiberix
PedvaxHIB
Hepatitis A vaccine HepA Havrix
Vaqta
Hepatitis B vaccine HepB Engerix-B
Recombivax HB
Human papillomavirus vaccine HPV Gardasil 9
Influenza vaccine (inactivated) IIV Multiple
Influenza vaccine (live, attenuated) LAIV FluMist
Measles, mumps, and rubella vaccine MMR M-M-R II
Meningococcal serogroups A, C, W, Y vaccine MenACWY-D Menactra
MenACWY-CRM Menveo
Meningococcal serogroup B vaccine MenB-4C Bexsero
MenB-FHbp Trumenba
Pneumococcal 13-valent conjugate vaccine PCV13 Prevnar 13
Pneumococcal 23-valent polysaccharide vaccine PPSV23 Pneumovax
Poliovirus vaccine (inactivated) IPV IPOL
Rotavirus vaccine RV1 
RV5
Rotarix
RotaTeq
Tetanus, diphtheria, and acellular pertussis vaccine Tdap Adacel
Boostrix
Tetanus and diphtheria vaccine Td Tenivac
Td vaccine
Varicella vaccine VAR Varivax
Combination Vaccines (Use combination vaccines instead of separate injections when appropriate)
DTaP, hepatitis B, and inactivated poliovirus vaccine DTaP-HepB-IPV Pediarix
DTaP, inactivated poliovirus, and Haemophilus influenzae type b vaccine DTaP-IPV/Hib Pentacel
DTaP and inactivated poliovirus vaccine DTaP-IPV Kinrix
Quadracel
Measles, mumps, rubella, and varicella vaccines MMRV ProQuad
* Administer recommended vaccines if immunization history is incomplete or unknown. Do not restart or add doses to vaccine series for extended 
intervals between doses. When a vaccine is not administered at the recommended age, administer at a subsequent visit. The use of trade names is 
for identification purposes only and does not imply endorsement by the ACIP or CDC. 
Recommended Child and Adolescent Immunization Schedule
for ages 18 years or younger
How to use the child/adolescent 
immunization schedule
Recommended by the Advisory Committee on Immunization 
Practices (www.cdc.gov/vaccines/acip) and approved by the Centers 
for Disease Control and Prevention (www.cdc.gov), American 
Academy of Pediatrics (www.aap.org), American Academy of Family 
Physicians (www.aafp.org), and American College of Obstetricians and 
Gynecologists (www.acog.org).
UNITED STATES
2019
Report
 y Suspected cases of reportable vaccine-preventable diseases or 
outbreaks to your state or local health department
 y Clinically significant adverse events to the Vaccine Adverse Event 
Reporting System (VAERS) at www.vaers.hhs.gov or (800-822-7967)
Helpful information
 y Complete ACIP recommendations:  
www.cdc.gov/vaccines/hcp/acip-recs/index.html
 y General Best Practice Guidelines for Immunization:  
www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html
 y Outbreak information (including case identification and outbreak 
response), see Manual for the Surveillance of Vaccine-Preventable 
Diseases: www.cdc.gov/vaccines/pubs/surv-manual
U.S. Department of 
Health and Human Services 
Centers for Disease 
Control and Prevention 
1
Determine 
recommended 
vaccine by age 
(Table 1)
2
Determine 
recommended 
interval for 
catch-up 
vaccination 
(Table 2)
3
Assess need 
for additional 
recommended 
vaccines 
by medical 
condition and 
other indications 
(Table 3)
4
Review 
vaccine types, 
frequencies, 
intervals, and 
considerations 
for special 
situations 
(Notes)
Download the CDC Vaccine Schedules App for providers at  
www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.
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Table 1 Recommended Child and Adolescent Immunization Schedule for ages 18 years or youngerUnited States, 2019
These recommendations must be read with the Notes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the dark gray bars in 
Table 1. To determine minimum intervals between doses, see the catch-up schedule (Table 2). School entry and adolescent vaccine age groups are marked with a star.
Vaccine Birth 1 mo 2 mos 4 mos 6 mos 9 mos 12 mos 15 mos 18 mos 19-23 mos 2-3 yrs
Ì 
4-6 yrs 7-10 yrs
Ì 
11-12 yrs 13-15 yrs
Ì 
16 yrs 17-18 yrs
Hepatitis B (HepB) 1st dose 2nd dose W---------------------------- 3rd dose ----------------------------X
Rotavirus (RV) RV1 (2-dose 
series); RV5 (3-dose series) 1
st dose 2nd dose See Notes
Diphtheria, tetanus, & acellular 
pertussis (DTaP: <7 yrs) 1
st dose 2nd dose 3rd dose W----- 4th dose ------X 5th dose
Haemophilus influenzae type b 
(Hib) 1
st dose 2nd dose See Notes 3
rd or 4th dose, W-- See Notes --X
Pneumococcal conjugate 
(PCV13) 1
st dose 2nd dose 3rd dose W----- 4th dose -----X
Inactivated poliovirus  
(IPV: <18 yrs) 1
st dose 2nd dose W---------------------------- 3rd dose ----------------------------X 4th dose
Influenza (IIV) Annual vaccination 1 or 2 doses Annual vaccination 1 dose only
Influenza (LAIV) Annual vaccination  1 or 2 doses Annual vaccination 1 dose only
Measles, mumps, rubella (MMR) See Notes W----- 1st dose -----X 2nd dose
Varicella (VAR) W----- 1st dose -----X 2nd dose
Hepatitis A (HepA) See Notes 2-dose series, See Notes
Meningococcal (MenACWY-D 
≥9 mos; MenACWY-CRM ≥2 mos) See Notes 1
st dose 2nd dose
Tetanus, diphtheria, & acellular 
pertussis (Tdap: ≥7 yrs) Tdap
Human papillomavirus (HPV) See Notes
Meningococcal B
See Notes
Pneumococcal polysaccharide 
(PPSV23) See Notes
  Range of recommended ages for all children   Range of recommended ages for catch-up immunization   Range of recommended ages for certain high-risk groups   Range of recommended ages for non-high-risk groups that may receive vaccine, subject to individual clinical decision-making  No recommendation
oror
02/22/19
Table 1a - Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, 
Unit d States, 2019 
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The figure below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the 
time that has elapsed between doses. Use the section appropriate for the child’s age. Always use this table in conjunction with Table 1 and the notes that follow.
Children age 4 months through 6 years
Vaccine Minimum Age for 
Dose 1
Minimum Interval Between Doses
Dose 1 to Dose 2 Dose 2 to Dose 3 Dose 3 to Dose 4 Dose 4 to Dose 5
Hepatitis B Birth 4 weeks 8 weeks and at least 16 weeks after first dose. 
Minimum age for the final dose is 24 weeks.
Rotavirus 6 weeks  
Maximum age for first 
dose is 14 weeks, 6 days
4 weeks 4 weeks 
Maximum age for final dose is 8 months, 0 days.
Diphtheria, tetanus, and 
acellular pertussis
6 weeks 4 weeks 4 weeks 6 months 6 months
Haemophilus influenzae 
type b
6 weeks No further doses needed if first dose 
was administered at age 15 months or 
older.
4 weeks  
if first dose was administered before the 
1st birthday. 
8 weeks (as final dose)  
if first dose was administered at age 
12 through 14 months.
No further doses needed if previous dose was administered at age 15 months or older.
4 weeks 
if current age is younger than 12 months and first dose was administered at younger than age 7 months, 
and at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberix) or unknown. 
8 weeks and age 12 through 59 months (as final dose)
if current age is younger than 12 months and first dose was administered at age 7 through 11 months; 
OR 
 if current age is 12 through 59 months and first dose was administered before the 1st birthday, and second 
dose administered at younger than 15 months; 
OR 
 if both doses were PRP-OMP (PedvaxHIB; Comvax) and were administered before the 1st birthday. 
8 weeks (as final dose)  
This dose only necessary 
for children age 12 through 
59 months who received 3 doses 
before the 1st birthday.
Pneumococcal conjugate 6 weeks No further doses needed for healthy 
children if first dose was administered at 
age 24 months or older.
4 weeks  
if first dose administered before the 
1st birthday. 
8 weeks (as final dose for healthy 
children)  
if first dose was administered at the 
1st birthday or after. 
No further doses needed for healthy children if previous dose administered at age 24 months or older. 
4 weeks  
if current age is younger than 12 months and previous dose given at <7 months old. 
8 weeks (as final dose for healthy children)  
if previous dose given between 7-11 months (wait until at least 12 months old);  
OR  
if current age is 12 months or older and at least 1 dose was given before age 12 months. 
8 weeks (as final dose)  
This dose only necessary 
for children age 12 through 
59 months who received 
3 doses before age 12 months 
or for children at high risk who 
received 3 doses at any age.
Inactivated poliovirus 6 weeks 4 weeks 4 weeks if current age is < 4 years.  
6 months (as final dose) if current age is 4 years or older.
6 months (minimum age 4 years 
for final dose).
Measles, mumps, rubella 12 months 4 weeks
Varicella 12 months 3 months
Hepatitis A 12 months 6 months
Meningococcal 2 months MenACWY-
CRM
9 months MenACWY-D
8 weeks See Notes See Notes
Children and adolescents age 7 through 18 years
Meningococcal Not Applicable (N/A) 8 weeks
Tetanus, diphtheria;  
tetanus, diphtheria, and  
acellular pertussis
7 years 4 weeks 4 weeks  
if first dose of DTaP/DT was administered before the 1st birthday.  
6 months (as final dose)  
if first dose of DTaP/DT or Tdap/Td was administered at or after the 1st birthday.
6 months if first dose of DTaP/
DT was administered before the 
1st birthday.
Human papillomavirus 9 years Routine dosing intervals are recommended.
Hepatitis A N/A 6 months
Hepatitis B N/A 4 weeks 8 weeks and at least 16 weeks after first dose.
Inactivated poliovirus N/A 4 weeks 6 months 
A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 
6 months after the previous dose.
A fourth dose of IPV is indicated 
if all previous doses were 
administered at <4 years or if the 
third dose was administered <6 
months after the second dose.
Measles, mumps, rubella N/A 4 weeks
Varicella N/A 3 months if younger than age 13 years.  
4 weeks if age 13 years or older.
Table 2 Catch-up immunization schedule for persons aged 4 months—18 years who start late or who are more than 1 month behind, United States, 2019
02/22/19
Table 2a - Catch-up immunization schedule for persons aged 4 months-18 years who start late or who 
are more than 1 month behind, United States, 2019 
Table 3a - Recommended Child and Adolescent Immunization Schedule by Medical Indication, 
United States, 2019 
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Diphtheria, tetanus, and pertussis (DTaP) 
vaccination (minimum age: 6 weeks [4 years  
for Kinrix or Quadracel])
Routine vaccination
 y 5-dose series at 2, 4, 6, 15–18 months, 4–6 years
 - Prospectively: Dose 4 may be given as early as age 
12 months if at least 6 months have elapsed since dose 3.
 - Retrospectively: A 4th dose that was inadvertently given as 
early as 12 months may be counted if at least 4 months have 
elapsed since dose 3.
Catch-up vaccination
 y Dose 5 is not necessary if dose 4 was administered at age 
4 years or older.
 y For other catch-up guidance, see Table 2.
Haemophilus influenzae type b vaccination  
(minimum age: 6 weeks) 
Routine vaccination 
 y ActHIB, Hiberix, or Pentacel: 4-dose series at 2, 4, 6, 
12–15 months
 y PedvaxHIB: 3-dose series at 2, 4, 12–15 months
Catch-up vaccination
 y Dose 1 at 7–11 months: Administer dose 2 at least 4 weeks 
later and dose 3 (final dose) at 12–15 months or 8 weeks after 
dose 2 (whichever is later).
 y Dose 1 at 12–14 months: Administer dose 2 (final dose) at 
least 8 weeks after dose 1.
 y Dose 1 before 12 months and dose 2 before 15 months: 
Administer dose 3 (final dose) 8 weeks after dose 2.
 y 2 doses of PedvaxHIB before 12 months: Administer dose 3 
(final dose) at 12–59 months and at least 8 weeks after dose 2.
 y Unvaccinated at 15–59 months: 1 dose
 y For other catch-up guidance, see Table 2. 
Special situations
 y Chemotherapy or radiation treatment:  
12–59 months 
 - Unvaccinated or only 1 dose before age 12 months: 2 doses, 
8 weeks apart
 - 2 or more doses before age 12 months: 1 dose at least 
8 weeks after previous dose
Doses administered within 14 days of starting therapy or during 
therapy should be repeated at least 3 months after therapy 
completion.
 y Hematopoietic stem cell transplant (HSCT):
 - 3-dose series 4 weeks apart starting 6 to 12 months after 
successful transplant regardless of Hib vaccination history
 y Anatomic or functional asplenia (including sickle cell 
disease): 
12–59 months
 - Unvaccinated or only 1 dose before 12 months: 2 doses, 
8 weeks apart
 - 2 or more doses before 12 months:1 dose at least 8 weeks 
after previous dose
Unvaccinated* persons age 5 years or older
 - 1 dose
 y Elective splenectomy: 
Unvaccinated* persons age 15 months or older
 - 1 dose (preferably at least 14 days before procedure)
 y HIV infection: 
12–59 months
 - Unvaccinated or only 1 dose before age 12 months: 2 doses, 
8 weeks apart
 - 2 or more doses before age 12 months: 1 dose at least 
8 weeks after previous dose
Unvaccinated* persons age 5–18 years
 - 1 dose
 y Immunoglobulin deficiency, early component 
complement deficiency: 
12–59 months
 - Unvaccinated or only 1 dose before age 12 months: 2 doses, 
8 weeks apart
 - 2 or more doses before age 12 months: 1 dose at least 
8 weeks after previous dose
* Unvaccinated = Less than routine series (through 14 months) 
OR no doses (14 months or older)
For vaccine recommendations for persons 19 years of age and 
older, see the Recommended Adult Immunization Schedule.
Additional information
 y Consult relevant ACIP statements for detailed 
recommendations at www.cdc.gov/vaccines/hcp/acip-recs/
index.html.
 y For information on contraindications and precautions for the 
use of a vaccine, consult the General Best Practice Guidelines 
for Immunization and relevant ACIP statements at www.cdc.
gov/vaccines/hcp/acip-recs/index.html.
 y For calculating intervals between doses, 4 weeks = 28 days. 
Intervals of ≥4 months are determined by calendar months.
 y Within a number range (e.g., 12–18), a dash (–) should be read 
as “through.”
 y Vaccine doses administered ≤4 days before the minimum 
age or interval are considered valid. Doses of any vaccine 
administered ≥5 days earlier than the minimum age or 
minimum interval should not be counted as valid and should 
be repeated as age-appropriate. The repeat dose should be 
spaced after the invalid dose by the recommended minimum 
interval. For further details, see Table 3-1, Recommended 
and minimum ages and intervals between vaccine doses, in 
General Best Practice Guidelines for Immunization at www.
cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html.
 y Information on travel vaccine requirements and 
recommendations is available at wwwnc.cdc.gov/travel/.
 y For vaccination of persons with immunodeficiencies, see 
Table 8-1, Vaccination of persons with primary and secondary 
immunodeficiencies, in General Best Practice Guidelines 
for Immunization at www.cdc.gov/vaccines/hcp/acip-recs/
general-recs/immunocompetence.html, and Immunization 
in Special Clinical Circumstances (In: Kimberlin DW, Brady 
MT, Jackson MA, Long SS, eds. Red Book: 2018 Report of the 
Committee on Infectious Diseases. 31st ed. Itasca, IL: American 
Academy of Pediatrics; 2018:67–111).
 y For information regarding vaccination in the setting of a 
vaccine-preventable disease outbreak, contact your state or 
local health department.
 y The National Vaccine Injury Compensation Program (VICP) is a 
no-fault alternative to the traditional legal system for resolving 
vaccine injury claims. All routine child and adolescent vaccines 
are covered by VICP except for pneumococcal polysaccharide 
vaccine (PPSV23). For more information, see www.hrsa.gov/
vaccinecompensation/index.html.
Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2019Notes
02/22/19
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Hepatitis A vaccination  
(minimum age: 12 months for routine vaccination)
Routine vaccination
 y 2-dose series (Havrix 6–12 months apart or Vaqta 
6–18 months apart, minimum interval 6 months); a series 
begun before the 2nd birthday should be completed even if 
the child turns 2 before the second dose is administered.
Catch-up vaccination
 y Anyone 2 years of age or older may receive HepA vaccine if 
desired. Minimum interval between doses: 6 months
 y Adolescents 18 years and older may receive the combined 
HepA and HepB vaccine, Twinrix, as a 3-dose series (0, 1, and 
6 months) or 4-dose series (0, 7, and 21–30 days, followed by a 
dose at 12 months).
International travel
 y Persons traveling to or working in countries with high or 
intermediate endemic hepatitis A (wwwnc.cdc.gov/travel/):
 - Infants age 6–11 months: 1 dose before departure; 
revaccinate with 2 doses, separated by 6–18 months, 
between 12 to 23 months of age.
 - Unvaccinated age 12 months and older: 1st dose as soon as 
travel considered
Special situations
At risk for hepatitis A infection: 2-dose series as above 
 y Chronic liver disease
 y Clotting factor disorders
 y Men who have sex with men
 y Injection or non-injection drug use
 y Homelessness
 y Work with hepatitis A virus in research laboratory or 
nonhuman primates with hepatitis A infection
 y Travel in countries with high or intermediate endemic 
hepatitis A 
 y Close, personal contact with international adoptee (e.g., 
household or regular babysitting) in first 60 days after arrival 
from country with high or intermediate endemic hepatitis A 
(administer dose 1 as soon as adoption is planned, at least 
2 weeks before adoptee’s arrival)
Hepatitis B vaccination  
(minimum age: birth)
Birth dose (monovalent HepB vaccine only)
 y Mother is HBsAg-negative: 1 dose within 24 hours of 
birth for all medically stable infants ≥2,000 grams. Infants 
<2,000 grams: administer 1 dose at chronological age 1 month 
or hospital discharge.
 y Mother is HBsAg-positive:
 - Administer HepB vaccine and 0.5 mL of hepatitis B 
immune globulin (HBIG) (at separate anatomic sites) within 
12 hours of birth, regardless of birth weight. For infants 
<2,000 grams, administer 3 additional doses of vaccine (total 
of 4 doses) beginning at age 1 month.
 - Test for HBsAg and anti-HBs at age 9–12 months. If HepB 
series is delayed, test 1–2 months after final dose.
 y Mother’s HBsAg status is unknown: 
 - Administer HepB vaccine within 12 hours of birth, regardless 
of birth weight. 
 - For infants <2,000 grams, administer 0.5 mL of HBIG in 
addition to HepB vaccine within 12 hours of birth. Administer 
3 additional doses of vaccine (total of 4 doses) beginning at 
age 1 month.
 - Determine mother’s HBsAg status as soon as possible. If 
mother is HBsAg-positive, administer 0.5 mL of HBIG to 
infants ≥2,000 grams as soon as possible, but no later than 
7 days of age.
Routine series
 y 3-dose series at 0, 1–2, 6–18 months (use monovalent HepB 
vaccine for doses administered before age 6 weeks)
 y Infants who did not receive a birth dose should begin the 
series as soon as feasible (see Table 2).
 y Administration of 4 doses is permitted when a combination 
vaccine containing HepB is used after the birth dose.
 y Minimum age for the final (3rd or 4th ) dose: 24 weeks 
 y Minimum intervals: dose 1 to dose 2: 4 weeks / dose 2 to 
dose 3: 8 weeks / dose 1 to dose 3: 16 weeks (when 4 doses 
are administered, substitute “dose 4” for “dose 3” in these 
calculations)
Catch-up vaccination
 y Unvaccinated persons should complete a 3-dose series at 0, 
1–2, 6 months.
 y Adolescents age 11–15 years may use an alternative 2-dose 
schedule with at least 4 months between doses (adult 
formulation Recombivax HB only).
 y Adolescents 18 years and older may receive a 2-dose series of 
HepB (Heplisav-B) at least 4 weeks apart.
 y Adolescents 18 years and older may receive the combined 
HepA and HepB vaccine, Twinrix, as a 3-dose series (0, 1, and 
6 months) or 4-dose series (0, 7, and 21–30 days, followed by a 
dose at 12 months).
 y For other catch-up guidance, see Table 2.
Human papillomavirus vaccination  
(minimum age: 9 years)
Routine and catch-up vaccination
 y HPV vaccination routinely recommended for all adolescents 
age 11–12 years (can start at age 9 years) and through age 
18 years if not previously adequately vaccinated 
 y 2- or 3-dose series depending on age at initial vaccination: 
 - Age 9 through 14 years at initial vaccination: 2-dose series 
at 0, 6–12 months (minimum interval: 5 months; repeat dose 
if administered too soon) 
 - Age 15 years or older at initial vaccination: 3-dose series 
at 0, 1–2 months, 6 months (minimum intervals: dose 1 to 
dose 2: 4 weeks / dose 2 to dose 3: 12 weeks / dose 1 to dose 
3: 5 months; repeat dose if administered too soon) 
 y If completed valid vaccination series with any HPV vaccine, no 
additional doses needed
Special situations
 y Immunocompromising conditions, including HIV 
infection: 3-dose series as above
 y History of sexual abuse or assault: Start at age 9 years
 y Pregnancy: HPV vaccination not recommended until after 
pregnancy; no intervention needed if vaccinated while 
pregnant; pregnancy testing not needed before vaccination
Inactivated poliovirus vaccination  
(minimum age: 6 weeks)
Routine vaccination
 y 4-dose series at ages 2, 4, 6–18 months, 4–6 years; administer 
the final dose on or after the 4th birthday and at least 6 months 
after the previous dose.
 y 4 or more doses of IPV can be administered before the 
4th birthday when a combination vaccine containing IPV 
is used. However, a dose is still recommended after the 4th 
birthday and at least 6 months after the previous dose.
Catch-up vaccination
 y In the first 6 months of life, use minimum ages and intervals 
only for travel to a polio-endemic region or during an 
outbreak.
 y IPV is not routinely recommended for U.S. residents 18 years 
and older.
Series containing oral polio vaccine (OPV), either mixed OPV-
IPV or OPV-only series:
 y Total number of doses needed to complete the series is the 
same as that recommended for the U.S. IPV schedule. See 
www.cdc.gov/mmwr/volumes/66/wr/mm6601a6.htm?s_
cid=mm6601a6_w. 
Notes Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2019
02/22/19
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 y Only trivalent OPV (tOPV) counts toward the U.S. vaccination 
requirements. For guidance to assess doses documented as 
“OPV,” see www.cdc.gov/mmwr/volumes/66/wr/mm6606a7.
htm?s_cid=mm6606a7_w. 
 y For other catch-up guidance, see Table 2.
Influenza vaccination  
(minimum age: 6 months [IIV], 2 years [LAIV], 
18 years [RIV])
Routine vaccination
 y 1 dose any influenza vaccine appropriate for age and health 
status annually (2 doses separated by at least 4 weeks for 
children 6 months–8 years who did not receive at least 
2 doses of influenza vaccine before July 1, 2018)
Special situations
 y Egg allergy, hives only: Any influenza vaccine appropriate for 
age and health status annually
 y Egg allergy more severe than hives (e.g., angioedema, 
respiratory distress): Any influenza vaccine appropriate for 
age and health status annually in medical setting under 
supervision of health care provider who can recognize and 
manage severe allergic conditions
 y LAIV should not be used for those with a history of 
severe allergic reaction to any component of the vaccine 
(excluding egg) or to a previous dose of any influenza 
vaccine, children and adolescents receiving concomitant 
aspirin or salicylate-containing medications, children age 
2 through 4 years with a history of asthma or wheezing, 
those who are immunocompromised due to any cause 
(including immunosuppression caused by medications and 
HIV infection), anatomic and functional asplenia, cochlear 
implants, cerebrospinal fluid-oropharyngeal communication, 
close contacts and caregivers of severely immunosuppressed 
persons who require a protected environment, pregnancy, 
and persons who have received influenza antiviral 
medications within the previous 48 hours.
Measles, mumps, and rubella vaccination  
(minimum age: 12 months for routine vaccination)
Routine vaccination
 y 2-dose series at 12–15 months, 4–6 years
 y Dose 2 may be administered as early as 4 weeks after dose 1.
Catch-up vaccination
 y Unvaccinated children and adolescents: 2 doses at least 
4 weeks apart
 y The maximum age for use of MMRV is 12 years.
Special situations
International travel
 y Infants age 6–11 months: 1 dose before departure; 
revaccinate with 2 doses at 12–15 months (12 months for 
children in high-risk areas) and dose 2 as early as 4 weeks later.
 y Unvaccinated children age 12 months and older: 2-dose 
series at least 4 weeks apart before departure
Meningococcal serogroup A,C,W,Y vaccination 
(minimum age: 2 months [MenACWY-CRM, 
Menveo], 9 months [MenACWY-D, Menactra])
Routine vaccination
 y 2-dose series: 11–12 years, 16 years
Catch-up vaccination
 y Age 13–15 years: 1 dose now and booster at age  
16–18 years (minimum interval: 8 weeks)
 y Age 16–18 years: 1 dose 
Special situations
Anatomic or functional asplenia (including sickle cell 
disease), HIV infection, persistent complement component 
deficiency, eculizumab use:
 y Menveo
 - Dose 1 at age 8 weeks: 4-dose series at 2, 4, 6, 12 months
 - Dose 1 at age 7–23 months: 2-dose series (dose 2 at least 
12 weeks after dose 1 and after the 1st birthday)
 - Dose 1 at age 24 months or older: 2-dose series at least 
8 weeks apart
 y Menactra
 - Persistent complement component deficiency: 
  Age 9–23 months: 2 doses at least 12 weeks apart
  Age 24 months or older: 2 doses at least 8 weeks apart
 - Anatomic or functional asplenia, sickle cell disease, or 
HIV infection: 
  Age 9–23 months: Not recommended 
  24 months or older: 2 doses at least 8 weeks apart 
  Menactra must be administered at least 4 weeks after 
completion of PCV13 series.
Travel in countries with hyperendemic or epidemic 
meningococcal disease, including countries in the African 
meningitis belt or during the Hajj (wwwnc.cdc.gov/travel/):
 y Children age less than 24 months:
 - Menveo (age 2–23 months):
  Dose 1 at 8 weeks: 4-dose series at 2, 4, 6, 12 months
  Dose 1 at 7–23 months: 2-dose series (dose 2 at least 
12 weeks after dose 1 and after the 1st birthday)
 - Menactra (age 9–23 months): 
  2-dose series (dose 2 at least 12 weeks after dose 1; dose 
2 may be administered as early as 8 weeks after dose 1 in 
travelers)
 y Children age 2 years or older: 1 dose Menveo or Menactra
First-year college students who live in residential housing 
(if not previously vaccinated at age 16 years or older) or 
military recruits:
 y 1 dose Menveo or Menactra
Note: Menactra should be administered either before 
or at the same time as DTaP. For MenACWY booster dose 
recommendations for groups listed under “Special situations” 
above and additional meningococcal vaccination information, 
see meningococcal MMWR publications at www.cdc.gov/
vaccines/hcp/acip-recs/vacc-specific/mening.html.
Meningococcal serogroup B vaccination 
(minimum age: 10 years [MenB-4C, Bexsero;  
MenB-FHbp, Trumenba])
Clinical discretion
 y MenB vaccine may be administered based on individual 
clinical decision to adolescents not at increased risk age 
16–23 years (preferred age 16–18 years):
 y Bexsero: 2-dose series at least 1 month apart
 y Trumenba: 2-dose series at least 6 months apart; if dose 2 is 
administered earlier than 6 months, administer a 3rd dose at 
least 4 months after dose 2. 
Special situations
Anatomic or functional asplenia (including sickle cell 
disease), persistent complement component deficiency, 
eculizumab use:
 y Bexsero: 2-dose series at least 1 month apart
 y Trumenba: 3-dose series at 0, 1–2, 6 months
Bexsero and Trumenba are not interchangeable; the same 
product should be used for all doses in a series.
For additional meningococcal vaccination information, see 
meningococcal MMWR publications at www.cdc.gov/vaccines/
hcp/acip-recs/vacc-specific/mening.html.
Notes Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2019
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Recommended Adult Immunization Schedule
for ages 19  years or older
UNITED STATES
2019
Vaccines in the Adult Immunization Schedule*
Vaccines Abbreviations Trade names
Haemophilus influenzae type b vaccine Hib ActHIB
Hiberix
Hepatitis A vaccine HepA Havrix
Vaqta
Hepatitis A and hepatitis B vaccine HepA-HepB Twinrix
Hepatitis B vaccine HepB Engerix-B
Recombivax HB
Heplisav-B
Human papillomavirus vaccine HPV vaccine Gardasil 9
Influenza vaccine, inactivated IIV Many brands
Influenza vaccine, live attenuated LAIV FluMist Quadrivalent
Influenza vaccine, recombinant RIV Flublok Quadrivalent
Measles, mumps, and rubella vaccine MMR M-M-R II
Meningococcal serogroups A, C, W, Y vaccine MenACWY Menactra
Menveo
Meningococcal serogroup B vaccine MenB-4C
MenB-FHbp
Bexsero
Trumenba
Pneumococcal 13-valent conjugate vaccine PCV13 Prevnar 13
Pneumococcal 23-valent polysaccharide vaccine PPSV23 Pneumovax
Tetanus and diphtheria toxoids Td Tenivac
Td vaccine
Tetanus and diphtheria toxoids and acellular pertussis vaccine Tdap Adacel
Boostrix
Varicella vaccine VAR Varivax
Zoster vaccine, recombinant RZV Shingrix
Zoster vaccine live ZVL Zostavax
* Administer recommended vaccines if vaccination history is incomplete or unknown. Do not restart or add doses to vaccine 
series for extended intervals between doses. The use of trade names is for identification purposes only and does not imply 
endorsement by the ACIP or CDC.
Report
 y Suspected cases of reportable vaccine-preventable diseases or outbreaks to 
the local or state health department
 y Clinically significant postvaccination reactions to the Vaccine Adverse Event 
Reporting System at www.vaers.hhs.gov or 800-822-7967
Injury claims
All vaccines included in the adult immunization schedule except pneumococcal 
23-valent polysaccharide and zoster vaccines are covered by the Vaccine Injury 
Compensation Program. Information on how to file a vaccine injury claim is 
available at www.hrsa.gov/vaccinecompensation or 800-338-2382.
Questions or comments
Contact www.cdc.gov/cdc-info or 800-CDC-INFO (800-232-4636), in English or 
Spanish, 8 a.m.–8 p.m. ET, Monday through Friday, excluding holidays.
Helpful information
 y Complete ACIP recommendations:  
www.cdc.gov/vaccines/hcp/acip-recs/index.html
 y General Best Practice Guidelines for Immunization  
(including contraindications and precautions):  
www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html 
 y Vaccine Information Statements: www.cdc.gov/vaccines/hcp/vis/index.html 
 y Manual for the Surveillance of Vaccine-Preventable Diseases  
(including case identification and outbreak response):  
www.cdc.gov/vaccines/pubs/surv-manual 
 y Travel vaccine recommendations: www.cdc.gov/travel
 y Recommended Child and Adolescent Immunization Schedule, United States, 
2019: www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html
How to use the adult immunization schedule
1  Determine recommended vaccinations by age 
(Table 1)
2   Assess need for additional recommended vaccinations 
by medical condition and 
other indications (Table 2)
3   Review vaccine types, frequencies, and intervals, 
and considerations for 
special situations (Notes)
Recommended by the Advisory Committee on Immunization Practices  
(www.cdc.gov/vaccines/acip) and approved by the Centers for Disease  
Control and Prevention (www.cdc.gov), American College of Physicians  
(www.acponline.org), American Academy of Family Physicians (www.aafp.org), 
American College of Obstetricians and Gynecologists (www.acog.org), and 
American College of Nurse-Midwives (www.midwife.org).
Download the CDC Vaccine Schedules App for providers at  
www.cdc.gov/vaccines/schedules/hcp/schedule-app.html.
U.S. Department of 
Health and Human Services 
Centers for Disease 
Control and Prevention 
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Vaccine 19–21 years 22–26 years 27–49 years 50–64 years ≥65 years
Influenza inactivated (IIV) or 
Influenza recombinant (RIV) 1 dose annually
Influenza live attenuated
(LAIV)                                                                                                                        1 dose annually
Tetanus, diphtheria, pertussis 
(Tdap or Td) 1 dose Tdap, then Td booster every 10 yrs
Measles, mumps, rubella 
(MMR)                                                                       1 or 2 doses depending on indication (if born in 1957 or later)
Varicella  
(VAR) 2 doses (if born in 1980 or later)
Zoster recombinant  
(RZV) (preferred) 2 doses
Zoster live  
(ZVL)             1 dose
Human papillomavirus (HPV) 
Female 2 or 3 doses depending on age at initial vaccination
Human papillomavirus (HPV) 
Male 2 or 3 doses depending on age at initial vaccination
Pneumococcal conjugate 
(PCV13)                                                         
Pneumococcal polysaccharide 
(PPSV23)                                                              1 or 2 doses depending on indication 1 dose
Hepatitis A  
(HepA) 2 or 3 doses depending on vaccine
Hepatitis B  
(HepB) 2 or 3 doses depending on vaccine
Meningococcal A, C, W, Y 
(MenACWY) 1 or 2 doses depending on indication, then booster every 5 yrs if risk remains
Meningococcal B  
(MenB) 2 or 3 doses depending on vaccine and indication
Haemophilus influenzae type b 
(Hib) 1 or 3 doses depending on indication
1 dose
Table 1 Recommended Adult Immunization Schedule by Age Group United States, 2019
or or
oror
  Recommended vaccination for adults who meet age requirement,  lack documentation of vaccination, or lack evidence of past infection  Recommended vaccination for adults with an additional risk factor or another indication  No recommendation
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Vaccine Pregnancy
Immuno-
compromised 
(excluding HIV 
infection)
HIV infection 
CD4 count Asplenia, complement 
deficiencies
End-stage  
renal  
disease, on  
hemodialysis
Heart or 
lung disease, 
alcoholism1
Chronic liver 
disease Diabetes
Health care 
personnel2
Men who have 
sex with men<200 ≥200
IIV or RIV 1 dose annually
LAIV CONTRAINDICATED PRECAUTION 1 dose annually
Tdap or Td 1 dose Tdap each pregnancy                                                                                          1 dose Tdap, then Td booster every 10 yrs
MMR CONTRAINDICATED 1 or 2 doses depending on indication
VAR CONTRAINDICATED 2 doses
RZV(preferred) DELAY 2 doses at age ≥50 yrs
ZVL CONTRAINDICATED 1 dose at age ≥60 yrs
HPV Female DELAY 3 doses through age 26 yrs 2 or 3 doses through age 26 yrs
HPV Male 3 doses through age 26 yrs 2 or 3 doses through age 21 yrs 2 or 3 doses through age 26 yrs
PCV13
PPSV23
HepA
HepB
MenACWY
MenB PRECAUTION
Hib 3 doses HSCT3 recipients only
1 dose
1, 2, or 3 doses depending on age and indication
1 or 2 doses depending on indication, then booster every 5 yrs if risk remains
2 or 3 doses depending on vaccine and indication
2 or 3 doses depending on vaccine
2 or 3 doses depending on vaccine
1 dose
Table 2
or or
Recommended Adult Immunization Schedule by Medical Condition and Other Indications  
United States, 2019
  Recommended vaccination for adults who meet age requirement, lack 
documentation of vaccination, or lack 
evidence of past infection
  Recommended vaccination for adults with an additional 
risk factor or another 
indication
  Precaution—vaccine might be indicated if benefit of 
protection outweighs risk of 
adverse reaction
  Delay vaccination until after pregnancy if 
vaccine is indicated
  Contraindicated—vaccine should not be administered 
because of risk for serious 
adverse reaction
 No recommendation
oror
1. Precaution for LAIV does not apply to alcoholism. 2. See notes for influenza; hepatitis B; measles, mumps, and rubella; and varicella vaccinations. 3. Hematopoietic stem cell transplant.
Table 1b - Recommended Adult Immunization Schedule by Age Group, United States, 2019  
Table 2b - Recommended Adult Immunization Schedule by Medical Condition and Other Indications, 
United States, 2019 
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Haemophilus influenzae type b vaccination
Special situations
 y Anatomical or functional asplenia (including sickle 
cell disease): 1 dose Hib if previously did not receive 
Hib; if elective splenectomy, 1 dose Hib, preferably at 
least 14 days before splenectomy
 y Hematopoietic stem cell transplant (HSCT): 3-dose 
series Hib 4 weeks apart starting 6–12 months after 
successful transplant, regardless of Hib vaccination 
history
Hepatitis A vaccination
Routine vaccination
 y Not at risk but want protection from hepatitis A 
(identification of risk factor not required): 2-dose 
series HepA (Havrix 6–12 months apart or Vaqta 
6–18 months apart [minimum interval: 6 months]) or 
3-dose series HepA-HepB (Twinrix at 0, 1, 6 months 
[minimum intervals: 4 weeks between doses 1 and 2, 
5 months between doses 2 and 3]) 
Special situations
 y At risk for hepatitis A virus infection: 2-dose series 
HepA or 3-dose series HepA-HepB as above
 - Chronic liver disease
 - Clotting factor disorders
 - Men who have sex with men
 - Injection or non-injection drug use
 - Homelessness 
 - Work with hepatitis A virus in research laboratory or 
nonhuman primates with hepatitis A virus infection
 - Travel in countries with high or intermediate 
endemic hepatitis A
 - Close personal contact with international adoptee 
(e.g., household, regular babysitting) in first 60 days 
after arrival from country with high or intermediate 
endemic hepatitis A (administer dose 1 as soon 
as adoption is planned, at least 2 weeks before 
adoptee’s arrival)
Hepatitis B vaccination
Routine vaccination
 y Not at risk but want protection from hepatitis B  
(identification of risk factor not required): 2- or 3-dose 
series HepB (2-dose series Heplisav-B at least 4 weeks 
apart [2-dose series HepB only applies when 2 doses 
of Heplisav-B are used at least 4 weeks apart] or 3-dose 
series Engerix-B or Recombivax HB at 0, 1, 6 months 
[minimum intervals: 4 weeks between doses 1 and 2, 
8 weeks between doses 2 and 3, 16 weeks between 
doses 1 and 3]) or 3-dose series HepA-HepB (Twinrix at 
0, 1, 6 months [minimum intervals: 4 weeks between 
doses 1 and 2, 5 months between doses 2 and 3])
Special situations
 y At risk for hepatitis B virus infection: 2-dose 
(Heplisav-B) or 3-dose (Engerix-B, Recombivax HB) 
series HepB, or 3-dose series HepA-HepB as above
 - Hepatitis C virus infection
 - Chronic liver disease (e.g., cirrhosis, fatty liver 
disease, alcoholic liver disease, autoimmune 
hepatitis, alanine aminotransferase [ALT] or aspartate 
aminotransferase [AST] level greater than twice 
upper limit of normal)
 - HIV infection
 - Sexual exposure risk (e.g., sex partners of hepatitis B 
surface antigen (HBsAg)-positive persons; sexually 
active persons not in mutually monogamous 
relationships, persons seeking evaluation or 
treatment for a sexually transmitted infection, men 
who have sex with men)
 - Current or recent injection drug use
 - Percutaneous or mucosal risk for exposure to 
blood (e.g., household contacts of HBsAg-positive 
persons; residents and staff of facilities for develop-
mentally disabled persons; health care and public 
safety personnel with reasonably anticipated risk 
for exposure to blood or blood-contaminated body 
fluids; hemodialysis, peritoneal dialysis, home dialysis, 
and predialysis patients; persons with diabetes mel-
litus age younger than 60 years and, at discretion of 
treating clinician, those age 60 years or older)
 - Incarcerated persons
 - Travel in countries with high or intermediate 
endemic hepatitis B
Human papillomavirus vaccination
Routine vaccination
 y Females through age 26 years and males through 
age 21 years: 2- or 3-dose series HPV vaccine 
depending on age at initial vaccination; males age 
22 through 26 years may be vaccinated based on 
individual clinical decision (HPV vaccination routinely 
recommended at age 11–12 years)
 y Age 15 years or older at initial vaccination: 3-dose 
series HPV vaccine at 0, 1–2, 6 months (minimum 
intervals: 4 weeks between doses 1 and 2, 12 weeks 
between doses 2 and 3, 5 months between doses 
1 and 3; repeat dose if administered too soon)
 y Age 9 through 14 years at initial vaccination and 
received 1 dose, or 2 doses less than 5 months 
apart: 1 dose HPV vaccine
 y Age 9 through 14 years at initial vaccination and 
received 2 doses at least 5 months apart: HPV 
vaccination complete, no additional dose needed
 y If completed valid vaccination series with any HPV 
vaccine, no additional doses needed
Special situations
 y Immunocompromising conditions (including HIV 
infection) through age 26 years: 3-dose series HPV 
vaccine at 0, 1–2, 6 months as above
 y Men who have sex with men and transgender 
persons through age 26 years: 2- or 3-dose series 
HPV vaccine depending on age at initial vaccination  
as above
 y Pregnancy through age 26 years: HPV vaccination 
not recommended until after pregnancy; no 
intervention needed if vaccinated while pregnant; 
pregnancy testing not needed before vaccination
Recommended Adult Immunization Schedule
United States, 2019Notes
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Influenza vaccination
Routine vaccination
 y Persons age 6 months or older: 1 dose IIV, RIV, or 
LAIV appropriate for age and health status annually
 y For additional guidance, see www.cdc.gov/flu/
professionals/index.htm
Special situations
 y Egg allergy, hives only: 1 dose IIV, RIV, or LAIV 
appropriate for age and health status annually
 y Egg allergy more severe than hives (e.g., 
angioedema, respiratory distress): 1 dose IIV, RIV, or 
LAIV appropriate for age and health status annually 
in medical setting under supervision of health care 
provider who can recognize and manage severe 
allergic conditions
 y Immunocompromising conditions (including HIV 
infection), anatomical or functional asplenia, 
pregnant women, close contacts and caregivers 
of severely immunocompromised persons 
in protected environment, use of influenza 
antiviral medications in previous 48 hours, with 
cerebrospinal fluid leak or cochlear implant: 1 dose 
IIV or RIV annually (LAIV not recommended)
 y History of Guillain-Barré syndrome within 6 weeks 
of previous dose of influenza vaccine: Generally 
should not be vaccinated
Measles, mumps, and rubella vaccination
Routine vaccination
 y No evidence of immunity to measles, mumps, or 
rubella: 1 dose MMR
 - Evidence of immunity: Born before 1957 (except 
health care personnel [see below]), documentation 
of receipt of MMR, laboratory evidence of immunity 
or disease (diagnosis of disease without laboratory 
confirmation is not evidence of immunity)
Special situations
 y Pregnancy with no evidence of immunity to 
rubella: MMR contraindicated during pregnancy; after 
pregnancy (before discharge from health care facility), 
1 dose MMR
 y Non-pregnant women of childbearing age with no 
evidence of immunity to rubella: 1 dose MMR
 y HIV infection with CD4 count ≥200 cells/μL for at 
least 6 months and no evidence of immunity to 
measles, mumps, or rubella: 2-dose series MMR 
at least 4 weeks apart; MMR contraindicated in HIV 
infection with CD4 count <200 cells/μL
 y Severe immunocompromising conditions: MMR 
contraindicated
 y Students in postsecondary educational 
institutions, international travelers, and household 
or close personal contacts of immunocompromised 
persons with no evidence of immunity to measles, 
mumps, or rubella: 1 dose MMR if previously received 
1 dose MMR, or 2-dose series MMR at least 4 weeks 
apart if previously did not receive any MMR 
 y Health care personnel born in 1957 or later with 
no evidence of immunity to measles, mumps, or 
rubella: 2-dose series MMR at least 4 weeks apart for 
measles or mumps, or at least 1 dose MMR for rubella; 
if born before 1957, consider 2-dose series MMR at 
least 4 weeks apart for measles or mumps, or 1 dose 
MMR for rubella
Meningococcal vaccination
Special situations for MenACWY
 y Anatomical or functional asplenia (including sickle 
cell disease), HIV infection, persistent complement 
component deficiency, eculizumab use: 2-dose 
series MenACWY (Menactra, Menveo) at least 8 weeks 
apart and revaccinate every 5 years if risk remains
 y Travel in countries with hyperendemic or epidemic 
meningococcal disease, microbiologists routinely 
exposed to Neisseria meningitidis: 1 dose MenACWY 
and revaccinate every 5 years if risk remains
 y First-year college students who live in residential 
housing (if not previously vaccinated at age 
16 years or older) and military recruits: 1 dose 
MenACWY
Special situations for MenB
 y Anatomical or functional asplenia (including sickle 
cell disease), persistent complement component 
deficiency, eculizumab use, microbiologists 
routinely exposed to Neisseria meningitidis: 2-dose 
series MenB-4C (Bexsero) at least 1 month apart, 
or 3-dose series MenB-FHbp (Trumenba) at 0, 1–2, 
6 months (if dose 2 was administered at least 6 months 
after dose 1, dose 3 not needed); MenB-4C and MenB-
FHbp are not interchangeable (use same product for 
all doses in series)
 y Pregnancy: Delay MenB until after pregnancy unless 
at increased risk and vaccination benefit outweighs 
potential risks
 y Healthy adolescents and young adults age 
16 through 23 years (age 16 through 18 years 
preferred) not at increased risk for meningococcal 
disease: Based on individual clinical decision, may 
receive 2-dose series MenB-4C at least 1 month apart, 
or 2-dose series MenB-FHbp at 0, 6 months (if dose 
2 was administered less than 6 months after dose 
1, administer dose 3 at least 4 months after dose 2); 
MenB-4C and MenB-FHbp are not interchangeable 
(use same product for all doses in series)
Recommended Adult Immunization Schedule
United States, 2019Notes
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Pneumococcal vaccination
Routine vaccination
 y Age 65 years or older (immunocompetent): 1 dose 
PCV13 if previously did not receive PCV13, followed by 
1 dose PPSV23 at least 1 year after PCV13 and at least 
5 years after last dose PPSV23 
 - Previously received PPSV23 but not PCV13 at age 
65 years or older: 1 dose PCV13 at least 1 year after 
PPSV23
 - When both PCV13 and PPSV23 are indicated, 
administer PCV13 first (PCV13 and PPSV23 should not 
be administered during same visit)
Special situations
 y Age 19 through 64 years with chronic medical 
conditions (chronic heart [excluding hypertension], 
lung, or liver disease; diabetes), alcoholism, or 
cigarette smoking: 1 dose PPSV23
 y Age 19 years or older with immunocompromising 
conditions (congenital or acquired 
immunodeficiency [including B- and T-lymphocyte 
deficiency, complement deficiencies, phagocytic 
disorders, HIV infection], chronic renal failure, 
nephrotic syndrome, leukemia, lymphoma, 
Hodgkin disease, generalized malignancy, 
iatrogenic immunosuppression [e.g., drug or 
radiation therapy], solid organ transplant, 
multiple myeloma) or anatomical or functional 
asplenia (including sickle cell disease and other 
hemoglobinopathies): 1 dose PCV13 followed by 
1 dose PPSV23 at least 8 weeks later, then another 
dose PPSV23 at least 5 years after previous PPSV23; 
at age 65 years or older, administer 1 dose PPSV23 
at least 5 years after most recent PPSV23 (note: only 
1 dose PPSV23 recommended at age 65 years or older)
 y Age 19 years or older with cerebrospinal fluid leak 
or cochlear implant: 1 dose PCV13 followed by 1 dose 
PPSV23 at least 8 weeks later; at age 65 years or older, 
administer another dose PPSV23 at least 5 years after 
PPSV23 (note: only 1 dose PPSV23 recommended at 
age 65 years or older)
Tetanus, diphtheria, and pertussis vaccination
Routine vaccination
 y Previously did not receive Tdap at or after age 
11 years: 1 dose Tdap, then Td booster every 10 years
Special situations
 y Previously did not receive primary vaccination 
series for tetanus, diphtheria, and pertussis: 1 dose 
Tdap followed by 1 dose Td at least 4 weeks after Tdap, 
and another dose Td 6–12 months after last Td (Tdap 
can be substituted for any Td dose, but preferred as 
first dose); Td booster every 10 years thereafter
 y Pregnancy: 1 dose Tdap during each pregnancy, 
preferably in early part of gestational weeks 27–36
 y For information on use of Tdap or Td as tetanus 
prophylaxis in wound management, see www.cdc.gov/
mmwr/volumes/67/rr/rr6702a1.htm
Varicella vaccination
Routine vaccination
 y No evidence of immunity to varicella: 2-dose series 
VAR 4–8 weeks apart if previously did not receive 
varicella-containing vaccine (VAR or MMRV [measles-
mumps-rubella-varicella vaccine] for children); if 
previously received 1 dose varicella-containing 
vaccine: 1 dose VAR at least 4 weeks after first dose
 - Evidence of immunity: U.S.-born before 1980 (except 
for pregnant women and health care personnel 
[see below]), documentation of 2 doses varicella-
containing vaccine at least 4 weeks apart, diagnosis 
or verification of history of varicella or herpes zoster 
by a health care provider, laboratory evidence of 
immunity or disease
Special situations
 y Pregnancy with no evidence of immunity to 
varicella: VAR contraindicated during pregnancy; after 
pregnancy (before discharge from health care facility), 
1 dose VAR if previously received 1 dose varicella-
containing vaccine, or dose 1 of 2-dose series VAR 
(dose 2: 4–8 weeks later) if previously did not receive 
any varicella-containing vaccine, regardless of whether 
U.S.-born before 1980
 y Health care personnel with no evidence of 
immunity to varicella: 1 dose VAR if previously 
received 1 dose varicella-containing vaccine, or 2-dose 
series VAR 4–8 weeks apart if previously did not receive 
any varicella-containing vaccine, regardless of whether 
U.S.-born before 1980
 y HIV infection with CD4 count ≥200 cells/µL with no 
evidence of immunity: Consider 2-dose series VAR 
3 months apart based on individual clinical decision; 
VAR contraindicated in HIV infection with CD4 count 
<200 cells/μL
 y Severe immunocompromising conditions: VAR 
contraindicated
Zoster vaccination
Routine vaccination
 y Age 50 years or older: 2-dose series RZV 2–6 months 
apart (minimum interval: 4 weeks; repeat dose if 
administered too soon) regardless of previous herpes 
zoster or previously received ZVL (administer RZV at 
least 2 months after ZVL)
 y Age 60 years or older: 2-dose series RZV 2–6 months 
apart (minimum interval: 4 weeks; repeat dose if 
administered too soon) or 1 dose ZVL if not previously 
vaccinated (if previously received ZVL, administer RZV 
at least 2 months after ZVL); RZV preferred over ZVL
Special situations
 y Pregnancy: ZVL contraindicated; consider delaying 
RZV until after pregnancy if RZV is otherwise indicated
 y Severe immunocompromising conditions 
(including HIV infection with CD4 count <200 cells/
μL): ZVL contraindicated; recommended use of RZV 
under review
Recommended Adult Immunization Schedule
United States, 2019Notes
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Table 66. Vaccination coverage for selected diseases among children aged 19–35 months, by race, Hispanic 
origin, poverty level, and location of residence in metropolitan statistical area: United States, selected years 
1998–2016 
Excel version (with more data years and standard errors when available): https://www.cdc.gov/nchs/hus/contents2017.htm#066. 
[Data are based on telephone interviews of a sample of the civilian noninstitutionalized population, supplemented by a survey of interview 
participants' immunization providers] 
Race and Hispanic origin1 Poverty level2 Location of residence 
Not Hispanic or Latino Inside MSA3 
Native 
Hawaiian 
Black or American or Other At or 
African Indian or Pacific 2 or Below above 
Vaccination and year All 
White 
only 
American 
only 
Alaska 
Native only 
Asian 
only4 
Islander 
only4 
more 
races 
Hispanic 
or Latino 
poverty 
level 
poverty 
level 
Central 
city 
Remaining 
area 
Outside 
MSA3 
Combined 
7-vaccine series:5 Percent of children aged 19–35 months 
2009 44.3 45.2 39.6 * 38.6 * 40.7 45.9 41.3 45.7 44.8 44.6 42.4 
2010 56.6 56.9 54.5 64.1 59.3 * 61.3 55.5 52.8 58.7 56.5 57.2 55.2 
2012 68.4 69.3 64.8 * 71.6 * 71.5 67.8 63.4 71.6 67.6 69.4 68.0 
2013 70.4 72.1 65.0 70.1 72.7 * 71.8 69.3 64.4 73.8 68.8 72.5 69.1 
2014 71.6 72.6 65.4 * 69.5 * 68.5 74.3 65.7 75.4 70.8 72.7 71.2 
2015 72.2 72.7 69.1 68.2 77.9 * 73.7 71.7 68.7 74.7 72.5 72.5 70.2 
2016 70.7 72.2 64.1 68.5 72.3 * 71.5 71.0 66.0 72.5 71.3 71.1 67.0 
DTP/DT/DTaP 
(4 doses or more):6 
1998 83.9 86.6 77.3 82.9 89.1 - - - - - - 80.5 79.5 86.1 81.6 85.4 85.1 
2000 81.7 84.4 76.1 77.8 84.5 * 81.5 78.6 76.2 83.5 79.9 82.8 82.9 
2005 85.7 87.1 84.0 * 88.8 * 86.3 83.6 81.8 87.4 84.8 87.0 84.7 
2009 83.9 85.8 78.6 82.1 86.6 93.1 81.8 82.9 80.1 85.7 83.8 84.2 84.2 
2010 84.4 84.5 83.7 81.8 88.3 * 82.8 84.4 80.8 86.1 84.0 85.0 83.7 
2012 82.5 83.6 79.6 88.2 88.1 * 85.6 80.8 78.5 85.0 82.4 83.4 80.5 
2013 83.1 85.3 74.7 78.1 89.0 * 83.1 82.3 77.8 86.0 81.8 84.7 82.4 
2014 84.2 85.5 79.1 * 87.4 * 79.6 85.4 79.1 87.4 83.6 85.3 83.1 
2015 84.6 85.2 82.0 79.6 90.0 * 82.5 84.5 80.2 87.1 85.4 84.3 82.7 
2016 83.4 84.8 76.8 83.5 86.4 83.2 83.6 83.3 79.2 85.1 83.3 84.8 78.8 
Polio 
(3 doses or more): 
1998 90.8 92.2 87.8 85.1 93.4 - - - - - - 88.9 89.9 91.7 89.3 91.3 92.9 
2000 89.5 90.6 86.6 90.8 92.7 91.2 91.2 87.9 86.9 89.9 88.1 90.1 91.1 
2005 91.7 91.4 91.0 * 92.9 * 93.8 92.3 89.7 92.4 90.6 92.6 92.2 
2009 92.8 93.3 90.9 92.2 94.0 97.3 92.8 92.5 92.0 93.3 93.5 92.1 92.1 
2010 93.3 93.2 94.0 94.6 92.8 95.1 90.2 93.8 92.4 93.6 92.7 94.1 93.1 
2012 92.8 93.0 92.9 95.2 92.3 * 93.3 92.5 91.8 93.4 92.6 92.9 92.8 
2013 92.7 93.7 91.2 92.2 95.5 * 90.8 91.6 89.2 94.4 91.9 93.2 93.4 
2014 93.3 93.3 92.0 93.8 93.2 93.8 94.0 93.8 92.0 94.5 92.7 94.2 92.7 
2015 93.7 93.1 93.3 91.8 96.9 92.8 92.4 94.5 91.8 94.6 93.9 94.0 91.7 
2016 91.9 92.5 90.3 92.4 94.7 91.3 89.4 91.7 90.6 92.5 92.0 92.2 90.8 
Page 1 of 4 Trend Tables Health, United States, 2017 
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Table 66. Vaccination coverage for selected diseases among children aged 19–35 months, by race, Hispanic 
origin, poverty level, and location of residence in metropolitan statistical area: United States, selected years 
1998–2016 
Excel version (with more data years and standard errors when available): https://www.cdc.gov/nchs/hus/contents2017.htm#066. 
[Data are based on telephone interviews of a sample of the civilian noninstitutionalized population, supplemented by a survey of interview 
participants' immunization providers] 
Race and Hispanic origin1 Poverty level2 Location of residence 
Not Hispanic or Latino Inside MSA3 
Native 
Hawaiian 
Black or American or Other At or 
African Indian or Pacific 2 or Below above 
Vaccination and year All 
White 
only 
American 
only 
Alaska 
Native only 
Asian 
only4 
Islander 
only4 
more 
races 
Hispanic 
or Latino 
poverty 
level 
poverty 
level 
Central 
city 
Remaining 
area 
Outside 
MSA3 
Measles, 
mumps, rubella:7 Percent of children aged 19–35 months 
1998 92.0 93.1 88.8 91.4 92.2 - - - - - - 91.0 90.1 93.1 91.3 92.4 92.4 
2000 90.5 91.6 87.7 89.4 89.3 94.5 88.1 90.0 88.9 90.9 89.7 91.0 90.8 
2005 91.5 91.4 91.9 89.7 91.9 90.3 93.7 91.1 89.3 92.1 91.6 91.8 90.4 
2009 90.0 90.8 88.2 94.9 90.7 96.9 88.5 89.3 88.8 90.6 91.1 88.6 88.6 
2010 91.5 90.6 92.1 93.4 91.7 96.9 89.7 92.9 91.3 91.4 92.4 90.5 91.4 
2012 90.8 90.9 90.9 92.0 89.8 * 92.3 90.7 89.9 91.4 90.1 91.0 92.4 
2013 91.9 91.5 90.9 96.3 96.7 90.4 91.5 92.1 90.5 92.5 91.5 92.4 91.3 
2014 91.5 91.2 90.3 96.5 95.7 95.7 90.5 91.9 89.5 92.8 91.9 91.2 91.2 
2015 91.9 91.8 90.7 88.5 92.5 92.0 93.0 92.3 90.3 92.9 92.4 91.7 90.7 
2016 91.1 91.6 89.4 91.3 93.6 86.1 91.0 90.6 89.0 92.1 91.3 91.7 88.5 
Hib (full series):8 
2009 54.8 55.3 51.2 * 54.6 * 53.7 55.4 51.4 56.5 55.5 54.9 53.0 
2010 66.8 67.5 65.4 77.1 69.5 * 70.1 64.8 61.3 69.7 66.5 68.4 63.4 
2012 80.9 82.2 77.5 84.7 86.1 * 82.5 79.5 76.4 84.0 80.5 81.8 79.9 
2013 82.0 84.2 74.9 82.9 82.0 * 84.9 80.9 75.8 85.3 80.6 84.3 79.7 
2014 82.0 83.8 75.2 83.8 83.1 * 78.7 82.8 76.3 85.5 81.4 82.7 81.6 
2015 82.7 83.0 78.9 81.4 87.0 * 82.4 83.0 78.1 85.5 82.3 83.6 80.9 
2016 81.8 83.0 75.6 82.9 83.5 * 83.0 82.1 77.4 83.6 81.5 83.2 78.2 
Hepatitis A
 (2 doses or more): 
2009 46.6 46.2 41.3 33.2 50.9 * 47.8 49.3 47.3 46.2 48.2 46.9 42.0 
2010 49.7 45.8 48.6 * 50.8 * 49.8 57.0 51.0 49.1 52.4 48.8 45.1 
2012 53.0 52.6 52.0 * 57.5 * 49.4 54.4 49.4 55.4 54.7 53.0 48.2 
2013 54.7 53.4 49.1 * 67.3 * 57.8 56.6 53.5 56.1 55.5 55.2 50.1 
2014 57.5 55.4 56.7 * 67.7 * 53.7 61.6 54.0 59.2 58.9 58.1 51.2 
2015 59.6 58.7 59.3 61.3 67.8 * 54.1 60.9 56.0 61.7 60.5 59.6 55.7 
2016 60.6 60.0 53.9 69.8 69.7 * 57.4 63.6 56.9 61.9 62.1 60.5 55.6 
Hepatitis B
 (3 doses or more): 
1998 87.0 88.3 83.7 81.6 89.0 - - - - - - 85.7 85.3 87.7 85.3 88.3 87.4 
2000 90.3 91.4 88.8 91.9 89.5 93.1 92.6 88.2 87.3 91.4 89.4 90.3 92.3 
2005 92.9 93.1 92.7 90.1 92.7 * 94.4 92.7 91.4 93.5 91.8 93.9 93.4 
2009 92.4 92.3 91.6 92.5 93.1 96.2 93.3 92.6 92.3 92.7 92.8 91.8 91.8 
2010 91.8 91.4 92.1 97.2 91.7 96.7 89.9 92.5 91.5 92.0 91.2 92.0 92.7 
2012 89.7 89.3 89.7 94.0 93.2 * 92.2 89.4 89.4 89.8 89.5 89.6 90.7 
2013 90.8 91.0 91.1 96.1 92.0 94.9 90.7 89.7 88.3 92.0 89.6 91.8 91.4 
2014 91.6 90.7 92.3 98.5 92.9 95.2 92.9 91.9 91.3 92.0 90.5 92.5 91.9 
2015 92.6 92.0 93.3 92.4 95.5 94.1 91.4 93.2 92.5 92.7 92.9 92.5 92.1 
2016 90.5 91.3 90.0 91.0 93.8 86.0 88.8 89.1 90.5 90.5 90.9 89.9 91.2 
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Table 66. Vaccination coverage for selected diseases among children aged 19–35 months, by race, Hispanic 
origin, poverty level, and location of residence in metropolitan statistical area: United States, selected years 
1998–2016 
Excel version (with more data years and standard errors when available): https://www.cdc.gov/nchs/hus/contents2017.htm#066. 
[Data are based on telephone interviews of a sample of the civilian noninstitutionalized population, supplemented by a survey of interview 
participants' immunization providers] 
Race and Hispanic origin1 Poverty level2 Location of residence 
Not Hispanic or Latino Inside MSA3 
Native 
Hawaiian 
Black or American or Other At or 
African Indian or Pacific 2 or Below above 
Vaccination and year All 
White 
only 
American 
only 
Alaska 
Native only 
Asian 
only4 
Islander 
only4 
more 
races 
Hispanic 
or Latino 
poverty 
level 
poverty 
level 
Central 
city 
Remaining 
area 
Outside 
MSA3 
Varicella:7 Percent of children aged 19–35 months 
1998 43.2 41.9 42.4 28.0 52.6 - - - - - - 46.9 40.5 44.1 45.1 45.2 34.3 
2000 67.8 66.3 67.6 65.8 76.3 * 69.7 70.2 63.5 69.2 69.0 69.8 60.2 
2005 87.9 86.1 90.6 82.2 91.9 * 90.1 89.2 87.3 87.7 88.4 88.2 85.7 
2009 89.6 89.2 88.2 89.2 89.5 97.5 90.6 90.7 89.0 90.2 90.6 88.5 88.5 
2010 90.4 88.9 91.5 95.7 92.5 92.7 88.9 92.3 89.6 90.6 90.8 90.1 90.0 
2012 90.2 89.8 90.4 92.5 91.9 * 90.9 90.9 89.7 90.6 90.1 90.0 91.3 
2013 91.2 90.0 92.1 95.4 96.0 88.7 91.0 92.0 90.3 91.6 91.1 91.6 90.3 
2014 91.0 90.3 90.1 95.7 95.3 94.9 90.0 92.1 89.9 91.9 91.4 91.1 89.8 
2015 91.8 91.2 91.8 87.8 93.4 91.8 92.1 92.7 90.6 92.5 92.5 91.5 89.9 
2016 90.6 90.8 89.9 90.9 94.2 86.7 89.3 90.2 89.3 91.2 91.2 90.7 88.0 
PCV 
(4 doses or more):9 
2005 53.7 57.3 46.2 * 56.2 * 54.2 50.5 44.6 57.1 51.7 57.7 48.4 
2009 80.4 83.4 73.2 76.2 72.5 * 73.1 80.6 74.8 83.2 79.7 81.8 81.8 
2010 83.3 84.2 79.7 85.3 78.9 * 83.0 83.9 78.7 85.6 82.6 84.3 82.6 
2012 81.9 83.5 77.1 * 80.7 * 84.1 82.1 76.7 85.3 80.4 84.0 80.8 
2013 82.0 84.1 76.1 79.0 85.6 * 83.0 80.4 74.5 86.1 80.7 84.1 79.9 
2014 82.9 84.5 78.0 * 80.9 93.1 82.1 83.2 76.9 86.9 81.4 84.5 82.9 
2015 84.1 85.0 81.4 77.1 85.0 * 83.7 84.0 78.9 87.2 83.9 85.5 80.4 
2016 81.8 84.1 74.5 80.1 81.0 82.9 82.9 81.4 76.8 84.2 82.5 82.1 78.4 
Rotavirus vaccine:10 
2009 43.9 46.4 38.0 * 41.7 * 38.4 43.7 37.7 47.1 44.6 46.6 35.6 
2010 59.2 60.2 52.7 * 62.6 * 57.7 60.5 51.5 62.9 59.2 62.2 51.6 
2012 68.6 70.5 60.4 * 69.9 * 69.3 70.0 63.0 72.5 68.8 70.5 62.5 
2013 72.6 74.8 62.1 * 74.9 * 72.8 73.7 64.3 76.9 72.4 74.7 66.7 
2014 71.7 74.8 61.6 * 72.4 * 73.9 71.3 62.8 76.9 71.2 73.2 68.4 
2015 73.2 74.6 69.7 * 75.6 * 70.6 72.9 66.8 76.8 72.7 75.1 68.6 
2016 74.1 77.3 67.2 * 71.8 * 73.4 73.0 65.5 78.2 74.9 74.2 70.3 
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Table 66. Vaccination coverage for selected diseases among children aged 19–35 months, by race, Hispanic 
origin, poverty level, and location of residence in metropolitan statistical area: United States, selected years 
1998–2016 
Excel version (with more data years and standard errors when available): https://www.cdc.gov/nchs/hus/contents2017.htm#066. 
[Data are based on telephone interviews of a sample of the civilian noninstitutionalized population, supplemented by a survey of interview 
participants' immunization providers] 
Not Hispanic or Latino 
Black or African 
White only American only Hispanic or Latino 
At or 
Below above Below At or above Below At or above 
poverty poverty poverty poverty poverty poverty 
Vaccination and year level2 level2 level2 level2 level2 level2 
Combined 
7-vaccine series:5 Percent of children aged 19–35 months 
2009 43.2 45.6 37.8 43.5 43.5 48.5 
2010 48.7 59.0 53.4 56.3 55.0 55.2 
2012 58.2 72.1 62.7 68.5 68.1 68.3 
2013 61.3 74.9 60.4 69.1 68.6 70.2 
2014 61.2 75.4 61.5 71.0 71.8 79.4 
2015 64.1 75.4 65.8 73.2 72.9 70.1 
2016 61.2 74.6 65.0 64.4 70.8 68.9 
* Estimates are considered unreliable. For data prior to 2007 (shown in spreadsheet version), percentages are  not shown if the unweighted sample size for the numerator was less than 30, or the 
confidence interval half-width divided by the estimate was greater than 50%, or the confidence interval half-width was greater than 10. Starting with 2007 data, percentages are not shown if the 
unweighted sample size for the denominator was less than 30, or the confidence interval half-width divided by the estimate was greater than 58.8%, or the confidence interval half-width was 
greater than 10.
- - - Data not available. 
1Persons of Hispanic origin may be of any race. Starting with 2000 data, estimates were tabulated using the 1997 Revisions to the Standards for the Classification of Federal Data on Race and 
Ethnicity. Estimates for earlier years were tabulated using the 1977 Standards on Race and Ethnicity. See Appendix II, Hispanic origin; Race.
2Poverty level is based on family income and family size using U.S. Census Bureau poverty thresholds. In 2016, 3.7% of the 14,988 children with provider-reported vaccination history data, 6.3% 
of Hispanic, 2.4% of non-Hispanic white, and 6.5% of non-Hispanic black children, were missing information about poverty level and were omitted from the estimates of vaccination coverage by
poverty level (unweighted percentages). See Appendix II, Family income; Poverty. See Appendix I, National Immunization Survey (NIS).
3MSA is metropolitan statistical area. See Appendix II, Metropolitan statistical area (MSA).
4Prior to data year 2000, the category Asian included Native Hawaiian or Other Pacific Islander.
5The combined 7-vaccine series consists of 4 or more doses of either the diphtheria, tetanus toxoids, and pertussis vaccine (DTP), the diphtheria and tetanus toxoids vaccine (DT), and the 
diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP); 3 or more doses of any poliovirus vaccine; 1 or more doses of a measles-containing vaccine (MCV); 3 or more doses or 4 or 
more doses of Haemophilus influenzae type b vaccine (Hib) depending on Hib vaccine product type (full series Hib); 3 or more doses of hepatitis B vaccine; 1 or more doses of varicella vaccine; 
and 4 or more doses of pneumococcal conjugate vaccine (PCV). The vaccine shortage that ended in September 2004 might have reduced coverage with the fourth dose of PCV among children in 
the 2007 National Immunization Survey (NIS)–Child. See footnote 8 for additional information on (Hib) vaccination.
6Includes the diphtheria, tetanus toxoids, and pertussis vaccine (DTP), the diphtheria and tetanus toxoids vaccine (DT), and the diphtheria, tetanus toxoids, and acellular pertussis vaccine 
(DTaP).
7Includes children who may have been vaccinated with at least 1 dose of measles, mumps, rubella, and varicella vaccine. 
8Haemophilus influenzae type b vaccine (Hib) full series includes primary series and the booster dose. Before January 2009, NIS did not distinguish between Hib vaccine product types; therefore, 
children who received 3 doses of a vaccine product that requires 4 doses were misclassified as fully vaccinated. In addition, there was a Hib vaccine shortage during December 2007 –September 
2009. For more information, see: CDC. Changes in measurement of Haemophilus influenzae  serotype b (Hib) vaccination coverage —National Immunization Survey, United States, 2009. MMWR 
Morb Mortal Wkly Rep 59(33):1069 –72. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5933a3.htm?s_cid=mm5933a3_e%0d%0a.
9PCV is pneumococcal conjugate vaccine. Recommended in 2000. Data collection for PCV began in July 2001. Data for 4 doses of PCV are not available prior to 2005.
10Rotavirus vaccine includes 2 or more or 3 or more doses, depending on the product type received. Recommended in 2006. Data collection for rotavirus began in 2009. 
NOTES: Vaccine coverage is based on provider-reported vaccination data. Complex statistical methods were used to adjust vaccination estimates to account for refusals, households without 
telephones, and children whose vaccination histories could not be verified through their providers. Starting in 2011, the NIS sampling frame was expanded from a single-landline frame to dual-
landline and cellular telephone sampling frames. See Appendix I, National Immunization Survey (NIS). See Appendix II, Vaccination. Additional information on childhood immunizations is 
available from: https://www.cdc.gov/vaccines/schedules/index.html. Data for additional years are available. See the Excel spreadsheet on the Health, United States  website at: 
https://www.cdc.gov/nchs/hus.htm. 
SOURCE: NCHS and National Center for Immunization and Respiratory Diseases (NCIRD) (data for 1998–2014); NCIRD (data for 2015 onwards), National Immunization Survey–Child. Available 
from: https://www.cdc.gov/vaccines/imz-managers/nis/index.html. See Appendix I, National Immunization Survey (NIS). 
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